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chapter 1
Introduction
Gestational Trophoblastic Disease (GTD) is a rare pre-malignant condi-
tion that occurs in approximately one in 500 to 2000 pregnancies. On
pathologic examination, trophoblastic hyperplasia and hydropic
swelling of the chorionic villi are predominantly present. These villous
malformations of trophoblast can be subdivided in partial moles (both
paternally and maternally derived) and complete moles (solely paternally
derived). After evacuation of the hydatidiform mole, serum human
Chorionic Gonadotropin (hCG) is closely monitored to detect the
malignant development of Persistent Trophoblastic Disease (PTD). If
PTD occurs, patients are classified as having low or high lethal risk and
they are treated accordingly. Serum hCG is closely monitored in all
patients with GTD and PTD after the evacuation of the hydatidiform
mole. All patients with GTD are advised not to conceive within 6 to 12
months after normalisation of serum hCG. It remains to be elucidated
which patients with GTD will develop PTD. Furthermore, treatment
strategies need to be optimized in order to obtain cure in individual
patients as soon as possible with a minimum of side effects of
chemotherapy in a population of patients who are often anxious to con-
ceive. The main objective of this thesis is the development of strategies
for early identification of PTD and critical analysis of its treatment.
History
Aetius of Amida (502-575 AD), a physician from Mesopotamia who
studied in Alexandria and became the private physician to emperor Jus-
tinian I in Byzantium, was the first to introduce the term ‘mola hydati-
dosa’ in his extensive compilation of Greek and Christian traditions of
medicine. He described that women with a mole feel pregnant, have
swollen breasts and that the menses are suppressed. The distinction with
a real pregnancy could only be made on the basis of foetal movements.
Aetius also knew the cause of a hydatidiform mole: ‘an inflammation or
strenuous walking’(1). In 1276, a ‘Clerc uten laghen lande bi der see’(clerk
from ‘The Low Lands Near the Sea’; The Netherlands) reported that the
Dutch Countess Margaretha van Henneberg on Good Friday 1276 gave
gener al introduc tion
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birth to ‘as many children as days in a year’ as a punishment by God after
having insulted a poor beggar woman by saying she was promiscuous
because she was carrying a twin: the Countess believed that a twin must
have two different fathers (2-4). From the description of the 365 ‘chil-
dren’ (of which half were believed to be female and were named ‘Eliza-
beth’ and half male and were named ‘John’) it is clear that the pregnancy
was a hydatidiform mole. The Countess died soon after giving birth to
the ‘children’. The 365 ‘babies’ were baptised in a bowl. The basins were
stored in the church of Loosduinen, near The Hague, which became a
place of pilgrimage for women with fertility problems. In 1654, the poet
Jacob Westerbaen wrote (3):
‘Waerom hier menigh wijf gegaen komt of gereden
Die vruchtbaar hoopt te zyn en haest met kind gemaeckt
So maer haer handschoen een van dese beckens raeckt’
(‘Therefore many women come or drive here
Who hope to be fertile and are anxious to have a baby
And touch with her glove one of these bowls’).
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17th century French etching after a picture by the 17th century artist Petrus Kaerius,
depicting Margaretha van Henneberg in bed on the right and the 365 ‘children’ on a plate
on the left. Picture kindly provided by Mr A. Molenkamp, Museum ‘De Korenschuur’,
Loosduinen, The Netherlands
In 1895, Felix Marchand was the first to describe that the malignancy he
called chorionepithelioma, was derived from placental villous tropho-
blast which emerged after a normal pregnancy, a spontaneous abortion,
extra-uterine pregnancy or after a hydatidiform mole (5).
Clinical presentation
The clinical presentation of hydatidiform mole has changed consider-
ably over the last decades (6). In the 1960-1970s, the mean time for diag-
nosis was 16 weeks (6) and classic presentations were, in declining fre-
quency, vaginal bleeding (89-97%), uterine enlargement (38-51%) and
theca-lutein cysts due to ovarian hyperstimulation by high serum hCG
concentrations (20-46%) (7,8). Pre-eclampsia and hyperemesis occurred
in 12-27% and 20-26% of patients, respectively (7,8), and 2% of patients
with a hydatidiform mole presented with signs of hyperthyroidism (7).
The clinical presentation changed to earlier detection at a gestational age
of 10-12 weeks (9-11) over the recent years. Vaginal bleeding continues to
be the most common presenting symptom occurring in 58- 84% of
patients presenting with hydatidiform moles (9-11). Due to the availabili-
ty of ultrasound and sensitive hCG tests the diagnosis is nowadays gen-
erally made before the other classic symptoms develop (6).
Incidence of hydatidiform mole
Incidence of hydatidiform mole is highest in South-East Asia, Indonesia,
India and Turkey, with rates ranging from 2 to 12 per 1000 pregnancies.
In North America and Europe, incidence is lower: 0.5 to 1 per 1000 preg-
nancies. Interestingly, significant reductions of incidence of hydatidi-
form mole have been recently reported in Korea, Japan and Taiwan to
levels comparable to those in North America and Europe (12).
In the Netherlands, hydatidiform moles are registered at the Dutch
Central Registry for Hydatidiform Moles (DCRHM). Since the first reg-
istration in 1977 until the 1st of January 2006, 3203 cases were registered.
If a first or optionally a second histological specimen was diagnosed as
choriocarcinoma, the case was registered as a choriocarcinoma irrespec-
tive of whether a previous diagnosis was a hydatidiform mole.
Table 1 provides an inventory of the cases of GTD registered with the
DCRHM and compares the time periods from 1977 until end of 2003
with the time period 1994 until end of 2003 in which, respectively, 
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2821 and 1389 patients were recorded. Subdivision into complete moles,
partial moles, moles not specified, and other diagnoses of GTD (invasive
mole, hydropic degeneration, placental site trophoblastic tumour, chori-
ocarcinoma, remaining and unknown diagnoses) revealed percent rates
for the period 1977-2003 of respectively 50.6%, 26.1%, 8.8%, an 14.5%
and for the period 1994-2003 respectively 40.0%, 35.5%, 17.4% and 7.1%.
In both time periods the number of cases without development of PTD
following diagnosis of complete moles was approximately twice the
number of cases of complete moles with subsequent development of
PTD (18.5% and 9.1% in the period 1977-2003, and 17.6% and 10.5% in the
period 1994-2003). In the case of partial moles, PTD developed approxi-
12
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DCRHM DCRHM
Histological diagnosis and 
development of PTD 1977 - 2003 1994 - 2003
n % n %
Complete mole, no PTD 521 18.5 244 17.6
Complete mole, with PTD 257 9.1 146 10.5
Complete mole, PTD unknown 650 23.0 165 11.9
     Subtotal complete mole 1428 50.6 555 40.0
Partial mole, no PTD 363 12.9 268 19.3
Partial mole, with PTD 2.261 48   3.5
Partial mole, PTD unknown 311 11.0 176 12.7
     Subtotal partial mole 735 26.1 492 35.5
Mole not specified, no PTD 2.672 70   5.0
Mole not specified, with PTD 2.571 67   4.8
Mole not specified, PTD unknown 105 3.7 106   7.6
     Subtotal mole not specified 248 8.8 243 17.4
Invasive mole        0.25 3   0.2
Hydropic degeneration 1.955 12   0.9
Placental site trophoblastic tumour 1 0.0 1   0.1
Choriocarcinoma        58 2.1 29   2.0
Remaining diagnoses  30 1.1 20   1.4
Unknown  261 9.3 34   2.4
    Subtotal other diagnoses 410 14.5 99   7.1
Total 2821 100 1389 100
Table 1. Registered cases with the Dutch Central Registry for Hydatidiform
Moles (DCRHM)
mately six times less frequently than spontaneous regression of serum
hCG.
Since hospital-based incidence studies invariably tend to have elevated
incidence rates, especially those from regions of the world where uncom-
plicated pregnancies are not registered, population-based studies give
more reliable data on incidence of hydatidiform mole (13). Table 2 shows
a highest incidence of hydatidiform mole of 2.96 per 1000 pregnancies in
Japan (14) and the lowest incidence of hydatidiform mole in Paraguay
(15).
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Country pregnancies deliveries live births       Reference
Australia 0.57 0.7 (16)
Canada 0.83 (17)
England and Wales 1.54 (18)
Greenland 1.2 (19)
Italy 0.7 (20)
Japan 2.96 3.0 (14)
Netherlands 0.68 (21)
Northern Ireland 2.2 (22)
Paraguay 0.2 (15)
Singapore 1.2 (23)
Sweden 0.9 (24, 25)
Turkey 1.84 2.48 (26)
United Arab Emirates 2.0 (27)
USA 1.1 (28)
USA 0.8 (White Hawaiian) (29)
1.75 (Filippino)
USA 1.14 (Non-Hispanic whites) 1.04 (30)
1.14 (Hispanic whites) 1.34
2.23 (American Indians) 2.27
              Rate per 1000
Table 2. Incidence of hydatidiform mole from population-based studies*
* Adapted from Kim JS. Epidemiology. In: Hancock BW, Newlands ES, Berkowitz RS,
editors. Gestational Trophoblastic Disease. First ed. London: Chapman & Hall; 1997. 
p. 27- 42; with kind permission from Springer Science and Business Media
It is generally accepted that incidence of hydatidiform mole is highest
among American Indians, Eskimos, and Asian populations (13). In stud-
ies performed at Hawaii, women of Japanese and Philippine descent have
a significant higher risk for a mole pregnancy than women from Cau-
casian descent (13). However, the risk for a hydatidiform mole pregnancy
in Hawaiian women from Japanese descent is lower than for women liv-
ing in Japan (13). Two cytogenetic studies have reported the incidence of
balanced translocations to be as high as 4.6% in patients with a hydatidi-
form mole compared to an incidence of 0.6% balanced translocations in
unaffected populations (13). Furthermore, family clustering of hydatidi-
form moles has been described. These findings indicate a certain genetic
factor to be involved in the development of hydatidiform mole (12,13).
Next to race, geographical region and genetic factors, maternal age (<20
years or >40 years) and a previous history of hydatidiform mole (12,13)
are factors associated with an increased risk for a hydatidiform mole
pregnancy. No unequivocal association between the occurrence of a
hydatidiform and blood group, diet, cigarette smoking or exposure to
herbicides have been described (13).
The reported relative incidences of complete mole versus partial mole
are conflicting, ranging from 75% complete mole and 25% partial mole
(31,32) to exactly the opposite: 25% complete mole and 75% partial mole
(31,33). The large variation in the reported frequency of partial and com-
plete hydatidiform mole might be due to large inter- and intra-observer
variations brought about by the histological diagnosis of a partial hyda-
tidiform mole without adjuvant diagnostic aid. In a retrospective study
in which all first trimester abortions were reanalyzed both on histologi-
cal grounds and with flow cytometry, Jeffers et al. showed that the inci-
dence of partial mole is far more common than complete mole: 76% par-
tial mole and 24% complete mole (31). The reported frequency of PTD is
20 % in complete hydatidiform mole (34) and 0.5 % to 9.9 % in partial
hydatidiform mole (35-38). Again, the large dispersion in the incidence of
PTD after a partial hydatidiform mole might be caused by the difficult
diagnosis on histological grounds of a partial mole.
Pathology
The development of a placenta is relatively new in the evolution and
allows the development of a small number of foetuses within the protec-
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tive maternal organism (39). The Dutch professor of Zoology, Ambro-
sius Arnold Willem Hubrecht, was the first to introduce the term ‘tro-
phoblast’ in 1895 to designate those cells in the blastocyst that are not
part of the embryo, but are essential for its nourishment (40). The syncy-
tiotrophoblast develops from the trophoblastic stem cell or cytotro-
phoblast. These cells cover the chorionic villi (villous trophoblasts) and
invade the endometrium and the proximal third part of the myometrium
(extra villous trophoblast) (39,41,42).
A variety of pathologic entities is included in the diagnosis of GTD
that are divided in villous and non-villous malformations of tro-
phoblasts. Villous malformations of trophoblasts comprise hydatidi-
form mole which represents placentas with abnormally enlarged and
oedematous chorionic villi which are covered with abnormally prolifera-
tive trophoblasts (43). Non-villous malformations of trophoblast are
mainly choriocarcinoma, an extremely haemorrhagic tumour with no
villi, and the placental site trophoblastic tumour, derived from interme-
diate trophoblasts and occurring at the implantation site of the placenta
(43). Mola hydatidosa can be subdivided in complete and partial mole.
This subdivision is important, since these two histological entities have
different risks to develop malignant sequelae, i.e. PTD. A complete hyda-
tidiform mole is a diploid, androgenic conception (46 XX or rarely XY)
which is the result of an ‘empty’ oocyte (after degeneration of the nucle-
us) either being fertilized by one haploid sperm, followed by duplication
of its chromosome (44-46), or by two spermatozoa (47). The syndrome
of partial (incomplete) mole has an ascertainable foetus (alive or dead)
and a triploid karyotype (69 XXX or XXY) after fertilization of a normal
ovum by two spermatozoa (48). Distinction between a hydatidiform
mole and an abortion with hydropic villi can be difficult. Similar to hyda-
tidiform mole, a hydropic abortion may show villous edema with
hydropic swelling, although a hydropic abortion lacks the marked tro-
phoblastic hyperplasia (49).
Difficulty in proper diagnosing gestational trophoblastic disease
Howat et al. showed that out of 50 cases of partial mole, complete mole
and hydropic degeneration, 30% of hydatidiform moles were misdiag-
nosed (50). More than 80% of misdiagnoses concerned the discrimina-
tion of partial mole from hydropic degeneration. Interestingly, Paradinas
found upon reanalysis of 400 cases of partial mole that 50% of these par-
gener al introduc tion
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tial moles were misclassified, but the majority of misclassification in
their study concerned complete mole which had been initially diagnosed
as partial mole (51). Adjuvant diagnostic tools to distinguish complete
mole, partial mole and hydropic degeneration have been developed.
Triploid partial moles can be distinguished from diploid complete moles
with flow cytometry or fluorescent in situ hybridization (FISH)(52,53).
Cytometry or FISH does not contribute to make the distinction between
complete hydatidiform mole and hydropic degeneration. Genomic
imprinting refers to the phenomenon that for certain traits either the
paternal or maternal copy of the gene is expressed and hence the trans-
mission of the tract is dependent on the parental origin (54). To aid the
distinction between complete hydatidiform mole and hydropic degener-
ation, a histopathological staining technique using P57kip2 has been devel-
oped which identifies the paternally imprinted and maternally expressed
CDKN1C gene. The product of this gene is not present in a complete
(diploid) hydatidiform mole and present in (diploid) hydropic degenera-
tion (53). It is argued that besides pathological examination, other tech-
niques like DNA flowcytometry, imunohistochemical analysis for P57kip2
expression and genetic analysis (to determine whether in partial mole
two alleles were derived paternally or maternally) are helpful in estab-
lishing the proper diagnosis of hydatidiform mole (43,49,52,53).
Human chorionic gonadotropin
Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone pro-
duced by trophoblastic tissue and therefore a key marker in pregnancy
and GTD. HCG is composed of two non-covalently bound subunits (i.e.
the α- and β-subunit) (Figure 1). The α-subunit of hCG comprises 92
amino acids and is identical to the α-subunit of the pituitary glycoprotein
hormones Follicle Stimulating Hormone (FSH), Thyroid Stimulating
Hormone (TSH) and Luteinizing Hormone (LH). The hCG β-subunit is
composed of 145 amino acids, which distinguishes hCG from these
other glycoproteins. Two variants exist of intact hCG: non-nicked and
nicked hCG. Nicked hCG is cleaved either between amino acid 44 and 45
or 47 and 48 in the hCG β-subunit and has, unlike non-nicked hCG, little
biological activity (55). In addition to intact hCG, free hCG α-subunit,
non-nicked free hCG β-subunit, nicked free hCG β-subunit, and the
hCG β-subunit core fragment are present in blood.
16
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The main functions of serum hCG in uneventful pregnancy are antigo-
nadotrophic (by inhibiting LH and FSH avoiding ovulation during preg-
nancy) and steroidogenic (by stimulating progesterone production of the
corpus luteum in early pregnancy and the trophoblast at a later stage)
(39).
In uneventful pregnancy concentrations of intact hCG and free hCGβ
in blood double approximately every 2 days to reach a peak at 8-10 weeks
of gestation. From week 10 to 20, these concentrations decline to levels
comparable to those in early first trimester and from 20 weeks on they
remain constantly low (56). In contrast, hCGα concentrations in blood
increase steadily until the end of pregnancy (57). The production of sub-
units of hCG is under stringent physiological control in normal pregnan-
cy, and is reported to be different in pathological states such as hydatidi-
form mole (58-60), although the literature data are not unequivocal. In
gener al introduc tion
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* Adapted from Cole LA, Human Chorionic Gonadotropin assay. In: Hancock BW, New-
lands ES, Berkowitz RS, editors. Gestational Trophoblastic Disease. First ed. London:
Chapman & Hall; 1997. p. 77-94; with kind permission from Springer Science and Busi-
ness Media
Figure 1. The heterogeneity of hCG*
particular, the concentration of hCGβ and the ratio of hCGβ to total
hCGβ (explanation: see page 20) is reported to be increased in molar as
compared to normal pregnancy (61). Some studies, using a limited num-
ber of patients, reported that an increased ratio of hCGβ to total hCGβ
identifies patients with molar pregnancy who are at risk for developing
persistent twphoblastic disease (62-64), although other investigators did
not report such an association (58).
Why hCGβ is synthesized more abundantly in complete hydatidiform
mole than in partial moles or in uneventful pregnancy is unknown. hCG
is synthesized in cytotrophoblasts and more abundantly in syncytiotro-
phoblasts (65,66). Messenger-RNA for hCGα is encoded by a single
gene on chromosome 6 (67), whereas the β-subunit of hCG is encoded
by four genes: hCGβ-3, -5, -7 and -8, located on chromosome 19q13.3
(67,68). hCG α- and β-subunits are thus synthesized separately, and
their production is regulated independently during pregnancy and in tro-
phoblastic disease (69,70). Berkowitz et al. (58) suggested that the per-
cent free hCGβ level might reflect the level of differentiation and hyper-
plasia of the trophoblast, since the level of free hCGβ increases up to
0.5% at five weeks of normal gestation, to 1% in partial hydatidiform
mole, to 2.4% in complete hydatidiform mole, and as high as 9.2% in
choriocarcinoma. Hay (60) indeed proposed a regulatory mechanism to
link irregularities in trophoblastic differentiation to altered biosynthesis
of hCG. In proliferating syncytium formed by differentiating cytotro-
phoblasts, amplification of hCG genes results in excess mRNA for hCG
β-subunits. All free hCGα will be used to produce hCG and the remain-
ing hCGβ will be released together with intact hCG. In the same line it is
feasible to think that in partial mole, which contains both normal tro-
phoblast and hyperplastic trophoblasts, less free hCGβ is synthesized as
compared to complete moles.
Hyperglycosylated human chorionic gonadotropin
Four N-linked and four O-linked sugar side chains are attached to each
hCG molecule (72). Primarily mono- and biantennary N-linked
oligosaccharides, and tri-and tetrasaccharide-type- O- linked sugar units
were found in the β-subunit of hCG in normal and molar pregnancy. A
small proportion of more complex triantennary N-linked oligosaccha-
rides (0-30%) and larger hexasaccharide-type-O-linked sugar units (0-
20%) were also found in normal and molar pregnancy preparations. In
18
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contrast, primary triantennary N-linked oligosaccharides (up to 100%)
and hexasaccharide O-linked oligosaccharides (up to 100%) were found
in choriocarcinoma hCG (73). hCG with these larger N- and O-linked
oligosaccharides is called hyperglycosylated hCG (74).
In uneventful pregnancy, after implantation, hyperglycosylated hCG
is gradually replaced by hCG; hyperglycosylated hCG accounts respec-
tively for >80%, 63% and 50% in the first to third week after implantation
(72). In the third trimester, hyperglycosylated hCG has diminished to 2%
of total hCG (73). Kovalevskaya et al. showed that hyperglycosylated
hCG is produced in placental stem cells or cytotrophoblasts and that the
less glycosylated hCG form is synthesized mainly in syncytiotro-
phoblasts (75). Hyperglycosylated hCG accounted for virtually all hCG
produced in five individuals with choriocarcinoma (73). The finding that
hyperglycosylated hCG is produced by invasive normal pregnancy cells
during the first week of gestation and by invasive or cancerous tro-
phoblast cells in choriocarcinoma suggests that hyperglycosylated hCG
is a product of distinct trophoblast cells and that it may be synthesized by
invasive trophoblast cells (73).
gener al introduc tion
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free 
hCGβ
total hCG h-hCG
total hCG
h-hCG
free hCGβ
hCGβn
hCGn
Early normal pregnancy, week 3-6 PTD with increasing hCG
  
total hCG intact hCG+free hCGβ-subunit
free hCGβ free hCGβ-subunit
hCGn nicked intact hCG
hCGβn nicked free hCGβ-subunit
h-hCG hyperglycosylated hCG
Figure 2. Different hCG subtypes in normal early pregnancy and in PTD (71)
Measurement of human chorionic gonadotropin
The first pregnancy test measuring hCG was developed by Selmar Asch-
heim and Bernard Zondek. In 1928, they described a bioassay in which
young female mice were injected abdominally with urine of a pregnant
woman. If 48 hours later on autopsy the ovaries of the mice were enlarged,
the woman was pregnant (76). This test was considered to have a good
accuracy. In 1956, Solomon Berson and Rosalyn Yalow introduced the
concept of radioimmunoassay (RIA) (77). The principle of this new tech-
nique was based on the reaction of radioactive labelled analyte with an
antibody directed against that analyte. The urine or serum sample in
which the analyte (e.g., hCG) needs to be measured is added to this mix-
ture. The more analyte is present in the sample the less radioactive analyte
is captured by the antibodies and this leads to quantification of the analyte
in a competitive setting. To date, these assays use an antiserum directed
against the free hCG β-subunit as first described by Vaitukaitis et al. (78).
In The Netherlands, the Dutch Central Registry for Hydatidiform Moles
uses a comparable RIA which is based on privately raised hCGβ antisera
(79). These RIAs are erroneously called hCGβ RIAs because they apply
antisera raised against the free hCG β-subunit, and thus measure free
hCG β-subunit with greater affinity than intact hCG. Instead, these
assays should correctly be designated as hCG + hCGβ RIAs. Closely
related to this ‘total’ hCG RIA is the RIA specifically measuring the free
hCG β-subunit which employs a monoclonal antibody directed against
an epitope on the hCG β-subunit. This epitope is only accessible in case
that the α-subunit is not attached to the β-subunit, the reason why this
kind of assay specifically measures the free hCG β-subunit.
More recently, in the 1980s, the concept of double-antibody ‘sand-
wich’-type immunoassays was developed which now are widely used for
many purposes. In this type of assay, two antibodies are used to bind the
hCG molecule serving as the analyte; one antibody is bound to a solid
surface of the reaction tube and captures the hCG analyte (‘capture anti-
body’) while the other antibody (binding the hCG analyte as well) is
labelled with a (radioactive) tracer (‘signal antibody’). The principle is
based on an increase of signal with increasing concentrations of analyte
(‘proportional assay’). Application of ‘sandwich’-type assay formats are
primarily suited for pregnancy detection and these type of assays do not
necessarily detect the aberrant hCG molecules found in trophoblastic
disease (80).
20
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Treatment of gestational trophoblastic disease
Hydatidiform moles should be evacuated as soon as possible after diag-
nosis using suction curettage (81). Medical induction of labour or hys-
terotomy is not indicated since it increases the risk for PTD (82,83).
There is a theoretical concern that the use of strong oxytocic agents force
trophoblastic tissue into the circulation. Therefore oxytocin should only
be administered after the evacuation of the hydatidiform mole (82,84).
The routine use of a second curettage after evacuation of a hydatidiform
mole is advised by one author (81), but is advised against by others (82-
84). Hysterectomy with preservation of the adnexa is an alternative ther-
apy for hydatidiform mole in patients opting for sterilisation (81,83).
This therapy seems to reduce the chance to develop PTD to 3-5% (83).
After evacuation of a hydatidiform mole, hCG is monitored on a weekly
basis in order to diagnose malignant sequelae as soon as possible
(82,83,85).
Prophylactic chemotherapy
The use of prophylactic chemotherapy may be particularly beneficial in
patients with high-risk complete hydatidiform mole who cannot be fol-
lowed closely (86). The first descriptive studies on prophylactic
chemotherapy after evacuation of a hydatidiform mole showed an over-
all incidence of PTD ranging from 4-12% with either Methotrexate
(MTX) or Actinomycin D compared to an incidence of PTD without
prophylactic chemotherapy of 20% (36). The differences in the occur-
rence of PTD between the groups were not tested statistically and no
subdivision was made between patients at low or high-risk for the devel-
opment of PTD. Kashimura et al. performed the only prospective trial in
which it was concluded that prophylactic chemotherapy is beneficial for
all patients with hydatidiform mole, irrespective whether patients had a
high or low-risk for a malignant sequel (87). Their study dealt with 293
patients who were given chemoprophylaxis of 10 mg MTX that was
administered daily for seven days within three weeks after evacuation.
The control group comprised 127 patients who did not receive prophylac-
tic treatment. In the study group, PTD occurred significantly less
(p<0.01) (22 out of 293 patients, 7.5%) than in the control group (23 out of
127, 18.1%). No statistical difference in the occurrence of PTD was found
in a prospective trial with 71 patients who received MTX chemoprophy-
laxis after evacuation and 42 patients who were not treated prophylacti-
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cally (88). In subgroup analysis, however, patients with high-risk hyda-
tidiform mole according to the NETDC (New England Trophoblastic
Disease Center) criteria (89) were found to benefit from chemoprophy-
laxis. If PTD occurred, significantly more courses of chemotherapy were
needed for cure of the patients treated with chemoprophylaxis. A retro-
spective study by Park et al. (90) confirmed the statistically significant
reduction of PTD development following high-risk hydatidiform mole
according to the NEDTC criteria in the case that prophylactic
chemotherapy was given. Finally, in a double blind randomized con-
trolled trial, Limpongsanurak showed that patients with high-risk hyda-
tidiform mole according to the NETDC criteria and irrespective of
maternal age, had a significant risk reduction of 72.4 % to develop PTD
after prophylactic chemotherapy with Actinomycin D (13.8 % in the
study group versus 50.0 % in the control group) (86).
Persistent trophoblastic disease
In the first papers on women with PTD successfully treated with MTX,
the only criterion provided for PTD was ‘a sustained elevation of
gonadotropin titer for up to six months’(91-93). To date, an internation-
ally accepted definition as proposed by the International Federation of
Gynaecology and Obstetrics (FIGO) is used in which PTD is defined as a
plateau in serum hCG concentrations for three weeks, a hCG rise for
two consecutive weeks, the detection of hCG 6 months after evacuation,
or the histological finding of a choriocarcinoma (94), as accepted by the
majority of practitioners in the field (95). A persistent trophoblastic
tumour may have the histological features of either a hydatidiform mole
or a choriocarcinoma (6). When PTD develops, (new) tissue is often not
obtained and precise histopathological diagnosis may, therefore, not be
possible.
Several authors described serum hCG concentrations to be normal-
ized in 50 % of patients between 6 and 14 weeks after evacuation (96-
100). Using normal regression corridors, PTD as defined by exceeding
the 95th percentile (P95) of normal regression was diagnosed two weeks
earlier than in the case that the definition for PTD was derived from a
plateau or rise for three consecutive measurements (98,100). In The
Netherlands, the Dutch Society for Obstetrics and Gynaecology defines
PTD as a hCG plateau or rise for three consecutive weekly measure-
ments, with at least one measurement above P95 of a normal regression
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curve as published by Yedema et al. (99). The reason for this extended
definition is that it has been described by these authors that 15% of
patients with a plateau or rise for three weeks, but without a serum hCG
measurement exceeding P95 will still have spontaneous serum hCG
remission (99). Also, upon using a normal regression corridor for serum
hCG after evacuation of hydatidiform mole, Rotmensch et al. reported
that in retrospect 6 out of 21 patients (29%) who were treated for PTD
since serum hCG concentration was rising during two weeks or showed
a plateau for three weeks, the serum hCG concentration was below the
90th percentile of normal regression of serum hCG when chemotherapy
was started (96). In a previous study of our group it was found that in ret-
rospect 8% of patients treated for PTD had serum hCG levels below the
95th percentile of normal regression (99). It has been hypothesized that
the use of a normal hCG regression corridor together with the FIGO
definition for PTD makes a more expectant attitude towards the start of
treatment for PTD possible (99).
Classifications in high/low-risk persistent trophoblastic disease
In contrast to most other malignancies, in PTD the prognosis for
patients with similar pathological staging may differ greatly (95,101). It is
known that there are a number of clinical features beside extend of the
disease that affects the prognosis (101). In 1965 the International Union
against Cancer (UICC) proposed to adopt a clinical classification incor-
porating both histological and prognostic markers (95,101). In the same
year, Ross et al. identified the following clinical features to be associated
with poor prognosis in PTD: high hCG level, duration of disease longer
than four months and the presence of liver and/or brain metastases (101).
In line with this report, Hammond et al. proposed in 1973 to use a clinical
classification, dividing patients with PTD in non-metastatic or metastat-
ic. The metastatic group was further divided in patients with either a
‘good’ prognosis (urinary hCG<100 000 IU/24 hours or < 40 000 IU/L
in serum, symptoms for less than 4 months, no brain or liver metastases,
no prior chemotherapy and no term pregnancy preceding the PTD), or a
‘bad’ prognosis (urinary hCG>100 000 IU/24 hours or > 40 000 IU/L in
serum, symptoms for more than 4 months, brain or liver metastases, fail-
ure to prior chemotherapy or a term pregnancy preceding the PTD)
(102). In 1976, Bagshawe proposed a scoring system that weighs different
prognostic factors (103). This extensive scoring system included age, par-
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ity, antecedent pregnancy, histological diagnosis, interval between end
of (mole) pregnancy and start of treatment, hCG concentration, ABO
blood group in patient versus partner, number and site of metastases,
largest tumour mass, lymphocyte infiltration of the tumour, immune sta-
tus and relapse after chemotherapy (103). The WHO developed in 1983 a
simplified Bagshawe score excluding the items parity, lymphocyte infil-
tration and immune status (104). In 1992, FIGO introduced a revised
scoring which combined an anatomical staging (stage I: disease confined
to uterus, stage II: disease outside uterus but within genital organs, stage
III: disease extends to lungs, stage IV: disease at other metastatic sites)
with prognostic risk factors of serum hCG (>10 000 IU/L) and interval
between end of pregnancy and start of treatment >6 months (105). Sever-
al retrospective studies investigated the relationship between a clinical
marker and poor prognosis in PTD. Soper et al. showed that hCG level
and tumour size were not independent prognostic factors (106). Azab et
al. demonstrated that only patients with an antecedent non-mole preg-
nancy, more than one metastatic site and resistance to previous
chemotherapy, together with a histological diagnosis of choriocarcino-
ma had a poor prognosis (107). In 2000, a new FIGO staging (FIGO
2000) was introduced which combined the WHO prognostic scoring
and the FIGO 1992 anatomical staging. The risk score for the ABO blood
group was excluded and the risk factor for liver metastases was upgraded
from two to the maximum of four points (94,95,108). The worldwide use
of this system would be an important step forward in the management of
PTD because results can be compared among different centres and it
would facilitate enrolment of patients in large multi-centre trials (109).
To date, however, different classifications systems are used next to each
other.
The Dutch guideline for classification for PTD scores for antecedent
pregnancy (low-risk: mole or non-molar abortion, high-risk: term chori-
ocarcinoma), localisation of metastases (low-risk: no metastases or in
vagina or lungs only, high-risk: more than one organ with metastases or
remaining localisation of metastases), previous failure to chemotherapy
(low-risk: no failure, high-risk: earlier failure to any chemotherapy) and
the interval between end of pregnancy and beginning of treatment (low-
risk: ≤ 12 months, high-risk: > 12 months) (95,110,111). Unlike FIGO 2000
(94), the Dutch guideline issued in 1999 does not include scorings for
age, pre-treatment serum hCG concentration, the number of metastases
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or largest tumour size. Items scored in the Dutch scoring system as ‘low-
risk’ are given 0 points in FIGO 2000, except for the item antecedent
pregnancy where the Dutch system classifies a non-molar abortion as
‘low-risk’, whereas FIGO 2000 scores one point for non-molar abortion.
Although FIGO 2000 has been tested in 201 patients with persistent low
hCG or high-risk GTD (112) against the WHO scoring system (95) and
the in 1992 revised FIGO staging system (95), FIGO 2000 has not been
tested against the Dutch classification for PTD (95,110,111).
Predicting persistent trophoblastic disease
Goldstein et al. from the New England Trophoblastic Disease Center
published a list of risk factors for malignant sequelae after the evacuation
of a hydatidiform mole (89). These risk factors comprise the existence of
a pre-evacuation serum hCG > 100 000 IU/l, uterus large-for-date, theca
lutein cysts > 6 cm, maternal age > 40 years and other factors like a histo-
ry of GTD, hyperthyroidism, toxemia, trophoblastic embolisation and
disseminated intravascular coagulation.
Biomarkers in the prediction of persistent trophoblastic disease
To identify in a very early stage (before evacuation) those patients who
will develop PTD would be most challenging. Several studies have
explored the potency of different biomarkers to enable early detection of
PTD (58,62-64,113-123). Some studies, using a limited number of
patients, reported that an increased ratio of hCGβ to total hCGβ identi-
fies patients with molar pregnancy who are at risk for developing persis-
tent disease (62-64). Two of these studies analyzed pre-evacuation
serum samples (62,64). Neither study calculated a diagnostic accuracy of
this test, although these studies reported a true positive rate of 83% and
91.2% and a true negative rate of 89% and 61.4% at a cut off ratio of free
hCGβ over total hCGβ of 4 and 0.43, respectively (62,64). The third
study included serum samples up to 113 days after curettage and is there-
fore not very meaningful in the early identification of PTD (63). Other
investigators did not report an association between the ratio of free
hCGβ to total hCGβ and PTD (58).
Inhibin may be an important regulator of foetal and human development
(119). In clinical oncology, inhibins are used as markers for the diagnosis
and follow-up of granulosa cell cancer (120). Yohkaichiya et al. were the
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first to report that serum inhibin concentration was significantly more
elevated seven days after evacuation of a hydatidiform mole in two
patients who subsequently developed PTD as compared to four patients
who did not (123). Other studies did neither find inhibin, nor its subforms
inhibin A and B to be significantly different in a pre-evacuation serum
sample from patients who either or not developed PTD (115,117). Inhibin
is not considered to be of clinical relevance in the prediction or follow-up
of PTD (117,121). In two studies serum progesterone concentrations have
been found to be significantly elevated in pre-evacuation samples of
patients who will develop PTD as compared to those who will not
(115,122), whereas other studies did not report this finding (113,116).
Because of these conflicting findings, the value of progesterone in pre-
dicting PTD needs to be established in a prospective trial (121).
The tumour marker CA-125 measured in pre-evacuation serum sam-
ples is not found to be of value in the prediction of PTD (64,114,118), nor
are CEA, CA 15-3 and CA 19-9 (114). Finally, although Li et al. found that
leptin and the leptin receptor are up-regulated in GTD, no differences
were found between the group of patients who develop PTD and the
group with spontaneous remission of serum hCG (124). No other serum
biomarkers than hCG are reported to have clinical benefit in the detec-
tion and follow-up of PTD (121).
Molecular markers in gestational trophoblastic disease and persistent
trophoblastic disease
Many cell cycle regulators like TP53, P21, RB, MDM2, DOC-2/hDab2,
EGFR, C-erbB-2, C-erbB-3, C-erbB-4, Bcl-2, PTEN, and Cyclin E, are
differently expressed in complete hydatidiform mole, choriocarcinoma
and normal placenta (48,125-127). Cell adhesion molecules, e.g. Matrix
Metalloproteinases 1 and 2 (MMP 1 and MMP 2) and Osteopontin
(OPN), have significantly higher expression in choriocarcinoma than in
normal placenta, partial and complete mole (128). Interestingly, the
MMP inhibiting Tissue Inhibitor of Metalloproteinases (TIMPs) are less
expressed in choriocarcinoma compared to normal placenta, partial
mole and complete hydatidiform mole (128). The Heat Shock Protein 27
(HSP 27) which is involved in both placental differentiation and the
acquisition of chemotherapeutic drug resistance, is found to be signifi-
cantly down-regulated in choriocarcinoma as compared to normal pla-
centa (129). Finally, Bcl-2 which is considered to be an antagonist of
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apoptosis, is found to be strongly expressed in 84% of complete moles
and 72.7% of choriocarcinoma as compared to absence of expression in
normal placentas and expression of Bcl-2 in 5.8% of partial moles (130).
With respect to the development of PTD, several studies have identi-
fied a different expression pattern of anti-apoptotic-, onco- and tumour
suppressor genes. The anti-apoptopic gene MCL-1 is found to be up-reg-
ulated in patients who will develop PTD (131). With respect to onco-
genes, the Epidermal Growth Factor Receptor (EGFR) and its related
tyrosine kinases c-erbB-2 and C-erbB-3 were found to be up-regulated in
tissue of patients who would later be diagnosed with PTD (132,133).
Another tyrosine kinase, c-erbB-4 was not found to be differentially
expressed in tissue of patients who would later on develop PTD (133).
The oncogene, c-ras, believed to have a cell regulating function in normal
placenta (133), is found to have a decreased expression in PTD (133). Con-
cerning tumour suppressor genes, the p53 gene products were found to
be significantly more elevated in tissue of patients who would develop
PTD as compared to that of patients with spontaneous regression of
serum hCG (133). The DOC-2/hDab-2 gene is believed to be involved in
the growth regulation of normal trophoblastic cells (134). This DOC-
2/hDab-2 gene had a significantly decreased expression in a choriocarci-
noma cell line and in vivo material of choriocarcinoma (134). Transfec-
tion of this DOC-2/hDab-2 gene in the choriocarcinoma cell line result-
ed in a significantly reduced growth rate (134). The product of the Nm23
gene has been proposed as a candidate metastatic tumour suppressor
gene (133). The product of this gene was found to be significantly
decreased in histological specimen from patients who would develop
PTD as compared to patients who would not develop PTD (133).
Telomerase is a reverse transcriptase that stabilises the telomere ends
of human chromosomes. With every DNA replication, the telomeres are
shortened. Telomere shortening is believed to be a ‘mitotic clock count’:
excessive shortening of telomere ends will trigger the onset of cell senes-
cence (135). Most normal cells lack the telomerase activity. In hydatidi-
form moles of patients who developed PTD as compared to those with a
spontaneous regression, the ‘cell-life saving’ telomerase activity was
detectable in 75% versus 18.5% of cases, respectively (P<0.01)(135).
Although differences in the expression of imprinted genes like P57kip
have been found between normal pregnancy and GTD (136), its value to
predict PTD at an early stage remains to be elucidated (48).
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Treatment of persistent trophoblastic disease
Second curettage
A repeat or second curettage for patients with PTD has been recom-
mended by some authors (137,138), but the routine use of this procedure
is advised against by others (82,139). Two studies on the curative effect of
second curettage have been performed. The first retrospective study on
37 patients administered at the University of Southern California
Women’s Hospital between 1976-1980 and 1987-1989 showed a curative
effect from a second curettage in 4 out of 23 (16%) patients with non-
metastatic GTD. No curative effect was observed for the other patients
in this study (with metastatic GTD or in retrospect no PTD) (139). The
second, prospective study was executed by the Sheffield Trophoblastic
Disease Centre (138). Between 1991 and 2000, 4075 patients with GTD
were registered. Out of this cohort, 606 (15%) patients were diagnosed
with PTD on the basis of elevated hCG (time course not mentioned),
vaginal bleeding, abnormal tissue visible in utero on ultrasound or other
gynaecological symptoms not specified. Of these 606 patients, 544 were
treated with a second uterine evacuation. After this procedure, no fur-
ther chemotherapeutic treatment was necessary in 68% of these
patients. If PTD was diagnosed on elevated hCG only, 282 fulfilled the
premises for PTD of which 171 (60%) needed no further chemotherapy
for PTD. Unfortunately, the authors of this study did not specify the
duration for which hCG should be elevated or rising before the criteria
for the diagnosis of PTD were met. Upon request, the authors provided
their criteria for PTD in a personal communication, stating that any
patient whose serum hCG concentrations failed to normalize within 4-6
weeks after primary evacuation or had a rising hCG at any stage, were
diagnosed with PTD. In 1993, our group showed that serum hCG after
uneventful hydatidiform mole normalizes in 5% of patients 5 weeks evac-
uation, in 50% of patients after 11 weeks and in 95% after 26 weeks (99).
The FIGO 2000 prognostic scoring system for PTD, clearly defines PTD
if serum hCG shows a rise or plateau for three consecutive weeks (94).
Failure of serum hCG to normalize within 6 weeks after first evacuation
without plateau or rising in hCG (as defined by FIGO), in itself does not
make trophoblastic disease persistent. Advising patients to undergo a
second curettage 4-6 weeks after evacuation for “persistent trophoblas-
tic disease” according to the criteria which were applied in the study by
the Sheffield Trophoblastic Disease Centre (138) will put patients at risk
28
chapter 1
of complications of this procedure, which is unnecessary in the majority
of patients.
Chemotherapy for persistent trophoblastic disease
Until the discovery by Hertz et al. and Li et al. in the 1950s that MTX is
highly effective to cure PTD, this condition was highly lethal (91,93).
Once diagnosed and scored, low-risk PTD is nowadays typically treated
with single-agent chemotherapy (MTX or Actinomycin-D) (108,140). If
staged as high-risk PTD, multi-agent chemotherapy with EMA-CO
(Etoposide, MTX, Actinomycin-D, Cyclophosphamide and Vincristine)
is most widely used (141). Patients with high- risk PTD who are treated
with the EMA-CO regimen and whose serum hCG initially normalize
but show recurrence or persistent low hCG levels afterwards, should be
treated with the EMA-EP regimen (Etoposide, MTX, Actinomycin-
D,Cyclophosphamide and Vincristine) (142). If patients with high-risk
PTD fail to respond to Methotrexate containing regimens, cure has been
reached with different kinds of platinum and etoposide containing regi-
mens like BEP (Bleomycin, Etoposide, and Cisplatin), VIP (Etoposide,
Ifosfamide and Cisplatin) and ICE (Ifosfamide, Carbosplatin and Etopo-
side) (142).
Approximately 9-33% of patients treated with single-agent therapy for
low-risk PTD, will require multi-agent chemotherapy since they become
resistant to the first-line drug or that toxic side effects occur (142-144).
Repeated administration of MTX can induce MTX resistance (145),
mainly due to down-regulation of the reduced folate carrier which is
responsible for transport of MTX into the cell or amplification of the
gene for dihydrofolate reductase. This enzyme reduces dihydrofolate in
tetrahydrofolate which is essential in DNA synthesis (146,147). To date,
an internationally accepted definition for resistance to first-line
chemotherapy is lacking. In some clinics resistance to first-line
chemotherapy is defined as a plateau or rise in serum hCG and/or devel-
opment of new metastases (96,98,142-144). Others define resistance to
single-agent chemotherapy more quantitatively, a less than 10% decrease
of serum hCG concentrations within two weeks, or less than one log
decrease of serum hCG within six weeks (148,149).
After single-agent chemotherapy with MTX, no increase in the num-
ber of second primary tumours has been observed (150). In contrast,
patients with PTD who are treated with Etoposide containing multi-
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agent chemotherapy have a 50% increased Relative Risk to develop sec-
ondary malignancies, in particular myeloid leukaemia, colon carcinoma
and breast cancer, as compared to an age-matched control group (151).
Furthermore, multi-agent chemotherapy hastens the occurrence of
menopause by three years as compared to patients treated with single-
agent MTX (152) and can be accompanied by the occurrence of alopecia
and gastro-intestinal symptoms.
Regression corridors during treatment for persistent trophoblastic disease
Two studies have described the serum hCG regression pattern in
patients treated with first-line single agent therapy responding to this
therapy and in patients who do not. In the first study, Rotmensch et al.
described the only normogram for normalization of hCG in 21 patients
with non-metastatic trophoblastic disease treated with MTX, of whom 2
patients were treated with multi-agent chemotherapy after serum hCG
failed to normalize after first-line single-agent therapy (96). They
reported that the median time for serum hCG concentrations to normal-
ize in successfully treated patients with PTD is 50 days. The second study
included 72 patients with non-metastatic low-risk GTD (148). Sixty-nine
patients were treated with Actinomycin-D as a first-line treatment, one
patient was treated with MTX and two were treated with Etoposide. Of
these patients, 64 responded to single- agent therapy and 8 needed multi-
agent therapy since resistance occurred. In this study the median time to
normalization were four, two weekly courses (56 days). Rotmensch et al.
stated that in successfully treated patients with low-risk PTD, the medi-
an time to normalization is comparable to patients with uncomplicated
regression of serum hCG after hydatidiform mole (50 days) (96). Serum
hCG in two patients in the study by Rotmensch et al. failed to normalize
after primary chemotherapy (96). Serum hCG of these two patients was
above the P90 of the ‘normal regression with MTX’ at the start of the
MTX treatment. These investigators did not explore the diagnostic accu-
racy of serum hCG levels to detect resistance to single-agent chemother-
apy in low-risk PTD (96) nor did the authors of the second study (148).
The main objectives of this thesis are to assess:
1. The diagnostic accuracy of different serum hCG analytes and para-
meters to predict PTD (Chapters 2, 3, 4 and 5)
2. The value of second curettage in the management of PTD (Chapter 6)
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3. The development of a regression curve for the early detection of resis-
tance to first-line single-agent MTX therapy in patients treated for low-
risk PTD (Chapter 7)
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Abstract
Objective: Human Chorionic Gonadotropin (hCG) is widely used in the man-
agement of hydatidiform mole and persistent trophoblastic disease
(PTD). Predicting PTD after molar pregnancy might be beneficial since
prophylactic chemotherapy reduces the incidence of PTD.
Design: A retrospective study based on blood specimen collected in the
Dutch Registry for Hydatidiform Moles. A group of 165 patients with
complete (of which 43 had PTD) and 39 patients with partial moles (of
which 7 had PTD) were compared with 27 pregnant women with
uneventful pregnancy.
Methods: Serum samples from patients with hydatidiform mole with or with-
out PTD were assayed using specific (radio)immunoassays for free α-
subunit (hCGα), free β-subunit (hCGβ) and ‘total’ hCG (hCG +
hCGβ). In addition, we calculated the ratios hCGα/hCG + hCGβ,
hCGβ/hCG + hCGβ, and hCGα/hCGβ. Specificity and sensitivity were
calculated and paired in receiver-operating characteristic (ROC) curve
analysis, resulting in areas under the curves (AUCs).
Results: hCGβ, hCGβ/hCG + hCGβ and hCGα/hCGβ show AUCs ranging
between 0.922 and 0.999 and, therefore, are excellent diagnostic tests to
distinguish complete and partial moles from normal pregnancy. To dis-
tinguish partial from complete moles the analytes hCGβ, hCG + hCGβ
and the ratio hCGα/hCGβ have AUCs between 0.7 and 0.8. Although
hCGα, hCGβ and hCG + hCGβ concentrations are significantly elevat-
ed in patients who will develop PTD compared with patients with spon-
taneous regression after evacuation of their moles, in predictiong PTD,
these analytes and parameters have AUCs <0.7.
Conclusions: Distinction between hydatidiform mole and normal pregnancy
is best shown by a single blood specimen with hCGβ, but hCGβ/hCG +
hCGβ and hCGα/hCGβ are also excellent diagnostic parameters. To
predict PTD, hCGα, hCGβ, hCG + hCGβ and hCGα/hCGβ are mod-
erately accurate tests, although they are not accurate enough to justify
prophylactic chemotherapy treatment for prevention of PTD.
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Introduction
Human Chorionic Gonadotropin (hCG) is a glycoprotein hormone pro-
duced by trophoblastic tissue and therefore is a key marker in pregnancy
and gestational trophoblastic disease (GTD) (1). A variety of pathologi-
cal types of trophoblast are included in GTD comprising villous malfor-
mations of trophoblast: hydatidiform mole, subdivided in complete and
partial hydatidiform moles, and non-villous malformations of which
choriocarcinoma is the most frequent (2). Genetically, complete moles
are diploid (46 XX or XY) which is the result of an ‘empty’ oocyte (after
degeneration of the nucleus) being fertilized by one haploid sperm, fol-
lowed by duplication of its chromosome, or fertilization of an empty egg
by two spermatozoa (3). The syndrome of partial (incomplete) mole has
an ascertainable fetus (alive or dead) and a triploid karyotype (69 XXX
or XXY) after fertilization of a normal ovum by two spermatozoa (3).
Incidence of hydatiform mole is highest in South-East Asia, Indonesia,
India and Turkey with rates ranging from 2 to 12 per 1000 pregnancies. In
North America and Europe, incidence is lower: 0.5 to 1 per 1000 preg-
nancies. Interestingly, significant reductions in the incidence of hydatidi-
form mole have recently been reported in Korea, Japan and Taiwan to
levels comparable to those in North America and Europe (4). In persis-
tent trophoblastic disease (PTD), trophoblastic activity remains after
evacuation of the hydatidiform mole as shown by subsequent unaltered
high or even rising hCG concentrations in blood. The reported frequen-
cy of PTD is 20% in complete hydatidiform mole (5) and 0.5 to 9.9% in
partial hydatidiform mole (6-9). In order to prevent complications from
metastatic disease, PTD needs to be treated. Prophylactic chemotherapy
(started immediately after evacuation of the mole) reduces the incidence
of PTD to 4-12% (10,11). Because of the large proportion of patients who
will show spontaneous remission of molar pregnancy after evacuation
and because of the side effects of chemotherapy, clinicians are reluctant
to use prophylactic chemotherapy. It would therefore be helpful to iden-
tify patients at risk for developing PTD. hCG is composed of two non-
covalently bound α- and β-subunits. The α-subunit of hCG comprises 92
amino acids and is identical to the α-subunit of the pituitary glycoprotein
hormones follicle-stimulating hormone (FSH), thyrotropin (TSH) and
luteinizing hormone (LH). The β-subunit is composed of 145 amino
acids, which distinguish hCG from these other glycoproteins. In addi-
tion to intact hCG, free hCG α-subunit, free hCG β-subunit, and the
hcg analy tes and par ameter s in the diagnosis of mole pregnanc y and ptd
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hCG β-subunit core fragment are present in blood. Since most hCG
radioimmunoassays detect both intact hCG and free hCGβ, these tests
are designated ‘total hCG’ or ‘hCG + hCGβ’ assays. In normal pregnan-
cy, concentrations of intact hCG, hCG + hCGβ and hCGβ in blood dou-
ble approximately every 2 days to reach a peak at 8 to 10 weeks of gesta-
tion. From week 10 to 20, these concentrations decline to levels compara-
ble to those in early first trimester and from 20 weeks on they remain
constantly low (12). In contrast, hCGα concentrations in blood increase
steadily until the end of pregnancy (13). The production of subunits of
hCG is under stringent physiological control in normal pregnancy, and is
reported to be different in pathological states such as hydatidiform mole
(14-16), although the literature data are not unequivocal. In particular,
the concentration of hCGβ and the ratio of hCGβ to total hCGβ is
reported to be increased in molar as compared with normal pregnancy
(17). Some studies, using a limited number of patients, reported that an
increased ratio of hCGβ to total hCGβ identifies patients with molar
pregnancy who are at risk for developing persistent disease (18-20),
although other investigators did not report such an association (14).
The present retrospective study includes measurement of hCGα, hCGβ,
hCG + hCGβ and calculates the ratios of hCGα/hCG + hCGβ,
hCGβ/hCG + hCGβ and hCGα/hCGβ in blood taken before evacua-
tion from 203 patients with hydatidiform mole of which 43 developed
PTD. The aim of this study is to evaluate the clinical utility of the six
hCG parameters by receiver-operating characteristic (ROC) curve
analysis to distinguish normal pregnancy from hydatidiform mole, par-
tial from complete mole, and to predict the occurrence of PTD.
Materials and Methods
Patients
In The Netherlands, patients with hydatidiform mole can be registered,
after informed consent, at the Dutch Central Registry for Hydatidiform
Moles residing at the Radboud University Nijmegen Medical Centre
(RUNMC). We have included 1630 patients in this database. We excluded
all patients with a histological diagnosis of choriocarcinoma. In 692 reg-
istered patients with hydatidiform mole, hCG in blood was analyzed in
our department at the RUNMC. After collection, blood samples were
centrifuged and serum was sent to our institute and kept at -20 °C until
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assayed. Of these 692 patients, 430 had to be excluded since no blood
specimen was taken prior to evacuation. Another 58 patients were ex-
cluded to match the gestational age in the control group. This led to the
selection of 204 patients (mean age 27.9 years, range 16 to 54 years). Of
those 204 patients, 129 had a complete hydatidiform mole with normal
serum hCG regression (Group 1), as derived from a normal regression
curve constructed by Yedema et al. (21). Another 36 patients with a com-
plete mole developed PTD after evacuation (Group 2) while 32 patients
had a partial mole with normal hCG regression (Group 3) whereas 7
patients with a partial hydatidiform mole developed PTD after evacua-
tion (Group 4). The pathology institution of the Dutch Central Registry
reviewed the histology of all patients with a hydatidiform mole. The con-
trol group comprised 27 women (mean age 28.2 years, range 23 to 39 years)
with uneventful pregnancies, whose blood was collected on a weekly
basis between 7 and 16 weeks of gestation except in weeks 13 and 15.
Immunoassays
All the measurements of ‘total’ hCG (i.e. intact hCG and free β-subunit,
hCG + hCGβ) or its free α- or β-subunit in serum were performed with
sensitive and specific radioimmunoassays (RIAs) that have been devel-
oped in our laboratory. The RIAs of hCG + hCGβ and hCGβ have been
described previously (22), while the hCGα RIA was developed recently.
Polyclonal anti-rabbit antisera were used in the RIAs of hCG + hCGβ
and hCGα, and a monoclonal antibody (23) in the RIA for hCGβ. A
highly purified hCG β-subunit preparation labeled with iodine-125
(NaI125, Amersham plc, Amersham, Bucks, UK) was employed as a tracer
in the RIAs of hCG + hCGβ and hCGβ, while the RIA of hCGα used
I125-labeled hCG α-subunit as a tracer. The RIAs were calibrated with
the third International Standard (IS) Preparations for intact hCG, hCG
α-subunit or hCG β-subunit (WHO third IS hCG 75/537, hCGα 75/569
or hCGβ 75/551 respectively, all obtained from the National Institute for
Biological Standards, Potters Bar, Herts, UK).
Conversion factors are as follows: hCGα: 1µg/l is 0.0714 nmol/l and
equivalent to 1 IU/l; hCGβ: 1µg/l is 0.0426 nmol/l and equivalent to 1 IU/l;
hCG: 1 µg/l is 0.0267 nmol/l and equivalent to 9.29 IU/l. The measuring
ranges of the assays were 0.027-2.14 nmol/l (1-80 µg/l, equivalent to 9.29-
743 IU/l) for hCG + hCGβ, 0.0036-0.43 nmol/l (0.05-6.0 IU/l or µg/l) for
hCGα, and 0.0033-0.107 nmol/l (0.078-2.50 IU/l or µg/l) for hCGβ. All
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the RIAs applied the same assay protocol. In brief, the procedure com-
prised the following steps. To increase the sensitivity of the RIAs, the
mixtures of standard material or serum specimen together with the anti-
serum were incubated for 18 h at 20 °C, and after addition of labeled ana-
lyte this was followed by a second incubation (6 h at 20 °C). Antibody-
bound and free analyte were separated by applying second antibody don-
key anti-rabbit IgG coupled to cellulose (Sac-Cel, The Wellcome Foun-
dation Ltd, Dartford, Kent, UK) in the case of the hCG + hCGβ and
hCGα RIAs, and by donkey anti-mouse IgG coupled to cellulose in the
free hCGβ RIA. The RIA developed for hCGα cross-reacted 100% (on a
molar basis at 50% displacement) with the α-subunits of LH, FSH and
TSH, and 2%, 3.6%, 13% and 17% with the WHO International Reference
Preparations (IRP) of native hCG, TSH, LH, and FSH respectively.
Intact hCG and the free hCG β-subunit are abundantly present in
serum samples from normal or mole pregnancies (unlike LH and FSH
which both are suppressed during pregnancy while TSH concentrations
are very low). For this reason, it was necessary to conduct an affinity
chromatography procedure to eliminate intact hCG and free hCG β-
subunit from each serum sample prior to determining its free hCG α-
subunit concentration by this RIA. Thus, 100 µl of serum sample were
transferred to a HiTrap N-hydroxy-succinimide (NHS)-activated col-
umn (Pharmacia, Uppsala, Sweden) coupled to polyclonal antiserum
against free hCG β-subunit raised in rabbit, and the column effluent was
checked by RIA for absence of the intact hCG and free hCG β-subunit
present in the serum sample prior to chromatography. Next, the free
hCG α-subunit concentrations were determined with the hCGα RIA.
The free hCG β-subunit RIA showed a cross-reactivity with intact hCG
of 0.35% (on a mass basis, equivalent to 0.55% on a molar basis) as tested
with the WHO third IS 75/537 of hCG, 1.1% on a molar basis with nicked
hCG (hCGn, WHO 99/642 Reference Reagent) and 0.4% with hCGβn
(WHO 99/692 Reference Reagent) while the hCG + hCGβ RIA cross-
reacted 100% on a molar basis with intact hCG and 1000% with hCG β-
subunit, and 228% with hCGn and 507% with hCGβn (which is of minor
practical importance because these nicked forms of hCG mainly occur
in urine). The 95th percentile of the reference interval of healthy non-
pregnant controls for the hCG + hCGβ assay was established at 0.053
nmol/l (2 µg/l or 18.6 IU/l of the WHO third IS hCG 75/537) (22), 0.286
nmol/l (4.0 µg/l or IU/l of the WHO third IS hCGα 75/569) with the
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hCGα RIA, and 0.0085 nmol/l (0.20 µg/l or IU/l of the WHO third IS
hCGβ 75/551) with the hCGβ RIA (24). The intra- and interassay coeffi-
cients of variation (CVw, CVb) for means of duplicate measurements for
two serum pools (mean: 0.267 nmol/l (10 µg/l or 93 IU/l) and 1.50 nmol/l
(56 µg/l or 520 IU/l) were 7.3% and 12% for the hCG + hCGβ RIA, 3.3% -
5.6% (CVw) and 7.2% - 8.4% (CVb) with two serum pools (mean: 0.510
nmol/l (7.1 µg/l or IU/l) and 3.07 nmol/l (43 µg/l or IU/l)) in the case of the
hCGα RIA, and 5.2% - 5.8% (CVw) and 9.5% - 9.9% (CVb) with two
serum pools (mean: 0.014 nmol/l (0.33 µg/l or IU/l) and 0.041 nmol/l
(0.96 µg/l or IU/l)) in the hCGβ RIA.
Statistics
Calculation of reference values for normal pregnancy
To construct reference values for normal pregnancy, we collected blood
samples in our control group on a weekly basis from week 7 to 16 of ges-
tational age except in weeks 13 and 15. We determined the longitudinal
patterns (‘response curve’) of each experimentally determined hCG ana-
lyte (hCG + hCGβ, hCGα, and hCGβ, all expressed in nmol/l), as well as
for the calculated molar ratios of hCG α- and β-subunits to hCG +
hCGβ (hCGα/hCG + hCGβ and hCGβ/hCG + hCGβ) and the ratio of
hCGα to hCGβ (hCGα/hCGβ). In order to obtain normal Gaussian
distributed data for the control group consisting of 27 pregnant women,
we performed log transformations of all the determined hCGα concen-
trations (nmol/l) and calculated molar ratio of hCGα/hCGβ, while we
performed square root transformation of the serum concentrations of
hCGβ (nmol/l), hCG + hCGβ (nmol/l) and its calculated molar ratio.
Next, by subsequent pooling (over the weeks) of variances (25), we calcu-
lated P5, P50, and P95 for these transformed data (i.e. mean(log or
square root) ± 1.645 S.E. (log or square root)) to become, after back
transformation, the reference values (the 5th, 50th, and 95th percentiles,
P5, P50, P95) separately for each week of the gestational period for the
three analytes and three molar ratios.
Statistical comparison of pregnancy controls with molar pregnancy subsets
Each individual log- or square root-transformed hCG serum analyte or
parameter from the 27 control pregnancies were expressed as a multiple
of the median (MoM) for each gestational week. Because the longitudi-
nal patterns for each individual patient revealed rather constant MoMs
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along the gestational period studied, we could calculate the mean MoM
(mMoM) for each patient over the entire pregnancy period studied - 7 to
16. From these mMoMs for each patient we calculated the ‘grand’
mMoM ± S.E. Next, we calculated the MoMs for each of the available
individual log- or square root-transformed hCG serum analytes of all the
molar pregnancies. This was done for each mole by dividing the mea-
sured log- or square root-transformed blood concentration (or calculat-
ed ratios) of analyte or molar ratio by the corresponding P50 value of the
control pregnancies as calculated and matched for the corresponding
gestational week. Statistical significance of differences was tested with
the Mann-Whitney U-test between the mean MoMs of all control
pregnancies (the ‘grand’ mMoM) versus the calculated mean MoM of all
molar pregnancies or versus the various subsets of moles (complete
moles, partial moles), as well as between complete versus partial moles,
or the presence or absence of PTD in case of molar pregnancies. The cal-
culated MoM values of all six hCG analytes and parameters of control
and study groups were utilized to construct ROC curves and to calculate
areas under the curve (AUC) for assessment of diagnostic accuracy of
the test. All calculations were conducted with SPSS (version 12.0) for
Microsoft Windows XP (SPSS, Chicago, IL, USA).
ROC curves represent the full spectrum of possible sensitivity-speci-
ficity pairs for a test in a clinical application (26). Usually, it is assumed
that the study group has higher values of the tested parameters than the
control group, resulting in an AUC between 0.5 and 1.0. Conversely, if
results are lower in the study group than in the control group, an AUC
between 0.0 and 0.5 is found (27) but this can easily be circumvented by
reversing the state variable of control and study group.
Results
Serum hCG parameters in hydatidiform molar pregnancy
Median serum hCGα concentrations increased steadily in the control
pregnancies from 1.79 nmol/l (25 IU/l) at 7 weeks of gestation to 11.4
nmol/l (160 IU/l) at 16 weeks of gestation. Serum hCGβ and hCG +
hCGβ concentrations were 0.248 nmol/l (5.8 IU/l) and 37.6 nmol/l
(13100 IU/l) respectively at week 7, showed a peak at 8 - 9 weeks of gesta-
tion (0.417 nmol/l (9.8 IU/l) and 59.6 nmol/l (21000 IU/l) respectively)
and then subsequently decreased to 0.032 nmol/l (0.75 IU/l) and 18.7
nmol/l (6500 IU/l) respectively at week 16 of gestation. Fig. 1 shows the
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Figure 1. hCGα, hCGβ, hCG + hCGβ, hCGα/hCG + hCGβ, hCGβ/hCG + hCGβ and
hCGα/hCGβ in partial or complete mole with or without persistent trophoblastic dis-
ease compared with normal pregnancy (n=27). The two solid lines represent the 5th and
the 95th percentile, whereas the dotted line represents the 50th percentile of normal
pregnancy. Group 1 (), complete mole without PTD (n=129); Group 2 (), complete
mole with PTD (n=36); Group 3 (), partial mole without PTD (n=32); Group 4 (), par-
tial mole with PTD (n=7). The ratios of hCGα/hCG + hCGβ, hCGβ/hCG + hCGβ and
hCGα/hCGβ are given in mol/mol, %.
serum concentrations of hCGα, hCGβ, hCG + hCGβ and its calculated
ratios (hCGα/hCG + hCGβ, hCGβ/hCG + hCGβ and hCGα/hCGβ) in
complete and partial moles with or without PTD compared with the val-
ues in normal pregnancy between weeks 7 and 16 of gestation. In many
molar pregnancies, hCGα concentrations in serum (Fig. 1A) are below
the P50 levels of normal pregnancy. The hCGα/hCG + hCGβ ratio in
the majority of molar pregnancies is below P5 (Fig. 1D) while almost all
hCGα/hCGβ ratios are below P5 of normal pregnancy (Fig. 1F). In con-
trast to this, hCGβ and hCG + hCGβ concentrations, and the ratio
hCGβ/hCG + hCGβ are mostly above the corresponding P95 levels of
normal pregnancy (Fig. 1B, 1C and 1E).
Comparison of serum hCG analytes and parameters in hydatidiform 
molar vs normal pregnancy
For each of the six hCG analytes and parameters investigated, we calcu-
lated the mean MoM (mMoM) values and their standard errors (S.E.)
for the total and the individual groups of complete and partial molar
pregnancy as compared with normal pregnancy (Table 1). This table also
shows the comparisons between complete and partial moles, as well as
all moles (complete and partial) without vs all moles with PTD.
The mean MoMs calculated for the concentrations of hCGβ, hCG +
hCGβ and the ratio hCGβ/hCG + hCGβ were significantly higher in all
molar pregnancies as well as in the complete molar pregnancy group
compared with values in normal pregnancies (Table 1A and 1B). Compa-
rable differences were also observed in the case of partial molar vs nor-
mal pregnancy except for hCG + hCGβ value, which was not significant-
ly different (Table 1C). The mMoMs for the ratios of hCGα/hCG +
hCGβ and hCGα/hCGβ in the all moles group and in its two subset
groups were significantly lower than in normal pregnancy (Table 1A-C).
The increase of the mMoMs observed for the group of all molar preg-
nancies (Table 1A), as well as for the subsets of complete (Table 1B) or
partial (Table 1C) moles was highest in the case of hCGβ, followed by the
ratio of hCGβ/hCG + hCGβ (Table 1A-C). The decrease of the mMoMs
was highest in the case of the ratio of hCGα/hCG + hCGβ (Table 1A-C).
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Table 1. Mean multiple of the median (mMoMs)* for six hCG analytes and parameters 
compared in subsets of moles vs normal pregnancy, complete vs partial moles, and in moles 
without vs with persistent trophoblastic disease (PTD) (first column represents number of 
controls in A, B and C and number of patients in D and E).
Parameter Controls/ mMoM S.E. Patients (n) mMoM S.E. P value
Patients (n)
A Normal pregnancies vs all molar pregnancies
hCGα 27 0.999 0.343 136 0.804 0.765 NS
hCGβ 27 1.016 0.417 135 6.466 4.030 <0.001
hCG + hCGβ 27 1.001 0.137 204 2.430 1.265 <0.001
hCGα/hCG + hCGβ 27 0.997 0.254 136 0.449 0.295 <0.001
hCGβ/hCG + hCGβ 27 1.009 0.323 135 2.883 1.624 <0.001
hCGα/hCGβ 27 0.997 0.131 132 0.524 0.168 <0.001
B Normal pregnancies vs complete molar pregnancies
hCGα 27 0.999 0.343 108 0.833 0.667 NS
hCGβ 27 1.016 0.417 109 7.145 4.010 <0.001
hCG + hCGβ 27 1.001 0.137 165 2.586 1.205 <0.001
hCGα/hCG + hCGβ 27 0.997 0.254 108 0.414 0.264 <0.001
hCGβ/hCG + hCGβ 27 1.009 0.323 109 2.991 1.745 <0.001
hCGα/hCGβ 27 0.993 0.131 106 0.498 0.156 <0.001
C Normal pregnancies vs partial molar pregnancies
hCGα 27 0.999 0.343 28 0.689 1.071 NS
hCGβ 27 1.016 0.417 26 3.618 2.670 <0.001
hCG + hCGβ 27 1.001 0.137 39 1.769 1.315 NS
hCGα/hCG + hCGβ 27 0.997 0.254 28 0.583 0.368 <0.001
hCGβ/hCG + hCGβ 27 1.009 0.323 26 2.431 0.848 <0.001
hCGα/hCGβ 27 0.993 0.131 26 0.632 0.174 <0.001
D Complete mole pregnancies vs partial molar pregnancies
hCGα 108 0.833 0.667 28 0.689 1.071 NS
hCGβ 109 7.145 4.010 26 3.618 2.670 <0.001
hCG + hCGβ 165 2.586 1.205 39 1.769 1.315 <0.001
hCGα/hCG + hCGβ 108 0.414 0.268 28 0.583 0.368 0.036
hCGβ/hCG + hCGβ 109 2.991 1.745 26 2.431 0.848 NS
hCGα/hCGβ 106 0.498 0.156 26 0.632 0.174 <0.001
E Complete and partial moles without PTD vs complete and partial moles with PTD
hCGα 101 0.717 0.817 35 1.052 0.526 0.003
hCGβ 100 5.807 3.873 35 8.349 3.924 0.001
hCG + hCGβ 161 2.284 1.277 43 2.977 1.067 <0.001
hCGα/hCG + hCGβ 101 0.467 0.311 35 0.395 0.238 NS
hCGβ/hCG + hCGβ 100 2.917 1.819 35 2.787 0.866 NS
hCGα/hCGβ 99 0.534 0.168 33 0.493 0.164 NS
* mMoM and S.E. represent the natural logarithmic values of mMoM and S.E. in case of hCGα
and hCGα/hCGβ, while with all other analytes and parameters mMoM and S.E. apply to square
root mMoM and S.E. values.
NS, not significant.
Comparison of serum hCG parameters in groups of hydatidiform molar 
pregnancy
The comparison between the complete and the partial molar pregnan-
cies (Table 1D) showed that the mMoMs of both hCGα and the ratio of
hCGβ/hCG + hCGβ were not different, whereas the mMoMs for hCGβ
and hCG + hCGβ in the partial moles were significantly lower than in
the complete molar pregnancies (p<0.001). In contrast to this, the
mMoM of the ratios of hCGα/hCG + hCGβ and hCGα/hCGβ in par-
tial moles were significantly higher than those of complete molar preg-
nancy (Table 1D). In the case of all molar pregnancies with PTD as com-
pared with all molar pregnancies without PTD, the three calculated
ratios (hCGα/hCG + hCGβ, hCGβ/hCG + hCGβ and hCGα/hCGβ)
were not significantly different, whereas the mMoM of all measured
hCG analytes (hCGα, hCGβ and hCG + hCGβ) were significantly high-
er in those cases where women developed PTD as compared to those
who did not (Table 1E).
Diagnostic accuracy
We established diagnostic accuracy by calculating specificity and sensi-
tivity for the comparisons already presented in Table 1. Based on these
data we constructed the corresponding ROC curves for each of the three
hCG analytes determined in blood specimens collected prior to evacua-
tion as well as for the three ratios derived from these measurements (Fig.
2). We then calculated the corresponding AUCs for the six hCG analytes
and parameters (Table 2). The ROC curves of all molar pregnancies (Fig.
2A) vs normal pregnancy show AUCs ranging between 0.856 and 0.987
for all hCG analytes and parameters except for hCGα whose AUC was
0.618. hCGα/hCGβ, hCGβ/hCG + hCGβ and hCGβ showed sensitivi-
ties of, respectively, 79%, 93%, and 95%, all at 100% specificity. We also
found that hCG + hCGβ and hCGα/hCG + hCGβ displayed sensitivi-
ties of 82% and 85% at 90% specificity.
In the case of hCG + hCGβ and hCGα/hCG + hCGβ the subset of
complete moles (Table 2B, Fig. 2B) revealed higher AUCs (0.911 and
0.932) and the subset of partial moles revealed lower AUCs (0.621 and
0.788) (Table 2C, Fig. 2C) as compared with all molar pregnancies vs nor-
mal pregnancy (AUCs of 0.856 and 0.902) (Table 2A, Fig. 2A). Both in
complete and partial hydatidiform mole, hCGβ, hCGβ/hCG + hCGβ
and hCGα/hCGβ were excellent diagnostic tests with AUCs ranging
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Figure 2. ROC analysis for six hCG analytes and parameters compared in all moles (A)
and in subsets of moles (B, C) versus normal pregnancy, and compared in complete ver-
sus partial moles (D) and in all moles with PTD versus all moles without PTD (E).
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Table 2. Area under the curve (AUC) for six hCG analytes and parameters compared in sub-
sets of moles vs normal pregnancy, in subsets of complete vs partial moles, and in moles 
without vs with persistent trophoblastic disease (PTD) (first column represents number of 
controls in A, B and C, number of patients with complete moles in D and number of patients 
without PTD in E; second column represents number of patients in A, B and C, number of 
patients with partial moles in D and number of patients with PTD in E).
Parameter Controls/Complete/ Patients/Partial/ AUC 95% Confidence
No PTD (n) PTD (n) Interval
A Normal pregnancy vs all moles
hCGα 27 136 0.618 * 0.524-0.713
hCGβ 27 135 0.984 0.968-0.999
hCG + hCGβ 27 204 0.856 0.809-0.902
hCGα/hCG + hCGβ 27 136 0.902 * 0.856-0.948
hCGβ/hCG + hCGβ 27 135 0.985 0.968-1.00
hCGα/hCGβ 27 132 0.987 * 0.973-1.00
B Normal pregnancies vs complete moles
hCGα 27 108 0.614 * 0.513-0.715
hCGβ 27 109 0.999 0.996-1.00
hCG + hCGβ 27 165 0.911 0.870-0.952
hCGα/hCG + hCGβ 27 108 0.932 * 0.890-0.973
hCGβ/hCG + hCGβ 27 109 0.994 0.985-1.00
hCGα/hCGβ 27 106 0.994 * 0.985-1.00
C Normal pregnancies vs partial moles
hCGα 27 28 0.634 * 0.481-0.788
hCGβ 27 26 0.922 0.848-0.995
hCG + hCGβ 27 39 0.621 0.474-0.768
hCGα/hCG + hCGβ 27 28 0.788 * 0.662-0.914
hCGβ/hCG + hCGβ 27 26 0.947 0.871-1.00
hCGα/hCGβ 27 26 0.962 * 0.917-1.00
D Complete vs partial moles
hCGα 108 28 0.549 * 0.413-0.686
hCGβ 109 26 0.797 * 0.703-0.891
hCG+hCGβ 165 39 0.719 * 0.621-0.816
hCGα/hCG + hCGβ 108 28 0.629 0.504-0.754
hCGβ/hCG + hCGβ 109 26 0.602 * 0.477-0.726
hCGα/hCGβ 106 26 0.730 0.610-0.850
E All moles without vs with PTD
hCGα 101 35 0.666 0.569-0.764
hCGβ 100 35 0.698 0.595-0.801
hCG + hCGβ 161 43 0.688 0.605-0.772
hCGα/hCG + hCGβ 101 35 0.568 * 0.461-0.675
hCGβ/hCG + hCGβ 100 35 0.520 0.411-0.630
hCGα/hCGβ 99 33 0.591 0.478-0.704
* reversal of study and control groups reveals AUC>0.5.
between 0.922 and 0.999 to distinguish these subsets from normal preg-
nancy (Table 2B,C, Fig. 2B,C). In the comparison of complete vs partial
moles, five out of six hCG analytes and parameters tested (i.e. hCGβ,
hCG + hCGβ, hCGα/hCG + hCGβ, hCGβ/hCG + hCGβ and
hCGα/hCGβ) showed AUCs ranging between 0.602 and 0.797, while
hCGα showed an AUC of 0.549 (Table 2D, Fig. 2D). In the comparison
of moles without or with PTD, hCGα, hCGβ, hCG + hCGβ and
hCGα/hCGβ showed AUCs ranging between 0.591 and 0.698, whereas
the other two parameters revealed even lower AUCs (hCGβ/hCG +
hCGβ: 0.520, and hCGα/hCG + hCGβ: 0.568) (Table 2E, Fig. 2E).
Discussion
The aim of our retrospective study was to explore the significance of six
hCG analytes and parameters to distinguish hydatidiform mole from
normal pregnancy, to distinguish complete from partial mole, and to
assess whether any of these analytes and parameters is able to predict
PTD. Specificity and sensitivity of all six hCG analytes and parameters
in the various subsets of patient groups were explored in ROC curve
analysis and the various AUCs thereof were compared for diagnostic
accuracy. To distinguish hydatidiform molar from normal pregnancy,
hCGβ, hCGβ/hCG + hCGβ and hCGα/hCGβ proved to be excellent
diagnostic tests with AUCs>0.9 in the all moles group as well as in its
mole subsets. The comparison of the group of all moles vs normal preg-
nancy showed AUCs of 0.856 with hCG + hCGβ and 0.902 for the ratio
hCGα/hCG + hCGβ. The diagnostic accuracy of free hCGα was less
with AUCs of 0.6 in case of all the comparisons of moles with normal
pregnancy. To distinguish complete from partial moles, five out of the six
analytes and parameters tested (i.e. hCGβ, hCG + hCGβ, hCGα/hCG +
hCGβ, hCGβ/hCG + hCGβ and hCGα/hCGβ) were found to have
AUCs in the range of 0.6 to 0.8, whereas hCGα showed even a lower
AUC of 0.549. To predict PTD after evacuation of a hydatidiform mole,
we found hCGα, hCGβ, hCG + hCGβ and hCGα/hCGβ having AUCs
in the range of 0.6 to 0.7. The other two parameters proved to have even
lower AUCS ((between 0.5 and 0.6). Our finding that the values of
hCGβ, hCG + hCGβ, and the ratio of hCGβ/hCG + hCGβ in blood
withdrawn prior to evacuation are significantly higher, and the ratios of
hCGα/hCG + hCGβ and hCGα/hCGβ are significantly lower in
patients with hydatidiform mole as compared with normal pregnancy is
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in accordance with an earlier report which included only 5 patients with a
hydatidiform mole (15). Other studies, with limited numbers of patients
with hydatidiform mole, also showed that hCGβ concentration (17) and
the ratio hCGβ/hCG + hCGβ (17,19) were significantly higher while
hCGα concentrations were not different in hydatidiform mole (17).
Berkowitz et al. (14) reported significantly higher concentrations of
hCGα, hCGβ, percentage hCGα and percentage hCGβ (i.e. the free
subunit to total subunit ratios), and no effect on the hCGβ/hCGα ratio
in partial moles (n=8) compared with normal pregnancy. Our data on
hCGα/hCG + hCGβ and hCGα/hCGβ ratios are not in line with that
study as we found a significant decrease in these levels. Interestingly, in
the case of the complete mole subgroup comprising more patients
(n=20), the same authors reported significantly lower levels of hCGα to
intact hCG ratio and significantly higher concentrations of the
hCGβ/hCGα which is in line with our data. It has to be noted that
Berkowitz et al. (14) used intact hCG to calculate the ratios of free α and
free β to hCG, whereas we measured total hCG immunoreactivity,
which included intact hCG as well as free hCG β-subunit. Evidently, the
marked increased free hCGβ concentrations in molar pregnancy will
affect this ratio for which no correction could be made in the hCG +
hCGβ assay because of the very different affinities of the polyclonal anti-
serum towards the free hCG β-subunit and the hCGβ as a part of the
holo-hCG molecule. Very specific assays for all forms of hCGβ have
been described (28). The use of a specific, more generally used, holo-
hCG assay would have yielded different ratios. Nevertheless, we have
used a hCG + hCGβ assay because it is superior in the diagnosis of tro-
phoblastic tumors. To our knowledge the present study is the first to
evaluate the diagnostic accuracy of the 6 hCG analytes and parameters
in a substantial number of samples, showing that hCGβ, hCGβ/hCG +
hCGβ and hCGα/hCGβ are excellent diagnostic tests as indicated by
AUCs above 0.9 to distinguish partial and complete hydatidiform molar
from normal pregnancy. The sensitivities of these three diagnostic tests
to distinguish hydatidiform molar molar pregnancy from normal preg-
nancy were, respectively, 95%, 93%, and 79%, all at 100% specificity,
while we found sensitivities of 82% and 85% at 90% specificity with hCG
+ hCGβ and hCGα/hCG + hCGβ.
We found significantly lower mMoMs of hCGβ and hCG + hCGβ
and significantly higher hCGα/hCG + hCGβ and hCGα/hCGβ ratios
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in partial moles as compared with complete moles. hCGα and
hCGβ/hCG + hCGβ were not different in this comparison. Irrespective
of the presence or absence of statistical significance, none of these six
analytes or parameters proved to have meaningful AUCs (range: 0.549-
0.797). In a smaller study comprising 20 complete moles and 8 partial
moles, Berkowitz et al. (14) reported similar results for hCGα, hCGβ
and hCGα/hCGβ. These investigators found no significant difference in
intact hCG concentrations when distinguishing partial from complete
moles. Why hCGβ is synthesized more abundantly in complete hydatid-
iform mole than in partial moles or in normal pregnancy is unknown.
hCG is synthesized in cytotrophoblasts and more abundantly in syncy-
tiotrophoblasts (29,30). Messenger-RNA for hCGα is encoded by a sin-
gle gene on chromosome 6 (31), whereas the β-subunit of hCG is encod-
ed by four genes - hCGβ-3, -5, -7, and –8 - located on chromosome
19q13.3 (31,32). hCG α- and β-subunits are thus synthesized separately,
and their production is regulated independently during pregnancy and in
trophoblastic disease (33,34). Berkowitz et al. (14) suggested that the per-
centage free hCGβ level might reflect the level of differentiation and
hyperplasia of the trophoblast, since the level of free hCGβ increases up
to 0.5% at five weeks of normal gestation, to 1% in partial hydatidiform
mole, to 2.4% in complete hydatidiform mole, and as high as 9.2% in
choriocarcinoma. Indeed, Hay (16) proposed a regulatory mechanism to
link irregularities in trophoblastic differentiation to altered biosynthesis
of hCG. In proliferating syncytium formed by differentiating cytotro-
phoblasts, amplification of hCG genes results in excess mRNA for hCG
β-subunits. All free hCGα will be used to produce hCG and the remain-
ing hCGβ will be released together with intact hCG. In the same way, it
is feasible to think that in partial mole, which contains both normal tro-
phoblast and hyperplastic trophoblasts, less free hCGβ is synthesized as
compared to complete moles.
Identifying patients with increased risk for developing PTD after
evacuation of hydatidiform mole is of great interest. Approximately 20%
of patients with a complete hydatidiform mole will suffer from PTD that
requires chemotherapy treatment. Prophylactic chemotherapy reduces
the incidence of PTD to 4 - 12% (10,11). Optimism about prophylactic
chemotherapy is tempered by a prospective randomized controlled trial
by Kim et al. (35) who found that prophylactic chemotherapy indeed
reduced the incidence of PTD in high risk patients (from 31% to 10%), but
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these patients needed more courses of chemotherapy (mean 2.5 ± 0.5
(S.E.) vs 1.4 ± 0.5 courses, p<0.005), suggesting that prophylactic thera-
py increases tumor resistance and morbidity by selection and prolifera-
tion of cells that are resistant to the effect of chemotherapy. To prevent
unnecessary treatment as well as resistance to chemotherapy, it is chal-
lenging to find out an adequate diagnostic modality that identifies
patients at increased risk for developing PTD. We found that serum con-
centrations of hCGα, hCGβ, and hCG + hCGβ were significantly high-
er in patients with PTD as compared with those in which spontaneous
regression after evacuation occurred. These hCG analytes showed only
moderate diagnostic accuracy (with AUCs in the range of 0.6 to 0.7)
indicating a limited clinical relevance of the observed differences in hCG
concentrations between these groups. None of the calculated ratios were
significantly different and consequently all had a poor diagnostic accura-
cy to predict PTD. In contrast to our data, a number of studies, all with
limited patient samples, reported that the hCGβ/total hCG ratio is a pre-
dictor of PTD (18-20). These studies included patients with unspecified
hydatidiform (18,19) or complete (20) hydatidiform moles. Berkowitz et
al. (14) reported that none of the evaluated hCG parameters, equal to
those in our study, were associated with the development of PTD. Our
study showed that hCGα, hCGβ, hCG + hCGβ and the ratio
hCGα/hCGβ with AUCs in the range of 0.6 to 0.7 are of less value in the
prediction of PTD, and it is unlikely that a clinician will start prophylactic
chemotherapy on the basis of the results obtained with these tests.
Therefore, new modalities should be explored to find a reliable predictor
for PTD. Amongst these is the serum concentration of hCG β-core frag-
ment which was found to be rising prior to intact hCG in patients with
hydatidiform mole who developed PTD as compared with patients with
hydatidiform mole with remission of hCG after mole evacuation (hyda-
tidiform mole, n=14 of which 4 patients had PTD) (36). Another poten-
tially interesting parameter is hyperglycosylated hCG which was found
to rise from 25% to 80% of total serum hCG when patients with persis-
tent low levels of hCG developed gestational trophoblastic neoplasm
(37). The clinical value of this test in predicting PTD after hydatidiform
mole remains to be elucidated.
In summary, our study based on a large patient sample showed that
hCGβ in serum, and the ratios of hCGβ/hCG + hCGβ and hCGα/
hCGβ are excellent diagnostic tests and parameters to make the distinc-
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tion biochemically between hydatidiform mole and normal pregnancy at
the 100% specificity level with more than 90% sensitivity. For practical
use, the hCGβ assay is recommended. The distinction between com-
plete and partial hydatidiform mole cannot reliably be made with any of
the tested analytes or parameters because diagnostic accuracy of these
tests is at best qualified as moderately applicable. Finally, we found that
although hCGα, hCGβ and hCG + hCGβ concentrations are signifi-
cantly elevated in the case of PTD, none of the six investigated hCG para-
meters had adequate diagnostic accuracy to permit the clinician to advise
patients to undertake prophylactic chemotherapy after evacuation of a
hydatidiform mole. 
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Abstract
Objective: To assess the diagnostic potential of serum hCG concentration
ratios obtained at different intervals after evacuation of hydatidiform
mole to diagnose Persistent Trophoblastic Disease (PTD) and to com-
pare its diagnostic accuracy with the current FIGO 2000 criteria for
PTD.
Methods: A retrospective cohort study was performed on patients registered
with the Dutch Central Registry for Hydatidiform Moles between 1977-
2004. After exclusion for various reasons, serum hCG concentrations
were available in 204 cases (86 with and 118 without PTD). hCG concen-
trations after evacuation were used for calculation of hCG ratios. ROC
curve analysis was performed to calculate specificity, sensitivity and
Areas Under Curves (AUCs).
Results: hCG ratios showed an increasing diagnostic potential. The hCG
ratio obtained in week 1 and 5 after evacuation showed AUCs of 0.568
and 0.935, respectively, and identified 20% and 79% of patients with PTD
at the 95% specificity level. The median time to diagnose PTD with the
use of a hCG ratio was 3.0 weeks versus 4.7 weeks if FIGO 2000 criteria
were applied.
Conclusions: A ratio of two serum hCG concentrations obtained after evacu-
ation of the mole identifies patients with PTD approximately 2 weeks
earlier than the internationally accepted FIGO 2000 criteria. This ratio
makes it possible to identify more than 75% of patients who develop PTD
by the fifth week after evacuation. The hCG ratio calculated from two
post molar serum hCG concentrations provides a new quantitative mea-
sure which substantially improves the qualitative FIGO 2000 ‘increase’
and ‘plateau’ criteria.
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Introduction
A variety of pathologic subtypes of trophoblastic neoplasms are included
in gestational trophoblastic disease, comprising villous malformations,
hydatidiform mole -subdivided in complete and partial hydatidiform
mole-, and nonvillous malformations of which choriocarcinoma is the
most frequent (1). In Persistent Trophoblastic Disease (PTD), tro-
phoblastic activity remains after evacuation of a hydatidiform mole as
shown by subsequent unaltered high or even increasing serum hCG con-
centrations. The reported frequency of PTD is 20% in complete hydatid-
iform mole (2) and 0.5% to 9.9% in partial hydatidiform mole (3-6). The
International Federation of Gynaecology and Obstetrics (FIGO) defines
PTD as a plateau in serum hCG for three weeks, or a increase for two
consecutive weeks (7). To a plateau or increase for 3 weeks the Dutch
Society for Obstetrics and Gynaecology added to their definition for
PTD the condition that at least one serum hCG measurement should
exceed the 95th percentile (P95) of a normal hCG regression curve after
hydatidiform mole (8-10) since utilization of a normal hCG regression
corridor prevents over-treatment (9,11). Although several authors
described normal serum hCG regression corridors after uneventful
regression (9,11-14), it is not feasible to construct a normogram for every
hCG assay procedure. Thus, such a normogram is not available to every
physician who is involved in the follow-up of a patient with hydatidiform
mole.
Our hypothesis is that there is a substantial difference in the calculated
ratio from two serum hCG concentrations obtained after evacuation of
a mole in patients with PTD versus the ratio in patients without PTD. In
order to generate a more quantitative criterion for diagnosing PTD
instead of the qualitative concepts of ‘increase’ and ‘plateau’ which are
incorporated in the FIGO 2000 definition, the aim of the present study
was to assess the ability of serum hCG ratios obtained after evacuation
of the mole to distinguish patients who will develop PTD from those
patients who will not.
Materials and Methods
Patients
Between 1977 and 2004, 2872 patients were registered with the Dutch
Central Registry for Hydatidiform Moles. After informed consent,
patients are registered through their referring clinician. In the Nether-
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lands, after a histological diagnosis of mola hydatidosa or choriocarcino-
ma, PTD is diagnosed by means of a serum hCG plateau or increase for
three consecutive weekly measurements, with at least one measurement
exceeding the 95th percentile of an hCG regression curve established for
uneventful postmolar regression (9). We evaluated all patients’ data in
our database and included all patients with available serum hCG data
obtained after evacuation of the mole and assayed in our institution. In
retrospect we classified the hCG regression according to the FIGO 2000
guideline (7) (i.e., mola hydatidosa with serum hCG plateauing for three
consecutive weeks or increase for two consecutive weekly measure-
ments) and confined all the patients with proven PTD and according to
these criteria to the study group (n=86, 84 of which were treated with
chemotherapy or a hysterectomy and two were cured by a second curet-
tage only). Those with spontaneous regression of serum hCG after evac-
uation of the mole according to FIGO 2000 criteria were assigned to the
control group (n=118). Additionally, to be included in the evaluation, the
first hCG measurement should have been performed in a serum speci-
men taken within the first two weeks after evacuation of the mole. Rea-
sons for exclusion were (a) the histological diagnosis of choriocarcinoma
for which chemotherapy was initiated without awaiting a plateau or
increase in post molar serum hCG concentrations, or (b) persistence of
low hCG serum levels around 10 ng/mL after spontaneous regression.
For each patient in the study group we scored the week that PTD was
diagnosed according to FIGO 2000 criteria. The week in which therapy
for PTD was started was scored as well and data were censored from that
time point onwards.
Immunoassays
A privately developed (“in-house”) radioimmunoassay (RIA) that mea-
sured ‘total’ hCG (i.e., intact hCG and free β-subunit, hCG + hCGβ) was
used exclusively in the authors’ laboratory (15). Thus, this assay has been
utilized centrally for all measurements in sera sent to the Dutch Central
Registry for Hydatidiform Moles and was used in the development of a
normal hCG regression corridor for uneventful hydatidiform mole (9).
The RIA was calibrated with the third International Standard for intact
hCG (WHO third IS hCG 75/537 obtained from the National Institute
for Biological Standards, Potters Bar, UK). The measuring range for the
standard line of the assay was 1-80 µg/L (0.027-2.14 nmol/L, equivalent
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to 9.29-743 IU/L of the WHO third IS hCG 75/537)(15). The hCG +
hCGβ-RIA cross-reacts 100% on a mol/mol basis with intact hCG and
1000% with hCG β-subunit. Serum hCG concentrations were consid-
ered to be normalized if below 2 µg/L (0.053 nmol/L or 18.6 IU/L of the
WHO third IS hCG 75/537). The within- and between-assay coefficients
of variation (CVw, CVb) for means of duplicate measurements were at a
level of 10 µg/L (equivalent to 0.267 nmol/L or 93 IU/L) 7.5% and 10.3%,
respectively, and at a level of 56 µg/L (equivalent to 1.50 nmol/L or 520
IU/L), 7.3% and 12%.
Statistics
For each patient we calculated the ratio of the hCG concentrations
obtained in weeks 1 through 11 after evacuation. The hCG ratio of week 1
after evacuation was calculated by dividing the first by the second avail-
able hCG concentration taken in week 1. In week 2, the hCG ratio was
calculated by dividing the first available hCG concentration of weeks 1 or
2 by the hCG concentration of a specimen taken in week 2. From week 3
onwards until week 11, the hCG ratios were calculated by dividing the
first available hCG concentration of a specimen taken within the first
two weeks by the hCG concentration of a specimen taken in that particu-
lar week (these hCG ratios were designated hCG ratio week 1, 2, ..,11). In
the study group, the hCG ratios were excluded from analysis onwards
from the week that the curative therapy (chemotherapy, hysterectomy or
a curative second curettage) was initiated or performed. The accuracy to
diagnose PTD as derived from the calculated hCG ratios week 1 through
11 was investigated by Receiver Operating Characteristic (ROC) curve
analysis of the hCG ratios per week and resulted in calculations of
AUCs. Because the FIGO 2000 criteria to diagnose PTD are not suitable
for ROC curve analysis, we compared for each week the number of
patients identified by FIGO 2000 criteria as having PTD with those iden-
tified by hCG ratios per week. To make a direct comparison between the
diagnostic accuracy of either identification procedure, we calculated the
cumulative percent rate of identified patients with PTD as a function of
the week after evacuation of the mole. All statistical analyses were per-
formed using the SPSS statistical software package version 12.0.1 (SPSS
Inc., Chicago, Il, USA).
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Results
Table 1 depicts the ROC curve analyses of all available hCG ratios of
weeks 1 through 11 for the study and control group. For each week
analysed, the number of patients included in the PTD group ranged from
15 to 71 and in the control group from 33 to 89 patients. The AUC of the
hCG ratio was 0.568 in week 1 and increased steadily to a plateau ≥ 0.9 by
week 5. The calculated sensitivities at 95% specificity increased from
20% in week 1 to 79% in week 5 and declined to 48-52% in weeks 10-11.
The cut-off values represent the hCG ratios below which PTD can be
diagnosed with 95% specificity in a given week after evacuation. Figure 1
shows hCG ratios of weeks 1, 5 and 10. The study group fulfilled the crite-
ria for the diagnosis PTD at a median time point of 4.7 weeks when using
FIGO 2000 criteria. The median time point to diagnose PTD by using
the hCG ratio was 3.0 weeks.
In Table 2 we show at weekly intervals the proportion of patients with
a diagnosis of PTD (i.e., the study group) as identified with FIGO 2000
criteria as well as with the hCG ratio. In this cross-sectional analysis we
scored the number of patients that were identified with either test as hav-
ing PTD and expressed these as a proportion of the total number of PTD
patients with an hCG ratio in that week. FIGO 2000 criteria identified
zero out of 15 (0%) patients in week 1, while the hCG ratio of week 1
detected 3 patients (20%) to have PTD. In week 3 the FIGO 2000 criteria
identified 11 (16%) and the hCG ratio 35 patients (52%) out of 67 patients
with PTD. In week 7 FIGO 2000 criteria identified 70% (30/43) and the
hCG ratio 32 patients (74%) out of 43 patients with PTD. Afterwards, the
diagnostic ability of FIGO 2000 criteria increased steadily up to 89% in
week 11, whereas the hCG ratios detected 48-63% of PTD patients in
weeks 10-11 after evacuation of the mole.
Figure 2 depicts the cumulative number of patients with PTD once
identified by FIGO 2000 criteria, and by the hCG ratio of the corre-
sponding week. Out of the 86 patients with PTD, FIGO 2000 criteria
cumulatively identified zero patients in week 1 and 12 patient in week 3
(14%) to reach 60% by week 5, and more than 90% in weeks 10-11 after
evacuation. The hCG ratios of week 1 already identified 3.5% (3 cases) of
the patients with PTD and up to 51% in week 3 (44 cases). The maximum
cumulative detection rate (83%) of hCG ratio was reached in week 8.
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Table 1. ROC curve analysis of available hCG ratios per week
Number of patients Area 95-% Sensitivity hCG
Persistent under Standard confidence at 95% ratio
trophoblastic disease curve error interval specificity cut-off
Week absent present
1 33 15 0.568 0.090 0.391-0.744 20 1.0
2 67 44 0.740 0.047 0.647-0.833 34 2.7
3 87 67 0.826 0.033 0.761-0.892 52 2.8
4 89 63 0.891 0.026 0.841-0.941 59 4.0
5 76 71 0.935 0.020 0.897-0.974 79 11
6 74 56 0.931 0.021 0.889-0.973 75 15
7 69 43 0.946 0.021 0.905-0.986 74 27
8 65 33 0.902 0.031 0.842-0.963 58 27
9 56 28 0.909 0.030 0.850-0.969 61 33
10 64 25 0.895 0.033 0.830-0.960 48 34
11 49 23 0.922 0.031 0.861-0.983 52 40
Table 2. Comparison of number of patients identified by FIGO 2000 criteria and hCG ratios
per week as having PTD
Time after No. of PTD patients Positive scoring rates for
evacuation with hCG ratio FIGO 2000 criteria hCG ratio
Week available No. of patients % No. of patients %
1 15 0 0 3 20
2 44 1 2.3 15 34
3 67 11 16 35 52
4 63 24 38 37 59
5 71 47 66 56 79
6 56 37 66 42 75
7 43 30 70 32 74
8 33 24 73 19 58
9 28 20 71 17 61
10 25 20 80 12 48
11 23 17 89 12 52
Discussion
The aim of our retrospective study was to explore the value of serum
hCG concentration ratios to distinguish patients who will develop PTD
from patients who will have spontaneous regression of serum hCG after
evacuation of a hydatidiform mole and to compare the diagnostic poten-
tial of these hCG ratios with the current ‘gold standard’: PTD as diag-
nosed according to criteria provided by FIGO 2000. Specificity and sen-
sitivity of ratios obtained from hCG measurements after evacuation
74
chapter 3
A
C
B
1-specificity
se
n
si
ti
vi
ty
se
n
si
ti
vi
ty
se
n
si
ti
vi
ty
1-specificity
1-specificity
Figure 1. Examples of the ROC curves for study (PTD+) versus control group (PTD-):
A) hCG ratio week 1;  B) hCG ratio week 5;  C) hCG ratio week 10
were explored in ROC curve analysis and the various AUCs thereof were
compared for diagnostic accuracy. The hCG ratios obtained in week 1
through week 11 displayed an increasing diagnostic potential from week 1
onwards until a plateau was reached in week 5 after evacuation. For each
week after evacuation a cut-off value for this ratio was calculated, below
which PTD can be diagnosed at 95% specificity. The AUC of the hCG
ratios increased from 0.568 in week 1 to 0.935 in week 5 and stabilized at
AUCs of ≥0.9 afterwards. The hCG ratio and FIGO 2000 criteria identi-
fied 52% and only 16%, respectively, of patients to have PTD in week 3
after evacuation. In week 7 both the hCG ratio and the FIGO 2000 crite-
ria identified ≥ 70% of patients with PTD.
To our knowledge no studies have been performed on the potential of
hCG ratios in the diagnosis of PTD. In this study we analyzed at which
time point after evacuation the criteria for PTD were met according to
the internationally accepted FIGO 2000 criteria. We found that the
median time to reach the diagnosis of PTD in the study group was 4.7
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Figure 2. The cumulative distribution of patients with PTD (n=86) as identified on a
weekly basis by FIGO 2000 criteria (black bars) and the hCG ratio of the corresponding
week (open bars).
weeks when using FIGO 2000 criteria for PTD whereas the median time
to diagnose PTD by using the hCG ratio was 3.0 weeks. Thus, the hCG
ratio identified patients earlier than FIGO 2000 criteria.
The qualitative terms ‘increase’ and ‘plateau’ in serum hCG to con-
firm or reject the diagnosis PTD after evacuation of a hydatidiform mole
according to the FIGO criteria may be subject to inter- and intra observer
bias. To add a quantitative measure to the diagnosis of PTD, several nor-
mograms for spontaneous regression of serum hCG have been devel-
oped (9,11-14). The use of these normograms has been advocated since
their use may be an aid to prevent over-treatment of patients (9,11), but
bears the disadvantage that each individual hCG assay requires the con-
struction of its own specific normogram. Another qualitative, though
arbitrary addition to the definition of the FIGO 2000 criteria for PTD
was put forward by Kohorn who proposed to define an ‘increase’ of hCG
as an increase in terms of 10% or more for three values or more over a
period of at least 2 weeks (16). However, up till now no universal agree-
ment has been reached on this proposal (17). We now provide quantita-
tive data, that is, hCG ratios calculated from already available serum
hCG concentrations, that improve the accuracy for diagnosis of PTD. It
remains to be investigated in a prospective setting whether combining
these hCG ratios with the FIGO 2000 criteria improves the accuracy for
diagnosis of PTD.
It is still unclear why some hydatidiform moles develop into PTD
while others show a spontaneous regression. It is not very likely that
residual tissue after evacuation is the only cause to develop PTD. Nor-
mally, extra villous trophoblasts invades the myometrium up to one-
third of the entire uterine wall (18). With the commonly used suction
curettage for the evacuation of a hydatidiform mole, it is highly unlikely
that this molar tissue bearing the extra villous trophoblasts will be com-
pletely removed. The study by Lao et al. compared the ‘histology result’
(trophoblastic tissue or no trophoblastic tissue) of a routinely performed
second curettage in patients with a hydatidiform mole with the subse-
quent need for chemotherapy for PTD (19). The authors reported
absence of such a correlation, meaning that this result contradicts the
hypothesis that residual tissue after evacuation of a hydatidiform mole is
the entirely unique cause of PTD.
The search for genetic factors that can identify hydatidiform moles at
risk to develop into PTD is continuing (20). Recently, several cell growth
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regulating factors like MCL-1, EGFR, c-erbB-2 and c-erbB-3, c-ras, Nm-
23, p53, Cyclin E and telomerase (21-25) were found to have different
expression patterns in hydatidiform mole, which will develop PTD as
compared to hydatidiform mole with spontaneous regression of serum
hCG. This may lead to the development of new biochemical tools in the
future that will aid the diagnosis of patients who will develop PTD. At
present, no such tools are available.
In this retrospective study we found that the ratio of two serum hCG
measurements identified more than 50% of patients with PTD at the 95%
specificity level in week 3 after evacuation, whereas FIGO 2000 identi-
fied not more than 16% of patients with PTD at that week. With an hCG
ratio we were able to identify up to 79% of patients by week 5 after evacu-
ation at the 95% specificity level. These promising results justify that the
diagnostic utility of this hCG ratio in the context of the present FIGO
2000 criteria and applicability in the definition for PTD should be fur-
ther explored in a prospective study.
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Abstract
Background: After evacuation of hydatidiform mole, the spontaneous regres-
sion or the persistent trophoblastic disease (PTD) needing chemothera-
py is monitored by determination of serum human Chorionic
Gonadotropin (hCG) concentrations. Hyperglycosylated hCG (Inva-
sive Trophoblast Antigen, ITA) has been suggested to be of clinical value
in the diagnosis and follow-up of gestational trophoblastic disease
including PTD.
Methods: To further document the relationship between ITA and hCG in
spontaneous post-molar regression and during chemotherapy treatment
of PTD, we used distinct immunoassays to measure the concentrations
of hCG + hCGβ and ITA in serum from three groups of patients after
evacuation of moles. For each group (uneventful post molar hCG regres-
sion (group 1), PTD treated with Methotrexate (single-agent chemother-
apy, group 2), and PTD with MTX and multiagent chemo-therapy
(EMA-CO, group 3)), we compared the time course of the serum con-
centrations after evacuation, and determined the disappearance rates
(half-life) within and between treatment groups.
Results: Significantly longer mean serum half-lifes for hCG + hCGβ and ITA
were found in the multiagent-chemotherapy (Group 3: 3.02 and 2.51
weeks) as compared to the single-agent chemotherapy group (Group 2:
0.96 and 0.90 weeks) and the uneventful regression group (0.81 and 0.66
weeks) (all p=0.003), but no differences were observed between the sin-
gle-agent chemotherapy and the uneventful regression group. Signifi-
cantly shorter mean half-lifes for ITA than those calculated for hCG +
hCGβ were observed in all three groups of patients.
Conclusions: The implication and the possible clinical value of faster regres-
sion of ITA to baseline levels as compared to hCG + hCGβ remain to be
investigated prospectively.
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Introduction
The glycoprotein hormone human chorionic gonadotropin (hCG) is
produced by trophoblastic tissue and therefore is a key marker in preg-
nancy and gestational trophoblastic disease (GTD). The disappearance
of serum hCG concentrations is monitored by constructing a hCG
regression curve after mole evacuation (1). A treated molar pregnancy
may persist and may either lead to persistent trophoblastic disease
(PTD) or to development of choriocarcinoma. The reported frequency
of PTD is 15 to 20 % in complete hydatidiform mole (2), 4-9 % in partial
hydatidiform mole (3, 4), while choriocarcinoma occurs less frequently.
In order to prevent complications from metastatic disease, PTD and
choriocarcinoma need to be treated with chemotherapy. Once diagnosed
and classified, low-risk PTD is typically treated with single-agent therapy
(Methotrexate (MTX) or Actinomycin-D) (5, 6) while high-risk PTD is
most widely treated with combination therapy (EMA-CO: Etoposide,
MTX, Actinomycin-D, Cyclophosphamide and Vincristine) (5). PTD is
recognised by plateauing, or even increasing levels of hCG in three sub-
sequent weekly blood samples, with one or more hCG values above the
95th percentile of the hCG-regression curve (1). 
The glycoprotein hormone hCG (Mr 37,500) is composed of two non-
covalently bound subunits, α and β, with MW of 14,000 and 23,500,
respectively. The α-subunit of hCG is homologous with that of the het-
erodimeric pituitary glycoprotein hormones LH, FSH and TSH. The β-
chains distinguish these hormones from each other and they determine
the biological activity. Eight carbohydrate chains are attached to hCG
and comprise about one-third of the molecular mass of intact hCG: two
N-linked carbohydrate chains are attached to the hCG α-subunit, two
others to the hCG β-subunit, while four O-linked sugar side chains are
attached to hCGβ. Whereas normal and molar pregnancy show only
limited proportions of more complex triantennary N-linked oligosac-
charides (0 - 30 %) and larger hexasaccharide-type-O-linked carbohy-
drates (0 – 20 %), choriocarcinoma amounts up to 100 % of these larger
N- and O-linked oligosaccharides called hyperglycosylated hCG (7).
In normal pregnancy, hyperglycosylated hCG is gradually replaced by
hCG. Hyperglycosylated hCG (Mr 42,000) accounts for >80 % of total
hCG in the first week, to 50 % in the third week after implantation, while
in the third trimester it has diminished to 2 % (8). Kovalevskaya et al.
showed that hyperglycosylated hCG is produced in placental stem cells
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or cytotrophoblasts and that the less glycosylated hCG form is synthe-
sized mainly in syncytiotrophoblasts (9). Hyperglycosylated hCG is pro-
duced by invasive or cancerous trophoblast cells in choriocarcinoma.
This suggests that hyperglycosylated hCG is a product of separate tro-
phoblast cells and that it may be synthesized in invasive trophoblast cells,
the reason why hyperglycosylated hCG is also referred to as Invasive
Trophoblast Antigen (ITA) (8).
It has been suggested that ITA might be of clinical value in the diagno-
sis and follow up of GTD (10). In women with persistent low levels of
hCG following evacuation without signs of GTD, the proportions of
ITA account for less than 25 % of total hCG immuno-reactivity (11). ITA
was considered to be effective in detecting invasive trophoblastic disease
in patients with persistent low levels of hCG who experienced a sudden
steep rise in their serum hCG concentrations after years of persistent
low serum hCG concentrations because ITA then accounted for 81-100
% of the highly increased total hCG concentrations (11). However, it was
not explicitly stated that determination of ITA is able to exclude presence
of invasive trophoblastic disease in the reported cases with persistent
low levels of hCG without signs of PTD.
To further document the relationship between ITA and hCG in PTD,
we compared the time course and disappearance rate (half-life) in serum
of ITA with those of already available hCG + hCGβ data determined 
longitudinally in serum from three groups of patients following evacua-
tion of moles. These groups comprised uneventful post molar hCG
regression, management of PTD with MTX (single-agent chemothera-
py), and management of PTD with MTX and multiagent chemotherapy
(EMA-CO).
Material and Methods
Patients
All the patients participating in the present study gave, voluntary, their
informed consent before registration at the Dutch Central Registry for
Hydatidiform Moles residing at the Radboud University Nijmegen
Medical Centre (RUNMC). After collection, blood samples were
centrifuged and serum was sent to our institute where it was assayed for
“total” hCG and kept at -20 °C until further analysis. From this database,
we randomly selected 20 patients who were all registered between 2000
and 2002, and from whom longitudinally collected serum samples were
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available for ITA analysis. Of these 20 patients, 7 patients had a hydatidi-
form mole with uneventful hCG regression after evacuation, as derived
from the normal hCG regression curve (1). Thirteen patients with a
hydatidiform mole developed PTD after evacuation for which either sin-
gle-agent chemotherapy (with Methotrexate, MTX, n = 7), or single-
agent followed by multiagent chemotherapy (with EMA-CO, n = 6) was
indicated.
Immunoassays
The measurements of ‘total’ hCG (i.e., intact hCG and free β-subunit,
hCG + hCGβ) in serum were performed with a sensitive and specific
radioimmunoassay (RIA) that had been developed in our laboratory and
was described previously (12). The RIA used a polyclonal anti-rabbit
antiserum. A highly purified hCG β-subunit preparation labeled with
Iodine-125 (NaI125, Amersham plc, Amersham, England) was used as
tracer. The RIA was calibrated with the third International Standard
Preparations for intact hCG (WHO third IS hCG 75/537, obtained from
the National Institute for Biological Standards, Potters Bar, England).
The measuring range for the standard dose-response curve of the hCG +
hCGβ RIA was 0.027-2.14 nmol/L (equivalent to 9.29-743 IU/L). The
intra- and interassay coefficients of variation (CVw, CVb) for means of
duplicate measurements for two serum pools (mean: 0.267 nmol/L (93
IU/L) and 1.50 nmol/L (520 IU/L)) were 7.3 % and 12 %. The hCG +
hCGβ-RIA cross-reacted 100 % with intact hCG and 1000 % with
hCGβ. The 95th percentile of the reference interval of healthy control
pregnancies for the hCG + hCGβ assay was established at 0.053 nmol/L
(18.6 IU/L of the WHO third IS hCG 75/537) (12).
ITA was measured with the Nichols Advantage® Invasive Trophoblast
Antigen Assay (Nichols Institute Diagnostics, San Clemente, CA 92673,
USA) and the assay was performed according to the instructions provid-
ed by the manufacturer. The ITA assay is a two-step, two-site immuno-
chemiluminometric assay that uses two monoclonal antibodies. The
capture antibody (B152) is biotin labeled, while the second antibody
(B207) is labeled with acridinium ester and used for detection. The ana-
lytical sensitivity of the assay is <0.005 nmol/L (<0.2 µg/L). Cross reac-
tivity as documented by the supplier, is <1 % with recombinant hCG
(Sigma C6322), 5.4 % with nicked hCG, 4.5 % with non-nicked hCG, 1.5
% with nicked free βhCG, and 1.0 % with non-nicked free βhCG.
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Statistics
Both hCG + hCGβ and ITA concentrations were determined in the same
serum samples. Half-lifes for hCG + hCGβ and ITA were calculated for
each individual patient from linear regression analysis of log-trans-
formed concentrations against time. The first time-point preceding the
final phase of decreasing concentrations was taken as the starting point.
In the patients with persistent disease this coincided with the start of the
medication. Except for the first one encountered, values below the detec-
tion limits were excluded from calculation. Half-lifes were obtained for 7
patients with uneventful regression, and 13 patients with PTD, of which 7
patients received single-agent chemotherapy and 6 patients receiving
single-agent chemotherapy followed by multiagent chemotherapy. Half-
lifes of hCG + hCGβ and ITA were compared by paired t-test within the
three subgroups. Between the subgroups, the half-lifes of hCG + hCGβ
and ITA, respectively, were compared by the Kruskal-Wallis test (SPSS,
version 12.1).
Results
Table 1 shows characteristics of assay results and chemotherapy courses
of 7 patients with uneventful regression (Group 1), and of patients with
PTD treated either with MTX (Group 2, n=7) or with EMA-CO (Group
3, n=6). The total observation periods of the patients comprising groups
1, 2 and 3, respectively, ranged between 11 and 95, 13 and 93, and 38 and
129 weeks. During these follow-up periods, the total number of hCG +
hCGβ and ITA measurements ranged between 9-17 and 6-12 in Group 1,
between 9-23 and 6-10 for Group 2, and between 17-37 and 13-32 for
Group 3, respectively. Table 1 also shows that the observed maximum
concentrations of the two analytes tested increased in the order unevent-
ful regression (Group 1), single-agent (Group 2), multiagent chemother-
apy (Group 3). The maximum concentration observed for hCG + hCGβ
was 5.1 nmol/L in Group 1, 75 nmol/L in Group 2, and 590 nmol/L 
in Group 3. In case of ITA, these figures were 1.1 nmol/L in Group 1, 
45 nmol/L in Group 2, and 110 nmol/L in Group 3.
The number of MTX courses administered to the patients receiving
single-agent chemotherapy (Group 2) ranged between 3 and 9 courses
administered throughout postevacuation weeks 3 and 19. The 6 patients
comprising Group 3 received MTX courses ranging in number between
6 and 10 courses which were administered in the period of weeks 3 to 23
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Table 1. Treatment characteristics of patients after evacuation of molar pregnancy: 
Observation period, number of specimens tested (No.), concentration ranges of the 
compared two analytes, and number (n) and time period (start-end) of the chemotherapy
courses administered
Group/ Period, hCG+hCGβ, ITA Single-agent CT Multiagent CT 
Case weeks No. No. MTX, EMA-CO,
(min-max) n (start-end) n (start-end)
nmol/L weeks weeks
1/1 15 10 (<0.027 - 4.8) 9 (<0.005 - 0.95) none none
1/2 32 14 (<0.027 - 2.6) 6 (<0.005 - 0.81) none none
1/3 20 9 (<0.027 - 4.5) 7 (<0.005 - 1.1) none none
1/4 29 15 (<0.027 - 3.5) 12 (<0.005 - 0.33) none none
1/5 11 11 (<0.027 - 4.0) 11 (<0.005 - 0.60) none none
1/6 32 17 (<0.027 - 5.1) 11 (<0.005 - 0.39) none none
1/7 95 11 (<0.027 - 2.9) 6 (<0.005 - 0.93) none none
2/1 93 16 (<0.027 - 75) 10 (<0.005 - 15) 7 (5 - 16) none
2/2 66 23 (<0.027 - 75) 10 (<0.005 - 45) 8 (3 - 17) none
2/3 13 9 (<0.027 - 16) 7 (<0.005 - 1.9) 4 (6 - 11) none
2/4 59 18 (<0.027 - 4.3) 6 (<0.005 - 1.1) 6 (11 - 19) none
2/5 73 21 (<0.027 - 29) 9 (0.007 - 24) 9 (3 - 19) none
2/6 24 9 (<0.027 - 12) 8 (<0.005 - 1.4) 4 (4 - 12) none
2/7 68 17 (<0.027 - 6.7) 10 (0.006 - 1.4) 3 (12 - 18) none
3/1 129 37 (<0.027 - 290) 19 (<0.005 - 86) 7 (5 - 21) 4 (23 - 32)
3/2 38 22 (<0.027 - 43) 14 (<0.005 - 27) 6 (3 - 18) 5 (20 - 31)
3/3 61 17 (<0.027 -590) 16 (<0.005 -110) 10 (5 - 23) 1 (25)
3/4 41 34 (<0.027 - 250) 32 (<0.005 -110) 9 (4 - 19) 3 (24 - 29)
3/5 73 24 (<0.027 - 24) 13 (<0.005 - 13) 7 (6 - 19) 3 (21 - 34)
3/6 95 37 (<0.027 - 61) 20 (<0.005 - 31) 7 (3 - 16) 5 (20 - 27)
Group 1 Uneventful regression after evacuation of the molar pregnancy
Group 2 Persistent trophoblastic disease after evacuation of the molar pregnancy and 
treatment with single-agent chemotherapy (Methotrexate, MTX)
Group 3 Persistent trophoblastic disease after evacuation of the molar pregnancy and 
treatment with multiagent chemotherapy (EMA-CO) following MTX
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 Figure 1. Serum concentrations of hCG + hCGβ (solid line with ) and ITA (solid line
with ) after evacuation of molar pregnancy followed by spontaneous regression 
(panels A, B), or by persistent trophoblastic disease, treated either with single-agent
chemotherapy (Methotrexate, MTX) (panels C, D, ), or with MTX () followed by
multiagent chemotherapy (EMA-CO) (panels E, F, ).
The three solid lines (*) represent the 5th, 50th, and the 95th percentile of uneventful
regression of hCG + hCGβ.
The 95th percentile of the reference interval of healthy control pregnancies for the 
hCG + hCGβ assay (fat line) was established at 0.053 nmol/L (18.6 IU/L of the WHO
third IS hCG 75/537). Because the 95th percentile of the reference interval of healthy
control pregnancies for the ITA assay was not established, the analytical sensitivity of
the ITA assay (<0.005 nmol/L) is indicated (solid line).
Conversion factors used are: hCG + hCGβ: 1µg/L, equivalent to 9.29 IU/L, equivalent to
0.0267 nmol/L; ITA: 1µg/L, equivalent to 0.0238 nmol/L.
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Figure 2. 
A) Post molar regression of
hCG+hCGβ (bold line) and ITA
(thin line) in serum; spontaneous
regression (Group 1); 
B) PTD treated with MTX 
(Group 2); 
C) PTD treated with MTX and 
EMA-CO (Group 3).
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after evacuation of the molar pregnancy. Next to MTX treatment, Group
3 patients received multiagent chemotherapy in courses ranging between
1 and 5 that were administered in weeks 20 through 34 after evacuation of
their mole. Figure 1 depicts the time course of hCG + hCGβ and ITA
regression of two typical examples of each group studied.
Figure 2 depicts the mean time course of hCG + hCGβ and ITA con-
centrations as obtained for the three groups. The mean semi-logarithmic
regression lines for either analyte in case of uneventful regression
(Group 1) are given in Figure 2A, while those for the patients receiving
single-agent chemotherapy (Group 2), or single-agent chemotherapy fol-
lowed by multiagent chemotherapy (Group 3) are given in Figures 2B and
2C, respectively. Based on these data, we calculated the mean serum half-
lifes (disappearance rates) for the two analytes (Table 2). Significant 3- to
4-fold increases of mean serum half-lifes for either parameter was
observed in the group who received multiagent chemotherapy (Group 3)
as compared with Group 1 (uneventful regression, both p=0.003) or with
Group 2 (single- agent chemotherapy, both p=0.003). No significant dif-
ferences of mean serum half-life for either parameter were observed
between Group 1 and Group 2. Significantly shorter mean half-lifes for
ITA than those calculated for hCG + hCGβ were observed in the three
groups of patients. The ratios of ITA/hCG + hCGβ (given in mol/mol, %)
of Groups 1, 2 and 3 were 29.3, 28.2 and 35.4 mol/mol %, respectively, and
did not differ significantly between the three groups tested.
Discussion
The aim of the present study was to compare ITA with hCG + hCGβ
measurements in serum in the course of uneventful regression after
evacuation of hydatidiform mole as well as throughout the follow-up
period of single-agent, or single-agent and multiagent chemotherapy
treatment in cases where persistent trophoblastic disease occurred after
evacuation of the molar pregnancy. Disappearance rates of the two ana-
lytes were calculated for the three groups of patients and the resulting
half-lifes were compared between the three groups. The mean serum
half-lifes for the two parameters were significantly 3 to 4 times longer in
the group receiving single-agent and multiagent chemotherapy as com-
pared to the groups with either single-agent chemotherapy or uneventful
regression, while no significant differences were observed between the
group with single-agent chemotherapy and the one with uneventful
comparison of hcg + hcgβ and ita disappear ance r ates 
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regression. Significantly shorter mean half-lifes for ITA than those cal-
culated for hCG + hCGβ were observed in all three groups of patients.
Determination of disappearance rates of hCG + hCGβ and ITA
revealed that the half-life of hCG + hCGβ in the circulation was signifi-
cantly longer than that of ITA, irrespective of whether it regards
uneventful post molar regression, PTD treated with single-agent
chemotherapy, or PTD treated with single-agent followed by multiagent
chemotherapeutic agents. The longer half-life for hCG + hCGβ may be
due to the rather complex multi-exponential decay of intact hCG (medi-
an half-times between 3.6 - 53 h) and free hCG β-subunit (1 - 194 h) as
reported in serum of six women with term pregnancies throughout a
period of 21 days after delivery (13). Although the data are not fully com-
parable with those presented here for disappearance of hCG + hCGβ
during follow-up and treatment of PTD, these data indicate that pres-
ence of various molecular forms of hCG, all with different half-life
times, may affect the observed disappearance rates of total hCG
immuno-reactivity as measured with our hCG + hCGβ-RIA. Such data
on half-lifes of ITA are as yet not available.
The different degrees of (hyper)glycosylation of hCG and ITA may
also contribute to the differences in disappearance rates of these ana-
lytes. About one-third of the molecular mass of hCG consists of carbo-
hydrates attached to six glycosylation sites on hCGβ and two on hCGα.
The carbohydrate chains contain 8 – 15 terminal sialic acids, and there-
fore, hCG displays extensive heterogeneity (isoforms) (14). It has been
reported that hyperglycosylated hCG can vary greatly in sialic acid con-
tent, with molecules having between 0 and 19 sialic acid residues (7, 15,
16). Hyperglycosylated hCG generally contains less of this acidic sugars
than regular hCG (7). As terminal sialic acid protects the galactose
residues of the carbohydrate chains against metabolic degradation by
neuraminidases (17, 18, 19), and hCG has a higher sialic acid content than
ITA, regular hCG might be better protected against metabolic break-
down than ITA resulting in a longer half-life in the circulation of hCG
than of ITA. We also observed significantly longer half-lifes of hCG +
hCGβ or ITA in the PTD group treated with multi-agent chemotherapy
(Group 3) as compared with the two other groups. The presence of
severely persisting trophoblastic tissue in these patients unequivocally
requiring multi-agent chemotherapeutic treatment may be responsible
for this. Similar disappearance rates for hCG + hCGβ and ITA are found
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in the group with uneventful, spontaneously regressing trophoblast, and
in the PTD group responding to single-agent chemotherapy. Likewise,
the time needed for complete regression to normal serum concentra-
tions also are not different. Thus, the PTDs curable with single-agent
chemotherapy could be designated as ‘moderate persistent tro-
phoblasts’, and those requiring multiagent chemotherapy as ‘severe per-
sistent trophoblasts’.
The question whether ITA is a better marker of PTD than hCG +
hCGβ parallels the discussion by Okamoto et al. (20) regarding the use-
fulness of hCG β-core fragment (hCGβcf) for early prediction of subse-
quent development of post-molar PTD. These authors reported that, due
tot its short half-life, serum hCGβcf rapidly declined and became unde-
tectable after evacuation of the mole with subsequent spontaneous reso-
lution. A similar observation is obtained in the present study for ITA.
Okamoto et al. further argued that after evacuation, serum hCGβcf
remained elevated or started to rise before PTD was diagnosed based on
the rise of hCG serum levels. They concluded that hCGβcf in the serum
after mole evacuation may indicate persistence of viable trophoblasts
more sensitive than hCG. Our present data are too limited to conclude
whether the same conclusion would hold for ITA. Okamoto et al. further
reported that, once chemotherapy has started, hCGβcf became more
rapidly undetectable than hCG because of its relatively low levels in
serum and the faster clearance from the circulation than hCG. There-
fore, it seems that hCGβcf may not be suitable for the follow-up of
patients receiving chemotherapy.
The significance of persistent low levels of hCG in serum of non preg-
nant patients without clinical evidence of PTD and its relationship with
ITA was studied by Khanlian et al. (11). These authors concluded that
either the absence of detectable ITA (i.e., serum concentrations for
ITA<0.005 nmol (<0.2 µg/L), or the presence of insignificant amounts of
ITA (accounting for <5 % of the total hCG immuno-reactivity deter-
mined with their total hCG assay) were indicative for the absence of
invasive cytotrophoblastic cells and that “quiescent PTD” was present.
Because low, significantly increased hCG serum concentrations were
present, these patients were treated, but despite treatment, low hCG lev-
els persisted. In 4 out of 38 cases, the low hCG concentrations suddenly
rose sharply, and the proportion of ITA in such samples then increased
to more than 80 % up to 100 % of the total circulating hCG. Similarly,
comparison of hcg + hcgβ and ita disappear ance r ates 
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this was also observed in specimens from 15 other cases with proven
GTD (choriocarcinoma or placental site trophoblastic tumor) (10, 11). In
the present study, we observed sharply decreasing hCG + hCGβ and
ITA concentrations in the post evacuation follow-up of patients with
uneventful regression, and in PTD treated with single-agent, or single-
agent followed by multiagent chemotherapy, respectively, although the
profiles of the serum ITA regression curves compared with those of total
hCG + hCGβ immunoreactivity did not seem to be different in the vari-
ous treatment groups tested. Thus, it may be questioned whether
absence of invasive trophoblastic disease (Group 1), or presence of this
disease with proven response to chemotherapy treatment (Groups 2 and
3) is accurately reflected by the proportion of ITA accounting for total
hCG immuno-reactivity. In this respect, it would be of interest to investi-
gate in a prospective randomised setting the effect of additional courses
of chemotherapy in the course of treatment at the time point where
serum ITA concentrations become nondetectable whereas hCG + hCGβ
determinations are as yet not normalised, but still declining and signifi-
cantly above the detection limit of the assay.
In conclusion, we have studied a series of patients with uneventful
post-molar hCG + hCGβ regression in a longitudinal setting and com-
pared these results with those of ITA. Similar comparisons were made in
groups of patients who developed post-molar PTD and normalised upon
treatment with either single-agent, or single-agent and subsequent mul-
tiagent chemotherapeutic agents. Serum half-lifes were calculated and
revealed lower disappearance rates for hCG + hCGβ than for ITA. Mul-
tiagent chemotherapy treatment of post-molar PTD displayed signifi-
cantly a longer half-life than single-agent chemotherapy treatment or
spontaneous regression. The implication and the possible clinical value
of faster regression of ITA to baseline levels as compared to hCG +
hCGβ remain to be investigated prospectively.
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chapter 5
Clinical utility of hyperglycosylated
hCG in serum taken before 
hydatidiform mole evacuation 
to predict persistent trophoblastic
disease
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Abstract
Objective: Human chorionic gonadotropin (hCG) is widely used in the man-
agement of hydatidiform mole and persistent trophoblastic disease
(PTD). Studies on hyperglycosylated human chorionic gonadotropin
(Invasive Trophoblast Antigen, ITA) in PTD are limited. In serum sam-
ples taken before evacuation of molar pregnancies we measured the con-
centrations of free hCG β-subunit (free hCGβ), "total" hCG (hCG +
hCGβ) and ITA, and we determined whether ITA, the two other hCG
analytes, or the calculated ratios of hCGβ/hCG + hCGβ, hCGβ/ITA
and hCG + hCGβ/ITA could predict the later development of PTD.
Design: A retrospective study based on blood specimens collected in the
Dutch Central Registry for Hydatidiform Moles. The study group com-
prised 97 patients with hydatidiform mole who did not develop PTD
after mole evacuation, and 33 patients who did develop PTD.
Methods: Serum samples from 130 patients with hydatidiform mole with or
without PTD were assayed using specific (radio)immunoassays for free
hCGβ, total hCG, and ITA. From these analytes we also calculated the
ratios hCGβ/hCG + hCGβ, hCGβ/ITA, and hCG + hCGβ/ITA. To pre-
dict development of PTD from these analytes and parameters we per-
formed receiver-operating characteristic (ROC) curve analysis resulting
in areas under the curve (AUCs), that represented the diagnostic accura-
cy which was rated in a range from excellent (AUC>0.9 or <0.1) to poor
(AUC 0.4-0.6).
Results: The diagnostic accuracy of ITA was moderate (0.618) and not differ-
ent from that of free hCGβ (0.610) and hCG + hCGβ (0.622).
Conclusions: ITA as well as the other analytes and parameters in serum taken
prior to evacuation from patients with molar pregnancies cannot be used
to predict the subsequent development of persistent trophoblastic dis-
ease.
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Introduction
Gestational trophoblastic disease (GTD) is an aberration of the tro-
phoblast during pregnancy. It consists of a spectrum of diseases includ-
ing molar pregnancies, persistent invasive mole, gestational choriocarci-
noma and placental-site trophoblastic tumor. Molar pregnancy is the
most common form of GTD, with a reported incidence of 0.5 to 2.5 out
of 1000 pregnancies (1). The incidence varies according to regional, eth-
nic, socioeconomic and age differences. Molar pregnancy may be classi-
fied as either a complete or partial, based on gross morphology,
histopathology and karyotype (2). Surgical uterine evacuation in the
form of suction curettage is considered to be the management of choice
in newly diagnosed GTD. PTD is seen in only 4-9% of cases after evacua-
tion of a partial mole (2, 3). In case of complete molar pregnancies, the
risk of PTD is thought to be 15-20% (4).
The human chorionic gonadotropin molecule is composed of an 
α- and β-subunit. The α-subunit is composed of 92 amino acids with two
N-linked oligosaccharide side chains. The β-subunit comprises 145
amino acids with two N-linked oligosaccharides and four O-linked sugar
structures on the C-terminal extension. A total of eight carbohydrate
chains comprising about one-third of the molecular mass of intact hCG
is attached to its α- and β- subunits. In comparison with normal pregnan-
cy, the glycosylation pattern of the hCG β-subunits of choriocarcinoma
is increased several fold (4). Whereas hCG during normal and molar
pregnancy shows only small proportions of more complex carbohy-
drates, hCG molecules in choriocarcinoma amount up to 100% of these
larger N- and O-linked oligosaccharides, called hyperglycosylated hCG
(5), also referred to as Invasive Trophoblast Antigen (ITA) (6). Cole et al.
suggest that hyperglycosylated hCG is produced by invasive trophoblast
cells during early pregnancy or in case of malignant trophoblast transfor-
mation as in choriocarcinoma (6).
Based on the use of a monoclonal antibody (B-152) raised against the
hyperglycosylated choriocarcinoma hCG, a hyperglycosylated isoform
produced by first-trimester cytotrophoblast cells can be detected in
maternal blood and urine during the first 6-7 weeks of pregnancy (7, 8).
Based on the findings of Khanlian et al., the USA hCG Reference Service
indicates that measurement of hyperglycosylated hCG may be used to
distinguish quiescent GTD from invasive disease (9, 10). It is the aim of
the present study to evaluate the clinical utility of ITA as a tumor marker
clinical utilit y of ita taken before evacuation to predic t ptd
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in the prediction of PTD prior to evacuation of a molar pregnancy. The
present retrospective study includes measurements of hCGβ, hCG+
hCGβ and ITA, and calculates the ratios of hCGβ/hCG + hCGβ, hCGβ/
ITA and hCG + hCGβ/ITA in blood taken before evacuation from 130
patients with hydatidiform moles.
Materials and Methods
Patients
In the Netherlands hydatidiform moles are registered at the Dutch Cen-
tral Registry for Hydatidiform Moles at the Radboud University
Nijmegen Medical Centre (RUNMC). The registry was established in
1977 and until 2004 we registered 2821 cases. In 692 registered patients,
hCG in blood was analysed in our department at the RUNMC. After
collection, blood samples were centrifuged and serum was sent to our
institute and kept at -20 °C until assayed. Of these 692 patients, 562
could not be analysed because we had not received a serum specimen
taken prior to evacuation, or the blood sample was exhausted and there-
fore no longer available for further analysis. We analysed hCGβ, hCG +
hCGβ and ITA in blood of the remaining 130 patients. Of these 130
patients, 97 had a normal serum hCG regression, as derived from a nor-
mal regression curve constructed by Yedema et al. (11). These patients did
not develop PTD. The remaining 33 patients ultimately developed PTD
after evacuation.
Immunoassays
We used two in-house developed radioimmunoassays (RIAs) that mea-
sured free hCG β-subunit (hCGβ) and “total” hCG (i.e., intact hCG and
free β-subunit, hCG + hCGβ) (12). The hCG + hCGβ assay is utilized for
all measurements in sera sent to the Dutch Central Registry for Hydatid-
iform Moles. Based on this assay we developed a normal hCG regression
corridor for uneventful hydatidiform mole (11). The RIAs of hCGβ and
hCG + hCGβ were calibrated with the third International Standard (IS)
preparations for hCG β-subunit or intact hCG (WHO third IS hCGβ
75/551 or hCG 75/537, respectively, obtained from the National Institute
for Biological Standards, Potters Bar, Herts, UK). The measuring range
for the standard line of the hCGβ assay was 0.078 – 2.50 µg/L or IU/L
(equivalent to 0.0033-0.107 nmol/L) and for the hCG + hCGβ assay 1-80
µg/L (0.027-2.14 nmol/L, equivalent to 9.29-743 IU/L of the WHO third
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IS hCG 75/537 (12). The free hCG β-subunit RIA showed cross- reactivi-
ty with intact hCG of 0.35% (on a mass basis, equivalent to 0.55% on a
molar basis) as tested with the WHO third IS 75/537 of hCG, 1.1% on a
molar basis with nicked hCG (hCGn) (WHO 99/642 Reference
Reagent) and 0.4% with nicked hCGβ (hCGβn) (WHO 99/692 Refer-
ence Reagent). The hCG + hCGβ-RIA cross-reacted 100% on a mol/mol
basis with intact hCG and 1000% with hCG β-subunit, and 228% with
hCGn (WHO 99/642 Reference Reagent) and 507% with hCGβn
(WHO 99/692 Reference Reagent) this is of minor practical importance
because these nicked forms of hCG mainly occur in urine. Serum hCG
concentrations were considered to be normalized if below 2 µg/L (0.053
nmol/L or 18.6 IU/L of the WHO third IS hCG 75/537) which equals the
95th percentile of the reference interval of healthy non-pregnant con-
trols. In the case of the hCGβ RIA, this was 0.20 µg/L or IU/L (0.0085
nmol/L of the WHO third IS hCGβ 75/551). The within- and between-
assay coefficient of variation (CVw, CVb) for the means of duplicate mea-
surements in the hCG + hCGβ RIA were at a level of 10 µg/L (equivalent
to 0.267 nmol/L or 93 IU/L) 7.5% and 10.3%, respectively, and at a level of
56 µg/L (equivalent to 1.50 nmol/L or 520 IU/L), 7.3% and 12%. In the case
of the hCGβ RIA, two serum pools (mean:0.014 nmol/L (0.33µg/L or
IU/L) and 0.041 nmol/L (0.96 µg/L or IU/L)) revealed 5.2%-5.8% (CVw)
and 9.5%-9.9% (CVb).
ITA was measured with the Nichols Advantage Invasive Trophoblast
Antigen Assay (Nichols Institute Diagnostics, San Clemente, CA 92673,
USA) and the assay was performed according to the instructions provid-
ed by the manufacturer. The ITA assay is a two-step, two-site immuno-
chemiluminometric assay that uses two monoclonal antibodies. The
capture antibody (B152) is biotin labelled while the second antibody
(B207) is labelled with acridinium ester and used for detection. The 
analytical sensitivity of the assay is <0.048 nmol/L (<0.2 µg/L). Cross
reactivity as documented by the supplier is <1 % with recombinant hCG
(Sigma C6322), 5.4 % with nicked hCG, 4.5 % with non-nicked hCG, 
1.5 % with nicked free βhCG, and 1.0 % with non-nicked free βhCG.
Statistics
The molar concentrations of hCGβ, hCG + hCGβ and ITA of mole with
PTD and mole without PTD were utilized to construct receiver-operat-
ing characteristic (ROC) curves and to calculate areas under the curves
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(AUCs) for assessment of diagnostic accuracy of the test. All calcula-
tions were conducted with SPSS (version 12.0) for Microsoft Windows
XP (SPSS, Chicago, IL, USA).
ROC curves represent the full spectrum of possible sensitivity-speci-
ficity pairs for a test in a clinical application (13). We present conventional
ROC curves (with x-axis representing ‘1-specificity’ and y-axis as ‘sensi-
tivity’), irrespective of whether AUC is <0.5 or >0.5. However, in those
cases where AUC<0.5, the x-axis should read “specificity” and the y-axis
‘1-sensitivity’ for correct interpretation of the ROC curve. To rank the
accuracy of a diagnostic test, we interpreted AUC values of 0.91-1.00 and
0.0-0.09 as excellent accuracy (++), 0.81-0.90 and 0.10-0.19 as good
accuracy (+), 0.61-0.80 and 0.20-0.39 as moderate accuracy (±), and
0.40-0.60 as poor accuracy (-).
Results
We established diagnostic accuracy by calculating specificity and sensi-
tivity. We constructed ROC curves for hCGβ, hCG + hCGβ and ITA
analytes determined in blood specimens collected prior to evacuation as
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Table 1. AUC for six hCG analytes and parameters compared in moles without 
and with PTD
PTD- PTD+ AUC 95% CI DA
Parameter n n
free hCGβ 91 33 0.610 0.500-0.719 ±
hCG+hCGβ 97 33 0.622 0.512-0.732 ±
ITA 96 33 0.618 0.509-0.727 ±
hCGβ/hCG + hCGβ 91 33 0.526 0.412-0.639 -
hCGβ/ITA 91 33 0.485 0.368-0.602 -
hCG + hCGβ/ITA 95 33 0.461 0.342-0.580 -
PTD- absence of Persistent Trophoblastic Disease
PTD+ presence of Persistent Trophoblastic Disease
AUC Area-Under-Curve
n number of patients
95%CI 95% Confidence Interval
DA Diagnostic Accuracy; ± moderate; - poor
clinical utilit y of ita taken before evacuation to predic t ptd
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Figure 1. ROC curve analysis for hCG parameters compared in study group (all moles
with PTD) versus control group (all moles without PTD)
A) free hCGβ B) hCG + hCGβ C) ITA
D) hCGβ/hCG + hCGβ E) hCGβ/ITA F) hCG + hCGβ/ITA
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well as for the three ratios derived from these measurements (Figure 1, 
A-F). Table 1 gives the corresponding AUCs for hCGβ, hCG + hCGβ
and ITA, analytes and the three molar ratios hCGβ/hCG + hCGβ,
hCGβ/ ITA and hCG + hCGβ/ITA.
The AUCs of hCGβ (0.610), hCG + hCGβ (0.622) and ITA (0.618)
from the groups of moles with PTD versus moles without PTD show
moderate (±) diagnostic accuracy. Thus, the diagnostic accuracy of the
two hCG and ITA analytes are not different. For the ratios hCGβ/
hCG + hCGβ (0.526), hCGβ/ITA (0.485) and hCG + hCGβ/ITA
(0.461) the diagnostic accuracy was poor (-).
Discussion
The aim of our retrospective study was to determine whether serum ITA
before evacuation of a molar pregnancy could predict the later develop-
ment of PTD. The specificity and sensitivity of hCGβ, hCG + hCGβ and
ITA in serum samples taken prior to evacuation in the groups of molar
pregnancy with PTD and molar pregnancy without PTD were explored
by ROC curve analysis, resulting in AUCs for the three analytes and 
the three calculated ratios hCGβ/hCG + hCG, hCGβ/ITA and hCG +
hCGβ/ITA. Our study does not support that ITA is a reliable marker for
predicting which patients with molar pregnancies are at high risk of
developing persistent disease after evacuation. ITA has only moderate
diagnostic accuracy in predicting PTD in blood samples taken prior to
evacuation. The results were in the same range as with the analytes
hCGβ and hCG + hCGβ. The three ratios derived from the three ana-
lytes only show poor diagnostic accuracy.
The incidence of PTD, which is the most important sequela of hyda-
tidiform mole, was found to vary between 18.7% and 31.1% (14). Several
prognostic factors in predicting the development of PTD have been
described. Most of these were clinical features, i.e., age, uterine size, and
the presence of theca-lutein cyst. A laboratory test that could predict the
later development of PTD, would facilitate early appropriate manage-
ment. To establish the clinical utility of hyperglycosylated hCG or inva-
sive trophoblastic antigen, the use of these isoforms of hCG was
explored in the prenatal diagnosis of Down syndrome, the prediction of
pre-eclampsia and the management of quiescent GTD (9). With regard
to the possible role of hyperglycosylated hCG in hydatidiform mole, ITA
was found to rise from 25% to 80% of total serum hCG when patients
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with persistently low levels of hCG developed gestational trophoblastic
neoplasm (9). The source of hyperglycosylated hCG in pregnancy was
reported to originate from cytotrophoblast tissue.
Kovaleskaya et al. reported that hCG is produced and/or accumulated
in the syncytiotrophoblast cells and that the cytotrophoblast cells are the
predominant source of the hyperglycosylated hCG isoform (8). Cole et
al. found that the hyperglycosylated hCG is the predominant form of
chorionic gonadotropin in very early pregnancy (16). The concentrations
of hyperglycosylated hCG diminish rapidly and are replaced by the hCG
isoform characteristic of later first trimester of pregnancy which pre-
dominates throughout the remainder of pregnancy (7, 8). High level of
hyperglycosylated hCG is associated with aggressive trophoblast inva-
sion in early pregnancy, at three to four weeks’gestation (7, 15) and tro-
phoblastic disease (6). Khanlian et al. evaluated 114 cases with persistent
low levels of hCG, all of whom were referred to the USA hCG Reference
Service for consultation (9). In four cases with malignant disease, the
proportions of ITA accounted between 81 to 100% of the detected hCG
immunoreactivity. Based on these results, the USA hCG Reference Ser-
vice indicated that measurement of hyperglycosylated hCG (ITA) may
be used to distinguish quiescent GTD from invasive disease (9). The Ser-
vice measures hyperglycosylated hCG as part of their routine consulta-
tion by means of the Nichols Advantage automated ITA test with JEG-3-
derived standard, which only detects hyperglycosylated hCG (9, 10). As
the present study also used the Nichols Advantage automated ITA assay
for determination of ITA, the observed differences in the results cannot
be explained by differences in assay procedures. The poor results from
measurement in sera collected prior to evacuation reported here, as
derived from the diagnostic accuracy by calculating specificity and sensi-
tivity for the analytes hCGβ, hCG + hCGβ and ITA, and the ratios of
hCGβ/hCG + hCGβ, hCGβ/ITA and hCG + hCGβ/ITA, do not sup-
port the idea that ITA is a powerful predictor of PTD. Still, it could be
interesting to study hyperglycosylated hCG in molar pregnancies at later
time points after the evacuation to predict patients with “high risk” dis-
ease or to identify patients who are likely to require chemotherapy for
persistent trophoblastic tumor. In conclusion, the ITA concentrations in
serum samples taken prior to evacuation as well as those of the other
hCG analytes and parameters tested show very limited diagnostic accu-
racy in the prediction of subsequent development of PTD.
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Abstract
Objective: To assess the curative effect of a second curettage in patients with
low-risk Persistent Trophoblastic Disease (PTD) after molar pregnancy.
Methods: A retrospective cohort survey was performed on 2122 patients reg-
istered with the Dutch Central Registry for Hydatidiform Moles
between 1987-2003. Of these, 422 patients developed PTD. For various
reasons, 128 patients were excluded. The study group comprised 85
patients with, according to the Dutch guidelines, low-risk PTD who
underwent a second therapeutic curettage as a part of the treatment for
PTD. The control group consisted of 209 patients with low-risk PTD
who did not undergo a second curettage. Patients in the study and con-
trol group were classified for high/low-risk PTD according to the inter-
nationally accepted FIGO 2000 guidelines. Primary outcome measure
was the need for chemotherapy and if applicable, the number of
chemotherapy courses.
Results: After second curettage, eight out of 85 patients (9.4 %) did not need
additional chemotherapy which significantly differs from the 209
patients in the control group who all needed chemotherapy (p<0.001). A
debulking effect of the second curettage was observed: a median of 6
courses (interquartile range 3 courses) in the control group versus 5
courses (interquartile range 3 courses) in the study group (p=0.036).
Four out of the 85 (4.8%) patients with a second curettage had a major
complication (uterine perforation or hemorrhage), which was managed
conservatively.
Conclusions: A second curettage cured 9.4% of patients with PTD in this his-
torical cohort and reduces the number of courses of chemotherapy. A
second curettage seems to benefit only a limited number of patients with
PTD. A randomised controlled prospective trial is needed to confirm
this observation.
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Introduction
In Persistent Trophoblastic Disease (PTD), trophoblastic activity remains
after evacuation of a hydatidiform mole as shown by subsequent unal-
tered high or even rising hCG concentrations in blood. A variety of
pathologic types of trophoblast are included in Gestational Trophoblas-
tic Disease (GTD), comprising villous malformations of trophoblast:
hydatidiform mole, subdivided in complete and partial hydatidiform
moles, and non-villous malformations of which choriocarcinoma is the
most frequent (1). The reported frequency of PTD is 20% in complete
hydatidiform mole (2) and 0.5 to 9.9% in partial hydatidiform mole (3-6).
For PTD, several staging classifications and prognostic scoring systems
have been developed (7). In The Netherlands, the Dutch Working Party
on Trophoblastic Tumours utilises a classification system based on the
following items: antecedent pregnancy (i.e., the pregnancy preceding
PTD development), location of metastases, previous chemotherapy and
the duration of the interval between end of pregnancy and the start of
treatment (7-9). To date, the FIGO 2000 staging and scoring system is
advocated by the Committee of the International Society for the Study
of Trophoblastic Diseases (ISSTD) and the International Society for
Gynaecological Cancer (IGCS) in order to generate univocal data (10).
Once diagnosed and scored, low-risk PTD is typically treated with sin-
gle-agent chemotherapy (Methotrexate or Actinomycin-D) (11,12). If
staged as high-risk PTD, multi-agent chemotherapy with EMA-CO
(Etoposide, Methotrexate, Actinomycin-D, Cyclophosphamide and
Vincristine) is most widely used (13). Although there are some patients
with persistent hemorrhage with anemia who require a second curet-
tage, most investigators are reluctant to recommend routine second
curettage in case of PTD (14,15).
Whether a second therapeutic curettage in PTD is of curative benefit
has recently been prospectively investigated: 171 out of 282 patients with
PTD (60%) were cured after the second curettage (16). The authors
defined PTD as a plateau or rise in hCG levels, but unlike the FIGO
guideline did not define the time period (10). The 60 % cure rate after
second curettage is in contrast with the only available retrospective
study dealing with the curative effect of a second curettage in patients
with PTD (15). Four patients in a subgroup of 23 patients (16%) with non-
metastatic PTD (out of a group of 37 patients) were cured by the second
curettage. No therapeutic effect was noticed in the remaining patients
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(with metastatic PTD or in retrospect no PTD) in this study. In three
(8.1%) out of the 37 patients included in this study, a uterine perforation
occurred during the second curettage. More studies have been per-
formed on the diagnostic utility of a second curettage (16-19): two stud-
ies found the histological finding of mole tissue in the second curettage
beneficial to predict the response to chemotherapy (17) or need for
chemotherapy (16) in patients with PTD, whereas the remaining two
studies did not find a second curettage to be beneficial in this respect
(18,19) .
The primary outcome measure of the present study, in which we
investigated the curative effect of second curettage only, was whether or
not chemotherapy was needed after the second curettage as compared to
a control group without a second curettage. To investigate a possible
debulking effect of the second curettage, the number of courses of
chemotherapy needed for complete cure and consolidation was com-
pared between patients with and without second curettage. Patient char-
acteristics at enrolment for high/low-risk PTD according to the Dutch
classification (7-9) were reconfirmed and in retrospect analyzed accord-
ing to the FIGO 2000 (10) classification and compared between the
study and control group.
Material and Methods
Patients
In The Netherlands, patients with hydatidiform mole are registered with
the Dutch Central Registry for Hydatidiform Moles residing at the Rad-
boud University Nijmegen Medical Centre (RUNMC). Between 1987
and 2003, 2122 patients were registered (Fig. 1). We found 1178 (55.5%)
patients to be eligible for analysis. From these eligible patients, we select-
ed all 422 (35.8%) patients with proven PTD according to Dutch guide-
lines (hCG plateau or rise for three consecutive weekly measurements,
with at least one measurement >P95 of normal regression according to
an uneventful hCG regression curve published earlier (20)). Of these 422
patients, treatment outcome was unknown in 78 cases (18.5%) and there-
fore these patients were excluded. In the remaining 344 (81.5%) patients
with PTD, 103 (29.9%) underwent a second curettage as part of the treat-
ment for PTD (study group). The remaining 241 (70.1%) patients did not
undergo a second curettage (control group). Eighteen patients (17.5%) of
the study group and 32 patients (13.3%) of the control group were exclud-
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ed. Reason for exclusion in either group were: choriocarcinoma (11 and
30, respectively), high-risk PTD according to the Dutch classification for
PTD ((7-9) (one patient in the study group), placental site trophoblastic
tumor (one case in the study group). One patient in the study group and
two patients in the control group were excluded because a hysterectomy
was performed at the patient’s request at the start of treatment of the
PTD. Four patients in the study group were treated first with chemother-
apy before second curettage and therefore excluded. Overall, 85 patients
were included in the second curettage group (study group) and 209
patients in the group who did not undergo a second curettage (control
group). Patients were scored according to the Dutch (7-9) and the FIGO
2000 (10) classification as high/low-risk at the moment PTD disease was
diagnosed.
Immunoassays
Serum hCG measurements were either performed in the Registry’s lab-
oratory (n = 61) or in the referring hospitals (n = 75). An in-house RIA
that measured "total" hCG (i.e., intact hCG and free β-subunit, hCG +
hCGβ) was applied (21). The RIA was calibrated with the third Interna-
tional Standard Preparations for intact hCG (WHO third IS hCG 75/537
obtained from the National Institute for Biological Standards, Potters
Bar, England). The measuring range for the standard line of the assays
was 0.027-2.14 nmol/L (equivalent to 9.29-743 IU/L).
The hCG + hCGβ-RIA cross-reacted 100% with intact hCG and
1000% with hCG β-subunit. The 95th percentile of the interval of non-
pregnant individuals for the hCG + hCGβ assay was established at 0.053
nmol/L (equivalent to 18.6 IU/L of the WHO third IS hCG 75/537) (21).
The intra- and inter-assay coefficients of variation (CVw, CVb) for means
of duplicate measurements for two serum pools (mean: 0.267 nmol/L 
(93 IU/L) and 1.50 nmol/L (520 IU/L)) were 7.3 % and 12 %. If no serum
was sent to the Registry’s laboratory, data on hCG levels were provided
by the referring hospital.
Statistics
All statistical analyses were performed using the SPSS statistical soft-
ware package version 12.0.1 (SPSS Inc). Normality of distributions were
explored by Kolmogorov-Smirnov testing. Differences in numerical data
between the study and control group were tested non- parametrically
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(Mann-Whitney U). Differences in categorical distributions between
study and control group were tested using the Pearson χ2 test. All tests
were considered significantly different at p<0.05.
Results
Table 1 gives the patient characteristics of the study and control group.
Between study and control group no significant differences were
observed with respect to age, gravidity, parity, serum concentration of
pre-evacuation hCG and interval between end of pregnancy and start of
treatment. The median number of courses of first-line chemotherapy
was significantly lower in the study group as compared to the control
group (5 courses of Methotrexate (MTX) with folinic rescue (leucovorin)
in the study and 6 courses in the control group, p= 0.036).
The Dutch classification for high/low-risk PTD takes into account site
of metastases, antecedent pregnancy, interval between end of pregnancy
and start of treatment, and previously failed chemotherapy (7-9). The
classification of all patients to have low-risk PTD according to the Dutch
guideline was reconfirmed by analysis of patient records in our registry.
An effort was made to score patients according to the FIGO 2000
classification for high/low-risk PTD in retrospect. In this classification,
the distribution of items is significantly different between study and con-
trol group in antecedent pregnancy (study group: 8 out of 84 pregnancies
non-mole abortion, control group: 4 out of 209 non-mole abortion), site
and number of metastases (study group: one patient with one lung
metastasis, control group: 19 patients with 1-4 lung metastases). Data
were missing on the following items in more than 30% of cases: pre-
treatment hCG, tumor size, interval between end of pregnancy and start
of treatment, and the site and number of metastases (Table 2). Data on
tumor size were missing in more than 95% of cases and therefore not
shown in this table.
The main outcome measure of this study was the curative effect of a
second curettage in patients with PTD. Table 3 shows that 8 of 85 patients
(9.4%) were cured after the second curettage given as first-line therapy,
while 76 (89.4%) needed further chemotherapy. In the case of one
patient (1.2%), the treatment after second curettage was unknown. The
need for chemotherapeutic treatment was significantly more frequently
observed in the control group (P < 0.001). The final therapy (scored as:
no other treatment than first, multi-agent chemotherapy only, hysterec-
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tomy, or hysterectomy after multi-agent chemotherapy) leading to cure
in 100% of cases was not differently distributed between the groups. In
the study group, response to first-line MTX chemotherapy failed in
25.9% of patients and 20.6% of patients in the control group. Two
patients (2.4%) in the study group and two in the control group (1%) were
resistant to multi-agent chemotherapy, for which hysterectomy was per-
formed.
Two patients (2.4%) had severe blood loss of more than 1000 mL after
the second curettage, and 2 other patients (2.4%) had a uterine perfora-
tion during the second curettage which could be treated conservatively.
In the 85 patients in the study group, a second curettage was performed
in 51 cases (60%) for blood loss only or in conjunction with other reasons
and in 32 (37.6%) cases for other reasons than blood loss (rise or plateau
in serum hCG levels, abnormal tissue visible in utero).
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Figure 1. Selection of study group (second curettage) and control group (no second 
curettage) from Dutch Central Registry for Hydatidiform Mole, 1987-2003.
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Excluded
N=18
Second curettage
N=103
No Second curettage
N=241
Treatment outcome known
N=344
Treatment outcome unknown
N=78
No PTD
N=756
PTD
N=422
Number eligible for analysis
N=1178
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Study Group
N=85
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N=32
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Control Group
N=209
Exclusion criteria
Treatment outcome unknown
Choriocarcinoma
placental site trophoblastic
Hysterectomy at the start of PTD treatment
High risk PTD according to Dutch guidelines
Chemothearapy preceding second curettage
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Table 1. Patient characteristics, pre-evacuation hCG, interval between end of pregnancy and 
start of treatment, and number of courses of chemotherapy in study group (second curettage)
and control group (no second curettage)
Study group (n = 85) Control group (n = 209) P a
2nd curettage: yes 2nd curettage: no
Median Number Median Number 
(interquartile of (interquartile of 
range)b cases range)b cases
Age (years) 29 85 30 209 0.128
(6) (7)
Gravidity 2 83 2 192 0.124
(2) (1)
Parity 1 83 0 189 0.365
(1) (1)
Pre-evacuation hCG (IU/L) 1.8x105 28 2.0x105 108 0.974
(3.5x105) (3.2 105)
Interval (months) 2 66 2 126 0.095
(2) (2)
Number of courses MTX 5 67 6 145 0.036
(3) (3)
a Mann-Whitney U test.
b Interquartile range: P25-P75.
Discussion
In the present study, we evaluated whether a second curettage in patients
with low- risk PTD might be of clinical benefit. We tested the hypotheses
that a second curettage would cure patients (resulting in no additional
need for chemotherapeutic treatment after the second curettage) and/or
that a second curettage would have a “debulking” effect with less courses
of chemotherapy to obtain remission as a result. From the 2122 patients
registered between 1987 and 2003 at the Dutch Central Registry for
Hydatidiform Moles, we included 85 patients with low-risk PTD who
underwent a second curettage with or without chemotherapy, and 209
patients with low-risk PTD who received only chemotherapy for treat-
ment of established PTD. In order to assess whether baseline character-
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Table 2. Baseline risk factors for low/high risk according to FIGO 2000 in study group 
(second curettage) and control group (no second curettage)
Study group (n = 85) Control group (n = 209) P a
2nd curettage: yes 2nd curettage: no
Age (years) Number Rate, % Number Rate, %
< 40 b 82 96.5 195 93.3 0.291
≥ 40 c 3 3.5 14 6.7
Missing data 0 0.0 0 0.0
Total 85 100 209 100
Antecedent pregnancy
Mole b 76 89.4 205 98.1 0.004 
Non-mole abortion c 8 9.4 4 1.9
Term d 0 0.0 0 0.0
Missing data 1 1.2 0 0.0
Total 84 99 209 100
Interval end of pregnancy-
start treatment (months)
< 4 b 53 62.3 109 52.2 0.493
4-≤ 7 c 10 11.8 14 6.7
7-≤ 13 d 3 3.5 3 1.4
> 13 e 0 0 0 0.0
Missing data 19 22.4 83 39.7
Total 85 100 209 100
Pre-treatment hCG (IU/L)
< 1000 b 1 1.2 6 2.9 0.745
< 10000 c 1 1.2 1 0.5
< 100000 d 6 7.1 24 11.5
≥ 100000 e 20 23.5 77 36.6
Missing data 57 67.1 101 48.3
Total 85 100 209 100
Site of metastases
No metastases b 60 70.6 117 56.0 0.008
Lungs b 1 1.2 19 9.1
Spleen/Kidney c 0 0.0 0 0.0
Gastro-intestinal d 0 0.0 0 0.0
Liver/Braine 0 0.0 0 0.0
Missing data 24 28.2 73 34.9
Total 85 100 209 100
Number of metastases
No metastases b 60 70.6 117 56.0 0.008
1-4 c 1 1.2 19 9.1
5-8 d 0 0.0 0 0.0
>8 e 0 0.0 0 0.0
Missing data 24 28.2 73 34.9
Total 85 100 209 100
Previous failed chemotherapy
No b 85 100 209 100 1.00
Single drug d 0 0.0 0 0.0
2 or more drugs e 0 0.0 0 0.0
Missing data 0 0.0 0 0.0
Total 85 100 209 100
Total FIGO score of 6 or less: low risk; total FIGO score of 7 or more: high risk
a Pearson Chi-square, missing data excluded for analysis
b FIGO: no points c FIGO: 1 point d FIGO: 2 points e FIGO: 4 points
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Table 3 Treatment results and complications in study group (second curettage) and control group 
(no second curettage)
Study group (n = 85) Control group (n = 209) P a
2nd curettage: yes 2nd curettage: no
Age (years) Number Rate, % Number Rate, %
First-line therapy
MTX 76 89.4 209 100 <0.001
Multi-agent chemotherapy 0 0.0 0 0.0
Second curettage only 8 9.4 0 0.0
Missing data 1 1.2 0 0.0
Total 85 100 209 100
Final therapy
No other treatment than first 60b 70.6 164 78.5 0.320
Multi-agent chemotherapy 19 22.4 39 18.7
Hysterectomy 4 4.7 4 1.9
Multi-agent chemotherapy 
and hysterectomy 2 2.4 2 1.0
Missing data 0 0.0 0 0.0
Total 85 100 209 100
Multi-agent chemotherapy
Yes 21 24.7 41 19.6 0.332
No 64 75.3 168 80.4
Missing data 0 0.0 0 0.0
Total 85 100 209 100
Failed chemotherapy
No 60 70.6 165 78.9 0.119
MTX 22 25.9 43 20.6
Multi agent chemotherapy 2 2.4 1 0.5
Missing data 1 1.2 0 0.0
Total 85 100 209 100
Reason 2nd curettage
Bloodloss 51 60.0
Other 32 37.6
Missing data 2 2.4
Total 85 100
Complications with 2nd curettage
No complications 81 95.2
Fluxus with 2nd curettage 2 2.4
Perforation with 2nd curettage 2 2.4
Missing data 0 0.0
Total 85 100
a Pearson Chi-square, missing data excluded for analysis.
b Eight patients second curettage only and 52 patients cured following first line MTX treatment.
istics were comparable in study and control group, we reconfirmed that
all patients had low-risk PTD according the Dutch classification for per-
sistent trophoblastic disease (7-9). When classified according to the
FIGO 2000 scoring system for high/low-risk PTD (10), patient baseline
characteristics were significantly different between study and control
group with respect to three out of eight parameters. The hypothesis that
a second curettage is of curative benefit in PTD was confirmed by com-
plete remission as reflected by normalized serum hCG directly after the
second curettage without receiving any other treatment in case of eight
patients (9.4%, P < 0.001). A debulking effect of a second curettage was
observed in this study since significantly less courses of chemotherapy
were needed in the study group as compared to the control group. The
clinical benefit of second curettage was accompanied by 2 uterine perfo-
rations which could be managed conservatively and by 2 cases of blood
loss >1000 mL.
Whether a second curettage could have a curative effect, is preferably
investigated in groups with equal baseline characteristics for high- or
low-risk PTD. The Dutch guideline for classification for PTD scores for
antecedent pregnancy (low-risk: mole or non-molar abortion, high risk:
term choriocarcinoma), localisation of metastases (low-risk: no metas-
tases or in vagina or lungs only, high risk: more than one organ with
metastases or remaining localization of metastases), previous failure to
chemotherapy (low-risk: no failure, high risk: earlier failure to any
chemotherapy), and the interval between end of pregnancy and begin-
ning of treatment (low-risk: ≤ 12 months, high risk: >12 months) (7-9).
Unlike FIGO 2000 (10), the Dutch guideline issued in 1999 does not
include scorings for age, pre-treatment serum hCG concentration, the
number of metastases, or largest tumor size. Items scored in the Dutch
scoring system as “low-risk” are given 0 points in FIGO 2000, except for
the item antecedent pregnancy where in the Dutch classification a non-
molar abortion is classified as “low-risk” whereas FIGO 2000 scores one
point for non-molar abortion. To meet international criteria as recom-
mended by FIGO and the International Society for the Study of Tro-
phoblastic Diseases (ISSTD), we scored our patients according to the
FIGO 2000 classification (10). If this system were to be used worldwide,
it would be an important step forward in the management of gestational
trophoblastic neoplasia because results can be compared among differ-
ent centres and it would facilitate enrolment in large multicenter trials
the cur ative effec t of a second curet tage in ptd
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(22). Using the FIGO 2000 classification, we found significant differ-
ences between study and control group for antecedent pregnancy, tumor
size and number and site of metastases although, due to differences in
the two scoring systems, a substantial proportion of these parameters
were missing. It may be possible that gynecologists are more willing to
perform a second curettage in a patient with a non-mole histological
diagnosis from the first curettage but with persistent vaginal bleeding
and/or abnormal hCG regression. The number and localisation of
metastases were significantly distributed between the groups. The dis-
tribution of the remaining FIGO items (age, pre-treatment serum hCG
and tumor size) was not significantly different between the groups.
Although FIGO 2000 has been tested in 201 patients with persistent low
hCG or high-risk GTD (23) against the WHO scoring system (1983) (7)
and the revised FIGO staging system (1992) (7), FIGO 2000 has not been
tested against the Dutch classification for persistent trophoblastic dis-
ease (7-9). If staged according to FIGO 2000, we found significant differ-
ences between the study and control groups. These differences can be
explained by unequally distributed amounts of missing data between the
groups or due to a true difference between the groups.
Although there are some patients with PTD with continued hemor-
rhage and consequent anemia who require a second curettage, most
investigators are reluctant to recommend routine curettage (14,15). One
retrospective study by Schlaerth et al. (15) showed a curative effect in
patients with non-metastatic gestational trophoblastic disease in
approximately 16%. Enthusiasm about this curative effect was tempered
by the drawback that 8% of these patients had an uterine perforation
with the second curettage, for which in two cases a hysterectomy had to
be performed (15). The curative effect described by Schlaerth et al. is
comparable to our results: cure of PTD after second curettage by 9.4% at
a complication rate of 2.4% uterine perforations and 2 cases (2.4%) of
blood loss > 1000 mL. Schlaerth et al. and our results are in contrast with
the first prospective study on the curative effect of a second curettage in
patients with PTD by Pezeshki et al. (16). This study from the Weston
Park Hospital in Sheffield, showed a second curettage-only to be curative
in 60% of 282 patients with proven PTD. In this prospective study, crite-
ria for the diagnosis of PTD are given as a plateauing or rising hCG level,
without mentioning the period of plateauing. Upon request, the corre-
sponding author of this study communicated that PTD was diagnosed if
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serum hCG was not normalised between 4 and 6 weeks after the first
evacuation, or if serum hCG was increasing at any stage. In 1993, our
group constructed a normal regression curve for serum hCG in patients
with a hydatidiform mole with uneventful regression to normal after
evacuation (n = 129). We found a cumulative normalisation of serum
hCG in 5% of patients within 6 weeks after first evacuation, 50% within
11 weeks, and 95% within 25 weeks (21). Failure of serum hCG to normal-
ize within 6 weeks after first evacuation without plateau or rising in hCG
(as defined by FIGO (10)), as such does not make trophoblastic disease
persistent. Advising patients to undergo a second curettage 4-6 weeks
after evacuation for “persistent trophoblastic disease” according to
Pezeshki’s criteria will put patients at risk for complications of this pro-
cedure, which is unnecessary in the majority of patients. Interestingly,
the number of complications accompanying the second curettage is not
mentioned in the study by Pezeshki et al. In this study, chemotherapy was
needed in 206 out of 4075 patients (5%) with a hydatidiform mole. It is
unknown, whether this is significantly less than the 7.75% of patients
who needed chemotherapy for GTD in a study performed in England
and Wales between 1973-1983 (24).
In conclusion, we have tested the hypothesis that a second curettage
would cure or act as a “debulking” agent in PTD which would result in
less patients needing chemotherapy for their PTD and if chemotherapy
is needed, less courses of chemotherapy. We observed a curative effect in
9.4% patients who were cured after second curettage only. A “debulk-
ing” effect was noted, because of a reduction of a median of six
chemotherapy courses in the control group to five courses in the study
group. Although this reduction in the number of single agent chemother-
apy courses will not be the primary reason to perform a second curet-
tage, it confirms our biological hypothesis that a second curettage has a
debulking effect. The second curettage was accompanied by a uterine
perforation in 2 patients and blood loss >1000 mL in 2 cases. In this ret-
rospective cohort, we reconfirmed that all patients had low-risk PTD in
both study group (second curettage) and control group (no second curet-
tage) when classified according the guideline by the Dutch Society of
Obstetrics and Gynaecology (7-9). We did found differences between
the study and control group when staging according to FIGO 2000. This
study shows that a second curettage might have a curative and debulking
effect in patients with PTD. A randomised prospective controlled trial
the cur ative effec t of a second curet tage in ptd
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which takes into account the baseline risk of a patient of a subversive out-
come of their PTD classified according to an internationally accepted
classification for high/low-risk PTD, is needed to investigate this cura-
tive effect. In the meantime, gynecologists can expect a small curative
effect by performing a second curettage in patients with PTD.
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Abstract
Purpose: A generally accepted definition for resistance to first-line single-
agent chemotherapy for persistent trophoblastic disease (PTD) is lacking.
In the present study, a normogram for serum human chorionic gonado-
tropin (hCG) from patients with normalization of serum hCG after
first-line single-agent chemotherapy for PTD was constructed in order
to identify patients resistant to this first-line single-agent chemotherapy.
Patients and Methods: Between 1987 and 2004, data from 2132 patients were
registered at the Dutch Central Registry for Hydatidiform Moles. A nor-
mal serum hCG regression corridor was constructed for 79 patients
with low-risk PTD who were cured by single-agent methotrexate (MTX)
chemotherapy (control group). Another group of 29 patients with low-
risk PTD needed additional alternative therapies (Actinomycin-D and
multiagent chemotherapy) for failure of serum hCG to normalize with
single-agent chemotherapy (study group).
Results: Serum hCG measurement preceding the fourth and sixth single-
agent chemotherapy course proved to have excellent diagnostic accuracy
for identifying resistance to single-agent chemotherapy, with an area
under the curve (AUC) for receiver operating characteristic curve analy-
sis of 0.949 and 0.975, respectively. At 97.5% specificity, serum hCG
measurements after 7 weeks showed 50 % sensitivity.
Conclusions: In the largest study to date, we describe the regression of serum
hCG levels in patients with low-risk PTD successfully treated with
MTX. At high specificity, hCG levels in the first few courses of MTX can
identify half the number of patients who are extremely likely to need
alternative chemotherapy to cure their disease and for whom further
treatment with single-agent chemotherapy will be ineffective.
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Introduction
A variety of pathologic types of trophoblast neoplasms are included in
gestational trophoblastic disease, comprising villous malformations of
trophoblast, hydatidiform mole subdivided in complete and partial
hydatidiform mole, and nonvillous malformations of which choriocarci-
noma is the most frequent (1). In persistent trophoblastic disease (PTD),
trophoblastic activity remains after evacuation of a hydatidiform mole,
as shown by subsequent unaltered high or even increasing serum human
chorionic gonadotropin (hCG) concentrations. The internationally
accepted definition released by the International Federation of Gynecol-
ogy and Obstetrics (FIGO) defines PTD as a plateau in serum hCG for 3
weeks, or a rise for 2 consecutive weeks (2). In The Netherlands, the
Dutch Society for Obstetrics and Gynecology added to this definition
for PTD the condition that at least one serum hCG measurement should
exceed the 95th percentile (P95) of normal hCG regression after hyda-
tidiform mole (3-5).
The reported frequency of PTD is 20% in complete hydatidiform mole
(6) and 0.5% to 9.9 % in partial hydatidiform mole (7-10). For patients
with PTD, several staging classifications and prognostic scoring systems
have been developed (3). To date, the FIGO 2000 scoring system for
high- and low-risk PTD is advocated by The International Society for the
Study of Trophoblastic Diseases and the International Society for Gyne-
cological Cancer to generate univocal data (2). This scoring includes
serum hCG, age, antecedent pregnancy, interval between end of preg-
nancy and start of treatment, previous failure of chemotherapy and the
localization and number of metastases (2). The Dutch classification for
high- and low-risk PTD takes the same items into account, except for the
number of metastases and serum hCG concentration (3,11).
Once diagnosed and scored, low-risk PTD is typically treated with sin-
gle-agent chemotherapy (MTX or Actinomycin-D) (12,13). If staged as
high-risk PTD, multiagent chemotherapy with Etoposide, Methotrex-
ate, Actinomycin-D, Cyclophosphamide, and Vincristine (EMA-CO) is
the most widely used therapy (12).
Approximately 9% to 33% of patients treated with single-agent
chemotherapy for low-risk PTD will require multiagent chemotherapy
because resistance to the first-line drug or toxic adverse effects occurred
(14-16). Repeated administration of MTX could induce MTX resistance
(17), mainly as a result of downregulation of the expression levels of the
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reduced folate carrier that is responsible for transport of MTX into the
cell or amplification of the gene for dihydrofolate reductase. This
enzyme reduces dihydrofolate in tetrahydrofolate which is essential in
DNA synthesis (18,19). To date, an internationally accepted definition
for resistance to first-line chemotherapy is lacking. In some clinics, resis-
tance to first-line chemotherapy is defined as a plateau or increase in
serum hCG and/or development of new metastases (14-16,20,21).
After single-agent chemotherapy with MTX, no increase in the num-
ber of second tumors has been observed (22). In contrast, patients with
PTD who are treated with etoposide-containing multiagent chemothera-
py have a 50% increased relative risk to developing secondary malignan-
cies, in particular myeloid leukemia, colon carcinoma, and breast cancer,
compared with an age-matched group (23). Furthermore, multiagent
chemotherapy hastens the occurrence of menopause by 2 years com-
pared with patients treated with single-agent MTX (24) and can be
accompanied by the occurrence of alopecia and GI symptoms. To identi-
fy patients not responding to single-agent chemotherapy in an early
stage and, at the same time, to prevent unnecessary multiagent
chemotherapy, we constructed a normal serum hCG regression corridor
for patients successfully treated with single-agent chemotherapy.
Patients and Methods
Patients
Between 1987 and 2004, 2132 patients were registered at the Dutch Cen-
tral Registry for Hydatidiform Moles. After informed consent, patients
were registered by their referring clinician. The present study included,
in retrospect, all low-risk patients with proven PTD according to Dutch
guidelines (histological diagnosis mola hydatidosa or choriocarcinoma
with serum hCG plateau or increase for 3 consecutive weekly measure-
ments, with at least one measurement > P95 of normal regression
according to an uneventful hCG regression published earlier (4) if serum
was available in our registry. In the Netherlands, patients with low-risk
PTD are treated with MTX 1 mg/kg on day 1, 3, 5, and 7 and leucovorin 15
mg rescue on days 2, 4, 6, and 8, and this schedule is repeated every 14
days (13). Exclusion criteria were hysterectomy when PTD was diag-
nosed; cure after a second curettage; need for alternative therapies for
MTX toxicity (none in this cohort); persistent low serum hCG levels (2
to 10 µg/L) after spontaneous regression or persistent low serum hCG
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after MTX treatment, for which no multiagent chemotherapy was
administered; and recurrence of PTD after single-agent chemotherapy.
Of the 108 eligible patients, serum hCG normalized under single-agent
(MTX) treatment in 79 patients (73%; responders). The remaining 29
patients (27%) were treated with multiagent chemotherapy after the clin-
ician decided that the disease failed to respond to single-agent
chemotherapy.
Immunoassays
A privately developed (in-house) radioimmunoassay (RIA) that mea-
sured total hCG (ie, intact hCG and free beta-subunit (hCG + hCGβ)
was used exclusively in the authors’ laboratory (25). Thus, this assay has
been utilized centrally for all measurements in sera sent to the Dutch
Central Registry for Hydatidiform Moles and was used in the develop-
ment of a normal hCG regression corridor for uneventful hydatidiform
mole (4). The RIA was calibrated with the third International Standard
(IS) Preparations for intact hCG (WHO third IS hCG 75/537 obtained
from the National Institute for Biological Standards, Potters Bar, Eng-
land, United Kingdom). The measuring range for the standard line of the
assay was 1 to 80 µg/L (0.027 to 2.14 nmol/L, equivalent to 9.29-743 IU/L
of the WHO third IS hCG 75/537) (25). The hCG + hCGβ-RIA cross
reacts 100% on a mol/mol basis with intact hCG and 1,000% with hCG
β. Serum hCG concentrations were considered to be normalized if they
were less than 2 µg/L (0.053 nmol/L or 18.6 IU/L of the WHO third IS
hCG 75/537). The intra- and interassay coefficients of variation for
means of duplicate measurements for two serum pools (means: 0.267
nmol/L, or 10 µg/L or 93 IU/L, and 1.50 nmol/L, or 56 µg/L or 520 IU/L)
were 7.3% and 12%, respectively.
Statistics
All statistical analyses were performed using the SPSS statistical soft-
ware package version 12.0.1 (SPSS Inc, Chicago, IL). Normality of distri-
butions was explored by Kolmogorov-Smirnov testing. Differences in
numerical data between the control and study groups were tested non-
parametrically (Mann-Whitney U test) or parametrically (Student’s t
test). Within each patient group, serum hCG results (obtained before the
start of a new MTX course) were sorted by week from the start of MTX
treatment. To approximate normal distributions, serum hCG measure-
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ments were log transformed and sorted within each week. The per-
centiles of 2.5% (P2.5), 50% (P50), and 97.5% (P97.5) and the standard
deviation were calculated. In the control group, serum P2.5, P50 and
P97.5 were plotted for each week into a normogram. To describe the
complete serum hCG response of each patient, we calculated the serum
hCG half-life as derived from serum hCG measurements preceding the
first single-agent course until the point of normalization (cutoff, 2 µg/L).
After 17 weeks (before the ninth MTX course), statistics were censored
because of small numbers of patients (12 patients in control group and 11
in study group). The hCG half-life and hCG concentration in a certain
week from the start of MTX treatment of the control and study groups
were used to construct receiver operating characteristic (ROC) curves
and to calculate areas under the curve (AUCs). All tests were considered
significantly different at P <0.05.
Results
Table 1 lists age, prechemotherapy serum hCG, number of courses of
single-agent chemotherapy, hCG serum half-life and, if applicable, num-
ber of courses of multiagent chemotherapy in both the control (n = 79)
and study (n = 29) groups. No difference was observed between the
groups for age (median age, 30 years in both groups). Expectedly, serum
hCG concentration before the first course of single-agent chemotherapy
was significantly less elevated in the control group compared with the
study group (251 v 2,098 µg/L, respectively; P <0.001). Significantly fewer
courses of single-agent chemotherapy were administered in the control
group (median, five courses; range, three to 17 courses) compared with
the study group (median, seven courses; range, three to 16 courses; P =
0.003). As expected, the median serum hCG half-life was significantly
shorter in the control group (1.02 weeks; 95% CI, 0.91 to 1.13) compared
with the study group (1.92 weeks; 95% CI, 1.63 to 2.27 weeks; P <0.001).
The median number of courses of multiagent chemotherapy adminis-
tered in the study group was four (range, three to seven courses).
For each single-agent treatment course, the P2.5, P50 and P97.5 of
serum hCG concentration in the control group was calculated, and the
results were plotted into a normogram (Fig 1A). In the control group,
2.5% of patients were cured after 2 weeks (after one MTX course), and
50% were cured after 8 weeks (after four MTX courses). After 17 weeks,
the P97.5 of serum hCG in the control group remained at 4.3 µg/L and,
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thus, not less than the cutoff level of 2 µg/L. This is because, after 17
weeks, there were still some patients who needed additional MTX cours-
es who were, at that time point, not yet normalized.
In Figure 1B, the hCG levels of the two weekly intervals for the 29
patients in the study group were plotted into the normogram derived
from the serum hCG measurements of the control group. Before the
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Table 1. Age, Prechemotherapy hCG Concentration, Number of Courses and hCG Half-Life
During First-Line Single-Agent Chemotherapy in the Study (no regression after MTX) and
Control Groups (regression after MTX)
Complete Remission After First-Line 
Single-Agent Chemotherapy
Yes (n = 79) No (n = 29) P
Age, years NS*
No. of patients 78 29
Median 30 30
Range 17-50 24-43
hCG before chemotherapy, µg/L < 0.001*
No. of patients 76 29
Median 251 2,098
Range 6.2-12000 62-16000
Number of MTX courses < 0.003*
No. of patients 78 27
Median 5 7
Range 3-17 3-16
hCG half-life during 
MTX treatment, weeks < 0.001†
No. of patients 78 29
Median 1.02 1.92
95% CI 0.91 to 1.13 1.63 to 2.27
Number of courses of 
multiagent chemotherapy NA
No. of patients NA 24
Median 4
Range 3.0-7.0
Abbreviations: hCG, human chorionic gonadotropin; MTX, methotrexate; NS, not signifi-
cant; NA, not applicable.
* Mann-Whitney U test.
† Student’s t test.
start of the first MTX course, serum hCG in the study group exceeded
the P97.5 of the control group in four (13.8%) of 29 patients. After 7
weeks (before the fourth MTX course), serum hCG in the study group
exceeded the P97.5 of the control group in 22 (76 %) of 29 patients. After
17 weeks (before the ninth MTX course), serum hCG in the study group
exceeded the P97.5 of the control group in 25 (86 %) of 29 patients. These
results are in line with the finding of a significantly shorter median serum
hCG half-life in the control group compared with the study group, as
stated previously.
Figure 2 shows the normogram for serum hCG + hCGβ for the study
group. This normogram was plotted in the normogram for serum hCG
+ hCGβ derived from the control group. As shown, 2.5 % of patients in
the study group had normalization of serum hCG (ie, < 2 µg/L) after 9
weeks (before the fifth MTX course). These patients were administered
multiagent chemotherapy for persistent low hCG levels after treatment
with MTX. After 17 weeks (before the ninth MTX course), the P50 in the
study group was 13.8 µg/L, and the P97.5 was 122 µg/L. The overlapping
area between the study and control groups, is darkly hatched. The area
with hCG more than P97.5 of regression in the control group and with
hCG less than P97.5 of the study group, is lightly hatched.
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Table 2. AUC, Sensitivity at 97.5% Specificity for ROC of hCG Half-Life, Before Start of
MTX Treatment, After 7 Weeks (before the fourth MTX course), and After 11 Weeks (before
the sixth MTX course)
ROC for hCG
Measure Half-Life ROC Week 0 ROC Week 7 ROC Week 11
Study group, 
No. of patients 29 29 26 26
Control group, 
No. of patients 79 77 73 73
AUC 0.833 0.828 0.949 0.975
95% CI 0.753 to 0.914 0.742 to 0.914 0.910 to 0.989 0.947 to 1.00
Sensitivity. % 14 50 60
hCG cutoff, µg/L 9600 56.0 24.0
Abbreviations: AUC, area under the curve; ROC, receiver operating characteristic; hCG,
human chorionic gonadotropin; MTX, methotrexate.
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Figure 1. A) Normal serum human chorionic gonadotropin (hCG) regression curve
under methotrexate (MTX) in the control group (n = 79). B) Normal serum hCG regres-
sion under MTX in control group (n = 79), with all individual measurements in the study
group (n = 29). The different shapes refer to longitudinal serum hCG  patterns of individ-
ual patients.
Diagnostic accuracy of serum hCG half-life was derived from the cal-
culation of an AUC of a ROC curve (Fig. 3A). In addition, the diagnostic
accuracies of serum hCG levels before the first (Fig. 3B), fourth (Fig. 3C),
and sixth (Fig. 3D) first-line single-agent chemotherapy course were
established by the calculation of the AUCs of these ROC curves. The
corresponding AUCs for these ROC curves are listed in Table 2. The
AUC for serum hCG half-life throughout single-agent treatment was
0.833. The AUC of the serum hCG concentration preceding the first-sin-
gle chemotherapy course was 0.828, which increased to 0.975 preceding
the sixth course (after 11 weeks) of single-agent chemotherapy. This
means that, at that time point, an excellent diagnostic accuracy was
obtained because, after 11 weeks, 60 % of the patients needing alternative
therapy could be identified at the 97.5% specificity level.
Using serum hCG before the start of single-agent chemotherapy as a
diagnostic tool to identify patients who will need alternative chemother-
apeutic treatment for PTD, resulted in the identification of 14% of
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Figure 2. Regression of hCG in serum in control group (n = 79) versus the study group 
(n = 29)
patients who needed alternative therapy at the 97.5% specificity level
(hCG serum cutoff, 9600 µg/L). Serum hCG levels obtained before the
start of the fourth course to predict the need for alternative therapy,
would identify as much as 50% of patients at the 97.5% specificity level
(cutoff, 56 µg/L; Table 2).
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Figure 3. Receiver operating characteristic (ROC) analysis of the study versus control
group for A) serum human chorionic gonadotropin (hCG) half-life (T1/2) and B) serum
hCG concentration before the start of methotrexate (MTX) treatment (MTX1), C) after
7 weeks (before the fourth MTX course; MTX4), and D) after 11 weeks (before the sixth
MTX course; MTX6).
Discussion
The objective of this study was to clarify whether it is possible to identify,
at an early stage and from a single hCG measurement, patients with PTD
who will not be cured by single-agent chemotherapy. For this reason, we
established a serum hCG normogram with data from 79 patients with
low-risk PTD who were cured by single-agent MTX chemotherapy. This
normogram was applied to hCG measurements from 29 PTD patients
who needed alternative therapy after single-agent chemotherapy failed
to establish normalization of serum hCG. Using this normogram, we
found that it is possible to identify 14% of patients who will need alterna-
tive therapy before the start of first-line single-agent chemotherapy with
97.5% specificity. Likewise, on the basis of serum hCG measurements
obtained just before the fourth MTX course, we were able to identify
50% of patients who would not respond to single-agent chemotherapy at
97.5% specificity.
The international criteria used to diagnose PTD include an abnormal
serum hCG regression, with a plateau for 3 weeks or an increase for two
weeks (2). Normal serum hCG regression corridors for uneventful hyda-
tidiform moles have been constructed, with 50% of patients having nor-
malized serum hCG measurements between 6 and 14 weeks after evacu-
ation (4,20,21,26,27). The Dutch Society for Obstetrics and Gynecology
included the extra condition in the diagnosis for PTD that, in addition to
a serum hCG plateau or increase for 3 consecutive weeks, at least one
serum hCG measurement should exceed the P95 of normal hCG regres-
sion, as derived from an hCG normogram constructed from data of 130
patients with uneventful hydatidiform mole (4). There are two reasons
for the inclusion of this additional condition. First, PTD, as defined by
exceeding the P95 of normal regression, is diagnosed 2 weeks earlier than
if the definition for PTD of an hCG plateau or increase for 3 consecutive
measurements is used (21,27). Second, use of a normal hCG regression
corridor prevents overtreatment. One study described that 15% of
patients with a plateau or increase for 3 weeks but without a serum hCG
measurement exceeding the P95 will have spontaneous serum hCG
remission afterwards (4). Two retrospective studies showed that, in
patients treated for PTD on the basis of a plateau or increase of serum
hCG for 3 consecutive weeks, 29% had serum hCG measurements less
than the P90 of normal regression (20), and 8% had measurements less
than the P95 of normal regression (4).
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Although firm criteria for the diagnosis of PTD exist and the use of a
normogram for normal serum hCG regression identifies patients with
PTD earlier and prevents overtreatment, no firm criteria for the diagno-
sis of resistance to first-line single-agent therapy exist. A generally
accepted definition for resistance to first-line chemotherapy is lacking,
although some clinics define resistance to chemotherapy by a plateau or
increase in serum hCG or by detection of (new) metastases (14,15,20,21).
Rotmensch et al. (20) described the only normogram for normaliza-
tion of hCG in 21 patients with nonmetastatic trophoblastic disease
treated with MTX. They reported that the median time for serum hCG
to normalize in successfully treated patients with PTD is 50 days. The
authors stated that, in successfully treated patients with low-risk PTD,
the median time to normalization is comparable to patients with uncom-
plicated regression of serum hCG after hydatidiform mole (50 days).
Our results are in line with their results because we found that serum
hCG normalizes in 50% of patients after five, 2-week courses of MTX.
Our group previously developed a normogram for serum hCG regres-
sion after uneventful hydatidiform mole (4). In that study, median time
for normalization was 11 weeks, which is comparable to the five 2-week
courses that 50% of patients needed for normalization of hCG after suc-
cessful single-agent chemotherapy.
Serum hCG in two patients in the study by Rotmensch et al. (20) failed
to normalize after primary chemotherapy. Serum hCG of these two
patients was greater than the P90 of the normal regression with MTX at
the start of the MTX treatment. These investigators did not explore the
diagnostic accuracy of serum hCG levels to detect resistance to single-
agent chemotherapy in low-risk PTD. Shigematsu et al. (21), in their
study comprising 24 patients with PTD, indicated that women who
would show resistance to single-agent chemotherapy later on (as con-
cluded from increasing hCG for 2 weeks, a plateau for 3 weeks, or the
development of new metastases) exceeded the P95 of normal hCG
regression significantly earlier than patients who would respond well to
single-agent chemotherapy.
With the presented serum hCG regression corridor for patients treat-
ed with first-line single-agent MTX, we have an excellent diagnostic tool
to identify patients with resistance to first-line single-agent chemothera-
py at an early stage with great certainty. Before the fourth course of sin-
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gle-agent chemotherapy (after 7 weeks), serum hCG identifies 50% of
patients needing alternative therapy at the 97.5% specificity level.
The birthrate in the Netherlands is approximately 200000 persons
per year. With an estimated incidence of hydatidiform mole of 1 per 1000
to 2000 pregnancies (28) the 18-years period of our study could yield
1800 to 3600 patients with hydatidiform mole, of whom we would
expect 180 to 360 to have PTD. Registration with the Dutch Central Reg-
istry for Hydatidiform Moles is on a voluntary basis, and we registered
2132 patients with hydatidiform mole throughout the entire study peri-
od, of whom 108 patients with PTD were eligible for inclusion in our
study. Because of the low incidence of PTD and, in particular, the need
for alternative therapy, it is not feasible to perform a prospective study,
and we used our retrospective data for a proposal for a new treatment
regimen for patients with PTD.
In analogy with the regression curve for serum hCG after evacuation
of uneventful hydatidiform mole as earlier published by our group (4) we
developed a curve for the early detection of resistance to first-line single-
agent MTX chemotherapy. Because overtreatment with multiagent
chemotherapy is highly undesirable, we increased the cutoff from P95 to
P97.5 for normal regression of patients successfully treated with first-
line single-agent chemotherapy. If before the fourth course of single-
agent chemotherapy the serum hCG concentration exceeds the P97.5 of
this normal regression curve, it can be concluded with 50% sensitivity
that a change of treatment is mandatory to gain cure (Fig 2, lightly
hatched area). In line with the internationally accepted criteria for treat-
ment of PTD, the course of hCG (plateau or increase) should also be
included in the decision to start alternative therapy. The choice of 
second-line chemotherapy could be multiagent chemotherapy with
EMA-CO. In the United Kingdom, McNeish et al. (15) described a suc-
cessful regimen in which patients with resistance to MTX-leucovorin
were administered either Actinomycin-D if serum hCG was less than
100 IU/L or EMA-CO if serum hCG exceeded 100 IU/L. In this study, 58
of 67 patients treated secondarily with dactinomycin were cured by this
drug.
In conclusion, in the largest study to date, we describe the regression
of serum hCG levels in patients with low-risk PTD treated with MTX.
From these data, it can be concluded that serum hCG levels before the
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fourth course of MTX can identify half the number of patients who are
highly likely to need alternative therapy to cure their disease and for
whom further treatment with single-agent chemotherapy will be ineffec-
tive.
early identification of resistance to fir st-line mt x in patients with ptd
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chapter 8
General Discussion

This thesis describes our findings on the diagnostic utility of hCG mea-
surements in gestational trophoblastic disease (GTD) and persistent tro-
phoblastic disease (PTD) to distinguish biochemically hydatidiform
mole from uneventful normal pregnancy, to make the distinction
between complete and partial hydatidiform mole, and to investigate the
significance of several serum hCG analytes and parameters to predict
PTD after molar pregnancy (which might be beneficial since prophylac-
tic chemotherapy reduces the incidence of PTD) (Chapters 2 and 5). We
also explored the diagnostic potential of serum hCG ratios calculated
from hCG concentrations in blood samples taken after mole evacuation
to identify development of PTD at the most early stage (Chapter 3) and
we compared the disappearance rates of two hCG analytes (hCG +
hCGβ and hyperglycosylated hCG) in uneventful regression, as well as
during administration of single-agent and multiagent chemotherapy in
order to assess the clinical value of these two analytes in the follow-up of
PTD (Chapter 4).
Regarding the issue of therapeutic options in PTD we studied the
curative effect of a second curettage in patients with low-risk PTD after
molar pregnancy (Chapter 6), and, to identify patients with PTD not
responding to single-agent methotrexate chemotherapy in an early stage
and, at the same time, to prevent unnecessary multiagent chemotherapy,
we constructed a normal serum regression corridor for patients success-
fully treated with single-agent chemotherapy (Chapter 7).
We found that hCGβ and hCG + hCGβ concentrations, and the ratio
hCGβ/hCG + hCGβ are mostly above the corresponding P95 level of
normal pregnancy; hCGα concentrations in serum in many molar preg-
nancies are below the P50 level, while the majority of the hCGα/hCG +
hCGβ ratios and almost all hCGα/hCGβ ratios in molar pregnancy are
below P5 of normal pregnancy. Thus, our study based on a large patient
sample showed that hCGβ in serum, and the ratios of hCGβ/hCG +
hCGβ and hCGα/hCGβ are excellent diagnostic tests and parameters to
make the biochemical distinction between hydatidiform mole and nor-
mal pregnancy at the 100% specificity level with more than 90% sensitiv-
ity. For practical use, the hCGβ assay is recommended. Our study fur-
ther revealed that the distinction between complete and partial hydatidi-
form mole cannot reliably be made with any of the 9 tested hCG analytes
or parameters including hyperglycosylated hCG because diagnostic
accuracy of these tests is at best qualified as moderate. Finally, we found
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that none of the 9 investigated hCG analytes or parameters had adequate
diagnostic accuracy to permit the clinician to advise patients to under-
take prophylactic chemotherapy after evacuation of a hydatidiform
mole.
Why hCGβ is synthesized more abundantly in complete hydatidiform
moles than in partial moles or in normal pregnancy, is unknown. Howev-
er, the mechanism for transcriptional and translational regulation of
hCGα and hCGβ subunit synthesis indicates that both hCG α and β-
subunits are synthesized in cytotrophoblasts and syncytiotrophoblasts
in normal pregnancy, but more abundantly in syncytiotrophoblasts (1).
After subsequent posttranscriptional modification, subunits combine to
form intact hCG (2-4). hCGα is encoded by a single gene on chromo-
some 6 (4), whereas the β-subunit of hCG is encoded by four genes:
hCGβ-3, -5, -7, and -8, located on chromosome 19q13.3 (5). In normal
pregnancy, hCG synthesis is regulated by an autocrine feedback loop
whereby hCG down-regulates hCG/LH receptor gene expression (6). In
choriocarcinoma cells, self-regulation of hCG synthesis is lost due to a
defect in the hCG/LH receptor which resulted in truncated receptors
located predominantly inside the cells. Besides the rise in number of
hCG producing cells in hydatidiform mole, the truncation of the
hCG/LH receptor could also explain how hCG reaches such very high
levels in GTD (7). Recently, transcriptional regulation of the hCGα- and
hCGβ genes has been elucidated (8-10). For hCGβ5, the most abundant-
ly transcribed hCGβ gene in placentas of early and late gestational age
and in choriocarcinoma, selective promoter factors 1 and 3 (SP1 and 3)
and activating protein 2 (AP2) regulatory promoter sites were identified
(10). The hCGα subunit promoter was found to contain cAMP-response
elements (CREs) (9,11). With the promoter for hCGα synthesis being
cAMP dependent and the promoter for hCGβ not being cAMP depen-
dent, it might be explicable why in hydatidiform mole hCGβ is synthe-
sized more abundantly than hCGα. Loss of, or an increase in, particular
transcription factors during neoplastic transformation could lead to dis-
similar amounts of hCG subunits being produced by these cells. In the
same line, it is explicable that in partial mole, which contains both nor-
mal trophoblast and hyperplastic trophoblasts, less free hCGβ is synthe-
sized than in complete moles.
It may be difficult to distinguish a hydatidiform mole from an abor-
tion with hydropic villi because hydropic swelling often occurs in either
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entity. However, the marked trophoblastic hyperplasia is lacking in a
hydropic abortion (12). Diagnostic tools to distinguish complete mole
from partial mole or hydropic degeneration have been developed. One of
these tests makes use of ‘genomic imprinting’ which refers to the phe-
nomenon that for certain traits, either the paternal or the maternal copy
of the gene is expressed (13). It is argued that besides pathological exami-
nation, other techniques are beneficial in the proper diagnosis of hyda-
tidiform mole (12,14-16). As shown in our study described in chapter 2,
the distinction between a complete hydatidiform mole and normal preg-
nancy can be made with a diagnostic accuracy of 0.99 with the use of a
free hCGβ assay. It would be interesting to perform an experiment
which attempts to distinguish hydatidiform mole from hydropic degen-
eration with the same set of hCG parameters used in chapter 2 and to
compare the diagnostic power between the hCG parameters and for
instance the P57kip2genomic imprinting test, which identifies the pater-
nally not expressed and maternally expressed CDKN1C gene (16).
In our search for reliable biochemical predictors for PTD before evacu-
ation of molar pregnancy (Chapter 5) we also examined hyperglycosylat-
ed hCG because it has been put forward that high levels of hyperglycosy-
lated hCG are associated with aggressive trophoblast invasion in early
pregnancy, at 3-4 weeks gestation (17,18) and in trophoblastic disease
(19). It was also reported that this marker could distinguish quiescent
GTD from invasive mole in cases of persistent low levels of hCG after
mole evacuation (20). Our results indicate that none of the 9 hCG ana-
lytes or parameters tested including hyperglycosylated hCG had ade-
quate diagnostic accuracy to permit the clinician to advise patients to
undertake prophylactic chemotherapy after evacuation of a hydatidi-
form mole. This leads to the hypothesis that malignant transformation
of a hydatidiform mole into PTD occurs after evacuation (Chapters 2
and 5). To further confirm or reject the diagnosis of PTD we explored the
diagnostic potential of calculated serum hCG ratios from blood samples
taken after mole evacuation to identify development of PTD at the most
early stage (Chapter 3). Our retrospective study revealed that a ratio of
two hCG concentrations measured in 2 serum samples obtained at dif-
ferent time points after evacuation identifies the majority of patients
with PTD approximately 2 weeks earlier (i.e., by the seventh week after
evacuation) than the internationally accepted FIGO 2000 criteria. Cal-
culation of such a ratio from 2 already available serum hCG concentra-
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tions after evacuation may provide a quantitative addition to the qualita-
tive FIGO 2000 ‘increase’ and ‘plateau’ criteria. This kind of ratio appar-
ently reflects the residual activity of the hydatidiform mole after evacua-
tion (and supports the abovementioned hypothesis that malignant trans-
formation of a hydatidiform mole into PTD occurs after evacuation),
whereas a ratio calculated from an hCG concentration measured in a
serum sample taken before divided by an hCG concentration obtained
after evacuation would mirror the total tumour activity present before
evacuation. Several normograms for spontaneous regression of serum
hCG have been developed with 50 % of patients having normalized
serum hCG measurements between 6 and 14 weeks after evacuation (21-
25). To our knowledge no studies have been performed on the diagnostic
capacity of hCG-ratios in the diagnosis of PTD. In this study we ana-
lyzed at which time point after evacuation the criteria for PTD were met
according to the current guidelines. We found that the median time to
reach this diagnosis in the PTD group was at 4.7 weeks after evacuation
when using the current FIGO 2000 criteria, and 4.4 weeks after evacua-
tion if the Dutch guideline for PTD were applied. However, the median
time to initiate therapy was 7.2 weeks. Possibly, this delay occurred
because treating physicians were in doubt whether the criteria to diag-
nose PTD were truly met. Importantly, the median time to diagnose PTD
by using the hCG-ratio was 3.0 weeks. Thus, the hCG-ratio identified
patients earlier and possibly more accurate than in the case that the crite-
ria as provided by FIGO 2000 were used.
The qualitative terms ‘increase’ and ‘plateau’ in serum hCG to con-
firm or reject the diagnosis PTD after evacuation of a hydatidiform mole
may be subject to intra- and inter observer bias. Kohorn proposed to add
to the definition of PTD according the FIGO 2000 criteria that an
‘increase’ should be defined as an hCG rise of 10 % or more for 3 values or
more over a period of at least 2 weeks (26). However, no universal agree-
ment has been reached on this proposal yet (27). The disadvantage of
incorporating the premises of a 10 % rise for 2 weeks in the FIGO 2000
criteria for the diagnosis of PTD is that a rise within the range of normal
serum hCG regression will lead to the diagnosis of PTD. Although we
used these FIGO 2000 criteria for PTD as our ‘gold standard’ in our
study, it does not implicitly mean that FIGO 2000 provides the best diag-
nostic criteria to diagnose PTD; it is very well possible that less patients
are diagnosed with PTD while using normograms for normal hCG
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regression, as compared to situations in which the concepts of ‘increase’
or ‘plateau’ are used without incorporating the premises that a serum
measurement should exceed normal regression (21,24). However,
because the development of normograms for every hCG assay does not
seem feasible, the incorporation of a quantitative measure, for instance
an hCG-ratio, in the criteria for PTD adds diagnostic accuracy to this
definition.
Why is there such a large dispersion in the curative effect of a second
curettage between the present and other studies (28,29)? The retrospec-
tive study by Schlearth et al. dealing with second curettage demonstrated
a curative effect in approximately 16 % of patients and observed severe
complications in 8.1 % of the second curettages (28). Our data are in line
with the results of Schlearth et al.; we observed a curative effect in 9.4 %
of the patients with low risk PTD, while 4.8 % of the patients had a severe
complication due to second curettage (uterine perforation or hemor-
rhage> 1000 mL) (Chapter 6). Contrasting with the results of Schlaerth
et al. and our data are the findings of Pezeshki et al. who reported the first
prospective study on the curative effect of a second curettage in patients
with PTD (29). The latter study showed a second curettage-only to be
curative in 60 % of 282 patients with proven PTD. In this prospective
study, criteria for the diagnosis of PTD are given as a plateauing or
increasing serum hCG concentration without mentioning the period of
plateauing. Upon request, the corresponding author of this study com-
municated that PTD was diagnosed if serum hCG was not normalized
within 4 to 6 weeks after the first evacuation, or if serum hCG was
increasing at any stage. Our previous study on normal serum hCG
regression in patients with uneventful regression after evacuation
revealed that serum hCG cumulatively normalizes in 5 % of patients
within 6 weeks after first evacuation (and 50 % within 11 weeks and 95 %
within 25 weeks) (24). Thus, it appears that patients are put at risk for
complications if they are advised to undergo a second curettage 4-6
weeks after evacuation for ‘persistent trophoblastic disease’ according to
the criteria of Pezeshki et al. because it is unnecessary in the majority of
patients. 
Another explanation for the large dispersion in the curative effect of a
second curettage between our study and the study performed by
Schlearth et al. on the one hand, and the study of Pezeshki et al. on the
other hand may be that the Dutch Central Registry for Hydatidiform
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Mole registers patients on a voluntary basis. From 1987 until 2003, 2122
patients with GTD were registered of which 422 developed PTD (20 %)
(Chapter 6), 756 out of 2122 patients (36 %) had a spontaneous regression
and clinical outcome was unknown in 944 out of 2122 patients (44 %).
Due to ‘reporting’ bias, it may be possible that in the group of patients
with an unknown clinical outcome, second curettages have been per-
formed with possibly a curative effect.
Should patients with low-risk PTD be advised to undergo a second
curettage? On should first realize that all evidence so far is derived from
retrospective studies. To answer this question, the ‘benefits’ (cure,
debulking effect and no need for chemotherapy) should outweigh the
‘costs’ (chance of major complications caused by the second curettage).
The curative effect rates of a second curettage in PTD are reportedly 9.4
% (this thesis), 16 % (28) and 60 % (29). Major complications (uterine
perforations) occurred in 3 patients (8.1 %, with 2 patients needing an
hysterectomy) in one study (28), while our study reported a uterine per-
foration in 2 out of 85 patients (2.4 %, both managed conservatively)
(Chapter 6). If chemotherapy will be necessary after the second curet-
tage, it can be expected that one course less is needed. The ‘costs’ will be
that there is a risk of approximately 5 % to 10 % that the second curettage
will be complicated by uterine perforation for which a hysterectomy may
be necessary, or hemorrhage>1000 mL. Overall, the ‘benefits’ and ‘costs’
of a second curettage seem to be at equilibrium. It can be imagined that
some patients are reluctant to use chemotherapeutic agents, or do not
wish to conceive anymore. These are the patients who may benefit from a
second curettage. Patients with less reluctance towards chemotherapy,
or those who definitely wish to conceive again should not be advised to
have a second curettage for treatment of PTD to explicitly exclude the
risk of uterine perforation. The true curative effect of a second curettage
can only be investigated in a prospective randomized controlled trial.
It is remarkable that several different studies find that if single-agent
chemotherapeutic treatment is successful, the serum hCG half-lives or
median time to normalization is comparable with those of uneventful
hCG regression. Not only were the results for the median time to nor-
malization in the study of Rotmensch et al. comparable with our data
(median time for normalization 11 weeks, comparable to the 5 two-week-
ly courses needed by 50 % of patients for normalization of serum hCG
after successful single-agent chemotherapy (Chapter 7)), but we also
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described the serum half-lives in three groups of patients (spontaneous
regression of serum hCG, PTD cured by single-agent therapy and PTD
in which single-agent therapy was followed by multiagent therapy)
(Chapter 4). In this study, no significant differences were found between
the half-live of hCG + hCGβ in spontaneous regression and in hypergly-
cosylated hCG in spontaneous regression as compared with the regres-
sion of these two hCG parameters in patients successfully treated with
first-line single-agent therapy.
Regarding the pathogenesis of PTD development it is intriguing to
consider why approximately 15 % to 20 % of complete hydatidiform
moles and 0.5 % to 9.9 % of partial hydatidiform moles progress to PTD.
Hypothetically, several mechanisms could be underlying these malig-
nant sequelae of hydatidiform mole pregnancies:
1. Incomplete evacuation of trophoblastic tissue present in utero;
2. A defect in cell regulating mechanisms that is present at the moment
of the first evacuation of the hydatidiform mole;
3. A defect in cell regulating mechanisms that develops in residual molar
tissue after the evacuation of the hydatidiform mole.
Different from other solid malignancies, the diagnosis and prognosis of
PTD is not solely based on histology of the primary tumour and its stag-
ing. HCG is a highly accurate tumor marker for trophoblast activity. If
after a first evacuation hCG shows signs of residual trophoblastic activi-
ty (i.e. plateau or increase), PTD can be diagnosed and treatment can be
established. The first hypothetical mechanism for the development of
PTD is that this condition is the result of an incomplete evacuation. Nor-
mally, extra villous trophoblasts invade the myometrium up to a third of
the entire myometrial wall (30). With the commonly used suction curet-
tage for the evacuation of a hydatidiform mole, it is highly unlikely that
the first third part of the myometrium, bearing the extra villous tro-
phoblasts will be curetted as well. Therefore, this first hypothesis seems
quite unlikely to be the cause for the persistence of some tumors as most
patients will have residual tissue. Another finding that refutes the possi-
bility that residual trophoblast after the evacuation of a hydatidiform
mole is the cause of PTD, is presented in a study by Lao et al.(31). These
authors performed a study in which the ‘yield’ (trophoblastic tissue or no
trophoblastic tissue) of a routinely performed second curettage in
patients with a hydatidiform mole was compared with the subsequent
gener al discussion
151
need for chemotherapy for PTD; no such correlation was reported. Inter-
estingly, the authors described that 76.9 % of patients with trophoblastic
tissue detected in the second curetting showed no signs of PTD as
derived from abnormal serum hCG regression and that 14.1 % of
patients with no trophoblastic tissue detected with the second curetting,
had signs of PTD for which chemotherapeutic treatment was estab-
lished. This study indirectly contradicts our own finding (Chapter 6) and
two other studies (28,29), i.e. that a second curettage has a curative effect
in a small amount of patients with PTD. Possibly, the majority of PTD
have other causes than residual tissue, but a small proportion of PTD
seems to be caused by the remaining trophoblastic tissue in utero.
The second and third hypotheses for the development of PTD specifi-
cally address possible defects in cell-growth regulation as the mecha-
nism. However, these regulatory mechanisms are beyond the scope of
the present investigations and, for this reason, will not further be dis-
cussed. As already stated, the majority of PTD have possibly other caus-
es than residual tissue, and a small proportion of PTD seems to be caused
by the remaining trophoblastic tissue in utero. Thus, it appears reason-
able to further investigate the hypothesis that postmolar hCG ratios
(Chapter 3) reflect the residual tissue while pre-postmolar serum hCG
ratios (that is, an hCG-concentration in a serum specimen taken before
evacuation of the mole divided by an hCG concentration of a serum sam-
ple taken after evacuation) mirror the properties and potentials of all tis-
sue present before evacuation of the mole. It would be interesting to com-
pare the available results of the proportion of PTD predicted by postmo-
lar hCG ratios (Chapter 3) with the proportion of PTD predicted by the
pre-postmolar serum hCG ratios that still have to be calculated from
available data. In order to optimise the detection of PTD, another sug-
gestion is to assess the predictive potential of the two types of hCG
ratios with the results of the FIGO 2000 and the NVOG scoring systems
for detection of postmolar PTD.
Finally, recommendations for the Dutch Registry for Hydatidiform
Mole (CMRN) are:
1. Encouragement of registration
As stated in the introduction of the present thesis, probably only half the
total number of hydatidiform moles in the Netherlands are registered
with the CMRN. Since hydatidiform mole is a rare entity, central regis-
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tration is important to combine data and knowledge. In order to facilitate
this registration, an online advice and registration service should be
established.
2. Linking of the diagnoses registered with the Dutch Network and National Data-
base for Pathology (PALGA), with the CMRN concerning GTD
In order to gather reliable data on incidence of GTD, automatic output
from the PALGA system (registering all the histological diagnosis in The
Netherlands) towards the CMRN should be established.
3. Scoring for high/low risk PTD according to the FIGO 2000 classification
To facilitate and improve the comparison of data on PTD obtained in the
Netherlands with international data, gynaecologists and clinical oncolo-
gists should not only classify patients for high/low-risk PTD according
to the Dutch guidelines but also according to the internationally accept-
ed FIGO criteria. This will enable to compare both classifications, and
may facilitate the comparison between Dutch patient groups and other
patient groups in future research.
gener al discussion
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Summary

Chapter 1 introduces the different entities in Gestational Trophoblastic Dis-
ease (GTD), Persistent Trophoblastic Disease (PTD) and human Chori-
onic Gonadotropin (hCG).
Mola hydatidosa are villous malformations of trophoblast, which are
characterized by edematous villi covered with trophoblastic hyperplasia.
Both mola hydatidosa and the non-villous counterparts choriocarcino-
ma and placental site trophoblastic tumor are classified as GTD. Geneti-
cally, mola hydatidosa can be subdivided into complete and partial hyda-
tidiform mole. Distinction between a complete and a partial hydatidi-
form mole is important since they have a different propensity to have
malignant sequelae.
In PTD, trophoblastic activity of the hydatidiform mole remains after
termination of pregnancy that results in a plateau or increase of the
serum concentrations of the pregnancy hormone, hCG. To date, an
internationally accepted definition for diagnosis of PTD as proposed by
FIGO (International Federation of Gynaecology and Obstetrics) is used
in which PTD is defined as a plateau of serum hCG concentrations for
three weeks, an increase of hCG for two consecutive weeks, the detec-
tion of hCG six months after evacuation, or the histological finding of a
choriocarcinoma. In the Netherlands, the Dutch Society for Obstetrics
and Gynaecology defines PTD as a plateau or increase of serum hCG
concentrations for three consecutive weekly measurements, with at least
one measurement exceeding the 95th percentile of a serum hCG regres-
sion curve established for normal uneventful post-molar regression. The
reported frequency of PTD is 20 % in complete hydatidiform mole and
0.5 to 9.9 % in partial hydatidiform mole.
In normal pregnancy, intact hCG (i.e. a hCG α- attached to a hCG β-
subunit), represents the majority of hCG, but other variants like free
hCG α-subunit, free hCG β-subunits, nicked intact or nicked hCG-sub-
units and hyperglycosylated hCG are present as well. The production of
subunits of hCG is under stringent physiological control in normal preg-
nancy, and is reported to be different in pathological states such as hyda-
tidiform mole.
The present thesis studied the ability of several hCG parameters to
distinguish hydatidiform mole from normal pregnancy and to predict
the development of PTD. Regarding treatment of PTD, we explored the
curative effect of a second curettage and we constructed a ‘normal’
regression curve for the early detection of resistance to first-line single-
agent therapy in patients with low-risk PTD.
summary
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Chapter 2 explored the diagnostic accuracy of ‘total’ hCG (intact hCG+free
hCG β-subunit measured together (hCG + hCGβ)), free hCG α-sub-
units (hCGα) and hCG β-subunits (hCGβ) obtained prior to evacua-
tion, and the calculated ratios between these analytes to make the dis-
tinction between hydatidiform mole and normal pregnancy, between
complete and partial and hydatidiform mole and between spontaneous
regression and PTD.
Blood specimens collected in the Dutch Central Registry for Hydatid-
iform Moles were used to measure hCGα, hCGβ and hCG + hCGβ con-
centrations by radioimmunoassays. A group of 165 patients with com-
plete (of which 43 with PTD) and a group of 39 patients with partial
moles (of which 7 with PTD) were compared with 27 pregnant women
with uneventful pregnancy. In addition, we calculated the ratios
hCGα/hCG + hCGβ, hCGβ/hCG + hCGβ, and hCGα/hCGβ. Receiv-
er Operating Curve (ROC) analysis revealed that the distinction
between hydatidiform mole and normal pregnancy is best possible on a
single blood specimen with hCGβ, but also, excellent results are
obtained with hCGβ/hCG + hCGβ and hCGα/hCGβ , with Areas-
Under-the-Curve (AUCs) ranging between 0.922 and 0.999. To distin-
guish complete from partial hydatidiform mole, the six tested hCG ana-
lytes and parameters showed AUCs between 0.7-0.8. In predicting PTD,
the three analytes and three calculated parameters showed limited diag-
nostic significance with AUCs<0.7
Chapter 3 assessed the diagnostic potential of serum hCG concentration
ratios obtained after evacuation of hydatidiform mole to diagnose PTD
and compared its diagnostic accuracy with the current FIGO 2000 stan-
dard.
A retrospective cohort survey was performed on patients registered
with the Dutch Central Registry for Hydatidiform Moles between 1977-
2004. After exclusion for various reasons, serum hCG concentrations
were available for 278 patients. Of these, 87 patients developed PTD
(study group) and 191 had a spontaneous regression of serum hCG (con-
trol group). Serum hCG ratios were calculated of two concentrations
obtained after evacuation. Specificity and sensitivity were calculated and
paired in ROC curve analysis resulting in calculation of AUCs.
Serum hCG concentration ratios showed an increasing diagnostic
potential; the ratio obtained in week 1 and 5 after evacuation showed an
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AUC of 0.568 and 0.935, respectively, and identified 20 % and 79 % of
patients with PTD at the 95 % specificity level. The median time to diag-
nose PTD with the use of a ratio was 3.0 weeks versus 4.7 weeks if the cri-
teria for PTD according to FIGO 2000 were applied.
In this retrospective study we found that a ratio of two serum hCG
concentrations obtained after evacuation identifies patients with PTD
approximately 2 weeks earlier than the internationally accepted FIGO
2000 criteria. This ratio makes it possible to identify the majority of
patients who develop PTD by the seventh week after evacuation. The
additional calculation of a ratio from two already available serum hCG
concentrations obtained after evacuation may provide a quantitative
addition to the qualitative FIGO 2000 ‘increase’ and ‘plateau’ criteria.
It remains to be investigated prospectively, however, whether such an
addition leads to a gain in diagnostic accuracy of the present FIGO 2000
criteria.
Chapter 4 explored the disappearance rates of ‘total’ hCG and hyperglycosy-
lated hCG in serum after evacuation of a molar pregnancy.
We investigated the relationship between hyperglycosylated hCG and
‘total’ hCG concentrations after evacuation of the mole by comparing
the time-course and half-life in three groups of 7 patients each. The
patients of the first group had uneventful regression of their serum hCG
after evacuation of hydatidiform mole, those of the second group needed
single-agent chemotherapy (Methotrexate) for treatment of PTD and the
patients of the third group had PTD that failed to respond to single-agent
chemotherapy. Significantly longer mean values of serum half-life for
‘total’ hCG and hyperglycosylated hCG (Invasive Trophoblast Antigen,
ITA) were found in the group not responding to single agent chemother-
apy (Group 3: 3.02 and 2.51 weeks) as compared to the group that did
respond to single agent chemotherapy (Group 2: 0.96 and 0.90 weeks)
and the group that had uneventful regressions (Group 1: 0.81 and 0.66
weeks) (all p=0.003), but no differences were observed between the
groups responding to single-agent chemotherapy and with uneventful
regression. Significantly shorter mean half-life values for hyperglycosy-
lated hCG than those calculated for hCG + hCGβ were observed in all
three groups of patients. It is concluded that the possible clinical value of
faster regression of hyperglycosylated hCG to baseline levels as com-
pared with hCG + hCGβ remains to be investigated prospectively.
summary
161
Chapter 5 assessed the diagnostic potential of ITA, hCGβ and hCG + hCGβ
in serum samples obtained before evacuation and the calculated ratios of
hCGβ/hCG + hCGβ, hCGβ/ITA and hCG + hCGβ/ITA, to predict the
later development of PTD.
The study group comprised 97 patients with hydatidiform mole who
did not develop PTD after mole evacuation, whereas 33 other patients
developed PTD. Serum samples from 130 patients with hydatidiform
mole with or without PTD were assayed using specific (radio)immuno-
assays for hCGβ, hCG + hCGβ and ITA. From these analytes we also
calculated the ratios hCGβ/hCG + hCGβ, hCGβ/ITA, and hCG +
hCGβ/ITA. To predict development of PTD from these analytes and
parameters we performed ROC curve analysis resulting in AUCs which
were expressed as diagnostic accuracy ranging from excellent (AUC>0.9
or <0.1) to poor (AUC 0.4-0.6). The diagnostic accuracy of ITA is mod-
erate (0.618) and not different from that of free hCGβ (0.610) and hCG
+ hCGβ (0.622). It was concluded that ITA as well as the other analytes
and parameters in serum taken prior to evacuation from patients with
molar pregnancies cannot be used to predict the subsequent develop-
ment of persistent trophoblastic disease.
Chapter 6 explored the curative effect of a second curettage in patients with
low risk PTD in a retrospective cohort survey based on patients regis-
tered with the Dutch Central Registry for Hydatidiform Moles between
1987 and 2003.
The study group comprised 85 patients with low-risk PTD according
to the Dutch guidelines who underwent a second therapeutic curettage
as part of the treatment for PTD. The control group consisted of 209
patients with low-risk PTD who did not undergo a second curettage.
Primary outcome measures were the need for chemotherapy and if
applicable, the number of chemotherapy courses. After second curet-
tage, eight out of 85 patients (9.4 %) did not need additional chemothera-
py which significantly differs from the patients in the control group who
all needed chemotherapy (p<0.001). A debulking effect of the second
curettage was observed: a median of 6 chemotherapy courses (interquar-
tile range 3 courses) in the control group versus 5 courses (interquartile
range 3 courses) in the study group (p=0.036). Four out of the 85 (4.8 %)
patients with a second curettage had a major complication (uterine per-
foration or haemorrhage > 1000 mL). Since a second curettage cured
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9.4% of patients with PTD in this historical cohort and reduced the num-
ber of courses of chemotherapy, we concluded that a second curettage
seems to benefit a limited number of patients with PTD.
Chapter 7 explored the possibility to identify patients not responding to sin-
gle-agent chemotherapy in an early stage and to prevent unnecessary
multiagent chemotherapy at the same time.
We constructed a normal serum hCG regression corridor for patients
successfully treated with single- agent chemotherapy. We included data
from patients registered at the Dutch Central Registry for Hydatidiform
Moles between 1987 and 2004. A normal serum hCG regression corri-
dor was constructed from data of 79 patients with low-risk PTD who
were cured by single-agent (Methotrexate (MTX)) chemotherapy (con-
trol group). Another group of 29 patients with low-risk PTD needed
additional multiagent chemotherapy because their serum hCG failed to
normalize with single-agent chemotherapy (study group). We found that
this normogram made it possible to identify 14 % of patients who will
need multiagent chemotherapy before the start of first-line single-agent
chemotherapy with 97.5 % specificity. Likewise, serum hCG measure-
ments obtained just before the start of the fourth MTX course identified
up to 50 % of patients (at 97.5 % specificity) who would not respond to
single-agent chemotherapy. We concluded that in the first few courses of
MTX we are able to identify at high specificity half the number of
patients that are likely to need multiagent chemotherapy to cure their dis-
ease and for whom further treatment with single-agent chemotherapy
will be ineffective.
Chapter 8 comprises the general discussion, in which the value of different
hCG parameters is discussed in the diagnosis of complete and partial
moles and in the prediction of PTD. Next to that, a hypothesis why
hCGβ is synthesized more abundantly in GTD than hCGα, is put for-
ward. We state in our general discussion that, while the most widely
accepted definition of FIGO for the diagnosis of PTD which incorpo-
rates qualitative criteria like “increase” and “plateau” in its definition, a
more quantitative criterion like a hCG ratio might be of more value in
the definition of PTD. We also address the large dispersion which several
studies have reported on the curative effect of a second curettage in PTD
and we address the clinical benefits and drawbacks of this procedure. We
summary
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illuminate the clinical utility of serum hCG regression corridors in fol-
low-up of uneventful hydatidiform mole and in patients treated with sin-
gle-agent chemotherapy for low-risk PTD. Finally, based on these stud-
ies we provide some recommendations for the improvement of the
Dutch Registry for Hydatidiform Mole (CMRN).
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Samenvatting

In hoofdstuk 1 worden de verschillende entiteiten binnen de zwangerschaps-
gerelateerde trofoblastziekten (Gestational Trophoblastic Disease, GTD),
persisterende trofoblastziekte (Persistent Trophoblastic Disease, PTD) en
humaan choriogonadotropine (hCG), geïntroduceerd.
Typisch voor mola hydatidosa is de aanwezigheid van villeuze afwij-
kingen van de trofoblast, welke worden gekarakteriseerd door oedema-
teus gezwollen vlokken die bedekt zijn met hyperplastische trofoblastcel-
len. Zowel de mola hydatidosa als de niet-villeuze tegenhangers, chorio-
carcinoom en Placental Site Trophoblastic Tumour, behoren tot de GTD.
Genetisch kan mola hydatidosa onderverdeeld worden in complete en
partiële mola hydatidosa, hetgeen van belang is omdat beide een ver-
schillende kans hebben op maligne ontaarding.
Bij PTD blijft de trofoblast van de mola hydatidosa actief na het beëin-
digen van de zwangerschap met een plateau of stijging van het zwanger-
schapshormoon hCG in het bloed tot gevolg. Momenteel wordt er een
door de FIGO (Internationale Federatie voor Obstetrie en Gynaecolo-
gie) een internationaal geaccepteerde definitie gebruikt die PTD defi-
nieert als er sprake is van een plateau van het serum-hCG gedurende drie
weken, een stijging van de hCG-concentratie gedurende twee weken,
detecteerbaar hCG zes maanden na evacuatie van de mola, of de histolo-
gisch bevestigde diagnose van een choriocarcinoom. De Nederlandse
Vereniging voor Obstetrie en Gynaecologie definieert de aanwezigheid
van PTD als een plateau of stijging van het serum hCG gedurende drie
opeenvolgende wekelijkse metingen, waarbij ten minste één hCG-
meting het 95e percentiel van een eerder opgestelde serum hCG-curve
voor spontane regressie van het serum hCG dient te overschrijden. De
gerapporteerde frequentie van PTD is 20 % na een complete mola hydat-
idosa en 0,5 % tot 9,9 % na een partiële mola hydatidosa.
In de normale zwangerschap bestaat het merendeel van het aanwezige
hCG uit intact hCG (een hCG β-keten verbonden aan een hCG β-
keten), naast een aantal andere varianten, waaronder N-terminaal hete-
rogene vrije hCG α-ketens, vrije hCG β-ketens en (door ontbrekende
verbindingen in de β-ketens) specifiek afwijkende vormen daarvan (nic-
ked hCG en nicked hCGβ), naast hypergeglycosyleerd hCG. Tijdens de
normale zwangerschap staat de productie van de hCG-ketens onder
strenge fysiologische controle en is anders in pathologische situaties
zoals bij mola hydatidosa.
In dit proefschrift hebben wij de mogelijkheden bestudeerd om met
samenvat ting
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behulp van verschillende hCG parameters mola hydatidosa van een nor-
male zwangerschap te onderscheiden en om PTD in geval van mola te
voorspellen. Met betrekking tot de behandeling van PTD hebben wij het
curatieve effect van een tweede curettage bestudeerd en hebben wij een
curve voor ‘normale’ hCG-regressie tijdens behandeling met eerstelijns
monochemotherapie voor laagrisico PTD ontwikkeld om vroegtijdig
resistentie daarvan op te sporen.
In hoofdstuk 2 hebben wij de diagnostische accuratesse van vóór de evacu-
atie verkregen ‘totaal’ hCG (intact hCG en de vrije hCG β-keten samen
gemeten: hCG + hCGβ ), de vrije hCG α-keten (hCGα) en de vrije hCG
β-keten (hCGβ) onderzocht en de daarvan afgeleide, berekende ratio’s
om het onderscheid te maken tussen mola hydatidosa en normale zwan-
gerschap, tussen complete en partiële mola hydatidosa en tussen sponta-
ne remissie en PTD.
Bloedmonsters uit de Centrale Mola Registratie Nederland, verza-
meld voorafgaand aan mola-evacuatie, werden gebruikt voor het bepalen
van de hCGα, hCGβ en hCG + hCGβ -concentraties met behulp van
radioimmunoassays. Een groep van 165 patiënten met een complete
mola hydatidosa (waarvan 43 met PTD) en een groep van 39 patiënten
met een partiële mola hydatidosa (waarvan 7 met PTD) werden vergele-
ken met een groep van 27 vrouwen die van week 6 tot week 16 van hun
ongecompliceerde zwangerschap longitudinaal werden vervolgd. Daar-
naast werden uit deze metingen de ratio’s van hCGα/hCG + hCGβ,
hCGβ/hCG + hCGβ, en hCGα/hCGβ berekend. Receiver Operating
Characteristics (ROC) analyse toonde aan dat het onderscheid tussen
mola hydatidosa en normale zwangerschap vrijwel absoluut gemaakt
kan worden op basis van een hCGβ meting in een enkel bloedmonster,
maar er werden ook uitstekende resultaten behaald met hCGβ/hCG +
hCGβ en hCGα/hCGβ, met Areas-Under-Curve (AUC) variërend van
0,922 tot 0,999. Voor het onderscheiden van een complete mola hydati-
dosa van een partiële mola hydatidosa varieerden de AUC’s van de zes
geteste parameters AUCs tussen 0,7 en 0,8. Analoog hieraan was het
voorspellen van PTD vrijwel niet mogelijk omdat de drie gemeten para-
meters en de afgeleide ratio’s met AUC’s<0,7 slechts een zeer matige dia-
gnostische accuratesse vertoonden.
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Hoofdstuk 3 onderzoekt de waarde van serum hCG-ratio’s, berekend uit
bloedwaarden verkregen na evacuatie van mola hydatidosa voor het dia-
gnosticeren van PTD. De diagnostische accuratesse van deze serum
hCG-ratio’s werd vergeleken met de huidige FIGO 2000 standaard.
Een retrospectieve cohortstudie werd uitgevoerd met patiënten die
tussen 1977-2004 geregistreerd waren bij de Centrale Mola Registratie
Nederland. Na exclusie om verschillende redenen, waren bruikbare
serum hCG-concentraties beschikbaar van 278 patiënten. Van hen ont-
wikkelden 87 patiënten PTD (studiegroep) terwijl 191 patiënten een
spontane regressie van het serum hCG hadden (controlegroep). Serum
hCG-ratio’s werden berekend uit concentraties die verkregen zijn uit
twee serummonsters na evacuatie. ROC-curve analyse resulteerde in de
berekening van AUC’s en gaf inzicht in specificiteit en sensitiviteit.
Serum hCG-ratio’s toonden een toenemende diagnostische potentie;
voor ratio’s verkregen in week 1 en 5 na evacuatie werden AUC’s van
respectievelijk 0,568 en 0,935 vastgesteld en identificeerden 20 % en 79 %
van de patiënten met PTD bij 95 % specificiteit. De mediane tijd om PTD
te diagnosticeren met behulp van een ratio was 3,0 weken versus 4,7
weken indien de criteria voor PTD volgens FIGO 2000 werden toege-
past.
In deze retrospectieve studie hebben wij vastgesteld dat een ratio bere-
kend uit twee hCG-concentraties gemeten in serum verkregen na evacu-
atie in staat is patiënten met PTD ongeveer 2 weken eerder te identifice-
ren dan het geval is volgens de internationaal geaccepteerde FIGO 2000
criteria. Deze ratio maakt het mogelijk om de meerderheid van patiënten
die PTD ontwikkelen in de zevende week na evacuatie te identificeren.
Het berekenen van een ratio van twee toch al beschikbare serum hCG
concentraties zou een kwantitatieve aanvulling op de kwalitatieve FIGO
2000 criteria voor ‘plateau’ en ‘stijging’ kunnen zijn.
Vooreerst dient nog prospectief onderzocht te worden of een dergelij-
ke aanvulling ook leidt tot een betere diagnostische accuratesse van de
huidige FIGO 2000 criteria.
Hoofdstuk 4 onderzoekt de verdwijningssnelheid van ‘totaal’ hCG en
hypergeglycosyleerd hCG (Invasive Trophoblast Antigen, ITA) in serum
na de evacuatie van een mola hydatidosa. Wij onderzochten de relatie
tussen hypergeglycosyleerd hCG en ‘totaal’ hCG-concentraties na eva-
cuatie van een mola door het tijdsverloop en de halfwaardetijd in drie
samenvat ting
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groepen van ieder 7 patiënten te onderzoeken. De patiënten in groep 1
hadden een ongecompliceerde remissie van hun serum hCG na de eva-
cuatie van een mola hydatidosa, de patiënten in groep 2 hadden mono-
chemotherapie (Methotrexaat) nodig voor de behandeling van hun PTD
en de patiënten in groep 3 hadden PTD die niet reageerde op monoche-
motherapie.
Significant langere gemiddelde serum halfwaardetijden voor ‘totaal’
hCG en hypergeglycosyleerd hCG werden gevonden in de groep die niet
reageerde op monochemotherapie (Groep 3; 3,02 en 2,51 weken) in ver-
gelijking tot de groep die wel goed reageerde op monochemotherapie
(Groep 2: 0,96 en 0,90 weken) en de groep met een ongecompliceerde
remissie (Groep 1: 0,81 en 0,66 weken), maar geen verschillen werden
gevonden tussen de monochemotherapie- en de spontane remissie-
groep. Significant kortere gemiddelde halfwaardetijden van hypergegly-
cosyleerd hCG in vergelijking tot hCG + hCGβ werden in de drie patiën-
tengroepen waargenomen. Wij concluderen dat de mogelijke klinische
waarde van de snellere verdwijning van hypergeglycosyleerd hCG ten
opzichte van hCG + hCGβ prospectief verder onderzocht moet worden.
In hoofdstuk 5 hebben wij, ter voorspelling van PTD, de diagnostische waar-
de van ITA, hCGβ en hCG + hCGβ in serum verkregen voor evacuatie
en van de daaruit berekende ratio’s van hCGβ/hCG + hCGβ, hCGβ/ITA
en hCG + hCGβ /ITA, onderzocht.
In de studie werden 97 patiënten met een mola hydatidosa die geen
PTD ontwikkelden na evacuatie vergeleken met 33 patiënten die dat wel
deden. Serum bloedmonsters van deze 130 patiënten met mola hydatido-
sa met of zonder PTD werden geanalyseerd met specifieke (radio) immu-
noassays voor hCGβ, hCG + hCGβ en ITA. Wij berekenden ook de
ratio’s van hCGβ/hCG + hCGβ , hCGβ/ITA en hCG + hCGβ /ITA. Om
het optreden van PTD te voorspellen met deze metingen en afgeleide
parameters, voerden wij ROC-curve analyse uit hetgeen resulteerde in
AUC’s als maat voor de diagnostische accuratesse die varieerde van
excellent (AUC> 0,9 of <0,1) tot matig (AUC 0,4-0,6). De diagnostische
accuratesse van ITA is matig (0,618) en niet verschillend van die van
hCGβ (0,610) en hCG + hCGβ ( 0,622). Wij concluderen dat ITA en de
andere metingen en parameters die verkregen zijn uit serum dat afgeno-
men is bij patiënten voor evacuatie van de mola hydatidosa, niet gebruikt
kunnen worden om PTD te voorspellen.
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Hoofdstuk 6 onderzoekt het curatieve effect van een tweede curettage bij
patiënten met laagrisico PTD in een retrospectieve studie die gebaseerd
is op patiënten geregistreerd bij de Centrale Mola Registratie Nederland
tussen 1987 en 2003. De studiegroep omvatte 85 patiënten met laagrisico
PTD volgens de Nederlandse richtlijnen, die allen een therapeutische
tweede curettage ondergingen als onderdeel van de behandeling van
PTD. De controlegroep bestond uit 209 patiënten met laagrisico PTD
die geen tweede curettage ondergingen. De primaire uitkomstmaten
waren de noodzaak voor chemotherapie en, indien van toepassing, het
aantal chemotherapiekuren. Na een tweede curettage hadden 8 van de 85
(9,4 %) patiënten geen aanvullende chemotherapie meer nodig, wat sig-
nificant verschilde van de patiënten in de controlegroep die allemaal che-
motherapie nodig hadden. Een debulking effect werd na de tweede curet-
tage waargenomen: de controlegroep ontving een mediaan aantal van 6
chemotherapiekuren (interkwartiele spreiding 3 kuren) versus 5 chemo-
therapie kuren (interkwartiele spreiding 3 kuren) in de studiegroep
(p=0.036). Vier van de 85 (4.8 %) patiënten in de tweede curettagegroep
had een grote complicatie (uterusperforatie of bloedverlies >1000 mL).
Omdat een tweede curettage 9,4 % van de patiënten met PTD in dit his-
torische cohort genas en het aantal chemotherapiekuren reduceerde,
concluderen wij dat een beperkt aantal patiënten met PTD baat lijkt te
hebben bij een tweede curettage.
In hoofdstuk 7 onderzochten wij de mogelijkheid patiënten die niet reageren
op eerstelijns monochemotherapie in een vroeg stadium te identificeren
om tijdig op polychemotherapiebehandeling over te gaan. We constru-
eerden een normaal hCG-regressiecorridor voor patiënten die succesvol
met monochemotherapie behandeld werden.
Wij includeerden gegevens van patiënten die tussen 1987 en 2004
geregistreerd zijn bij de Centrale Mola Registratie Nederland. Een nor-
maal serum hCG-regressiecorridor werd geconstrueerd voor 79 patiën-
ten met laagrisico PTD die genezen werden met monochemotherapie
(MTX) (controlegroep). Een andere groep van 29 patiënten met laagrisi-
co PTD had aanvullend polychemotherapie nodig (studiegroep). Met dit
normogram bleek het mogelijk om 14 % van de patiënten die polychemo-
therapie nodig zouden hebben voor de start van de eerste monochemo-
therapiekuur met 97.5 % specificiteit te identificeren. Op dezelfde
manier kan met serum hCG-metingen die vlak voor de start van de vier-
samenvat ting
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de monochemotherapiekuur verkregen zijn, 50 % van de patiënten die
polychemotherapie nodig zullen hebben met 97.5 % specificiteit geïden-
tificeerd worden. Wij concluderen dat wij in de loop van de eerste mono-
chemotherapiekuren in staat bleken met een hoge mate van specificiteit
de helft van het aantal patiënten te identificeren die polychemotherapie
nodig hebben voor genezing en voor wie verdere monochemotherapie
niet meer effectief is.
Hoofdstuk 8 betreft de algemene discussie omtrent de waarde van verschil-
lende hCG-parameters voor het stellen van de diagnose complete en par-
tiële mola en bij het voorspellen van PTD. Daarnaast wordt ingegaan op
de vraag waarom er meer hCGβ dan hCGα in GTD geproduceerd
wordt. Wij stellen in de algemene discussie dat de gangbare definitie van
de FIGO voor de diagnose PTD met daarin kwalitatieve begrippen als
‘stijging’ en ‘plateau’ kan worden opgewaardeerd met een kwantitatiever
criterium zoals een hCG-ratio. Wij bespreken ook de grote variatie in
het curatieve effect van een tweede curettage zoals genoemd in verschil-
lende studies en gaan in op de klinische voor- en nadelen van deze
ingreep. Daarnaast gaan wij in op de klinische waarde van een regressie-
corridor van serum hCG bij de follow-up van patiënten met spontane
regressie en bij patiënten met laagrisico PTD die met monochemothera-
pie behandeld worden. Tenslotte adviseren wij de Centrale Mola Regis-
tratie Nederland de registratie van patiënten met hydatidiforme mola te
blijven aanmoedigen, zo mogelijk een koppeling aan te brengen met het
Pathologisch Anatomisch Landelijk Geautomatiseerd Archief (PALGA)
en te bevorderen dat de classificatie van laag-/hoogrisico PTD tevens
plaatsvindt volgens de FIGO 2000 classificatierichtlijnen.
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Dr PN Span, beste Paul, heel hartelijk dank voor je lessen, de grappige
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het schrijven. Als numerieke nul, heb ik door jouw hulp een heel klein
beetje gevoel voor getallen en statistiek gekregen!
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nis van Hamont, Irene van der Avoort en Angèle Oei. Naast de gezellig-
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ken voor jullie vriendschap en het meedenken op onderzoeks- en spon-
soringsgebied én de inburgeringcursus in Nijmegen. Inmiddels weet ik
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waar ik de lekkerste koekjes, biertjes, kookspullen enz. enz. kan kopen!
Echter, ik hoop dat jullie beseffen dat de poets die jullie me bakten met
een hotelkamer switch, nog terug betaald gaat worden!
De opleider en plaatsvervangend opleider in het Catharina Ziekenhuis te
Eindhoven, dr. THM Hasaart en dr. HWHM van der Putten, wil ik heel
graag danken voor het prettige en leerzame opleidingsklimaat én de
mogelijkheid om twee weken na aanvang van mijn opleiding, de benen
naar Hong Kong te mogen nemen.
Beste Drs. D Boll, Dr. PA van Dop, Drs. SMI Kuppens, Dr. BC Schoot en 
Dr. APHB Struyk, dank voor de leerzame en opbouwende tijd in het 
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Lieve Eveline en Doriene, lieve paranimfen. Het was even zoeken om twee
paranimfen te vinden met een geringere lengte dan ik, maar het is uitein-
delijk gelukt.
Lieve Eveline aka Eefje Peefje Paranimf. Vol goede moed sleurde jij me uit
mijn donkere hol in het lab. Het monopolie op De Enige Vriendin in Nij-
megen heb je misschien een heel klein beetje verloren. Maar de Knab-
bel&Babbel vriendschap die we bij de statistiekcursus ontwikkelden
(niemand kan zo goed uitleggen wat jij bedoelt als ik), reikt verder dan
Eindhoven en de Alpen!
Lieve Doriene. Ruim tien jaar geleden togen we samen voor het eerst naar
Paramaribo voor onze stage “billenwassen”. Door de jaren heen ben ik
steeds meer je tukkerse, nuchtere maar warme blik op de wereld gaan
waarderen. Je bent de spin in het web van veel verschillende vriendschap-
pen. Ik vind het heel bijzonder dat je me uit Amsterdam nagereisd bent
om nu in dezelfde straat in Nijmegen te wonen. Je bent mijn kleine grote
vriendin!
Lieve Ineke, lieve mam. Hoe kan je iemand bedanken die negen maanden met
je in haar buik heeft rondgesjouwd en vervolgens dertig jaar alles in het
werk heeft gesteld om je gelukkig te maken? Jouw weigering om in te zien
dat er een probleem zou zijn om een specialisatie en gezin te combine-
ren, hielp me over de schreef. Dank je wel.
Lieve Max, lieve pappa. Je leerde me dat haastige spoed zelden goed is. Ook
bood je eerste hulp bij drift aanvallen. Dank voor het meedenken met dit
onderzoek, dichtbij en op afstand.
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Lieve Hielke en Klaar. Lieve broer, we kennen elkaar al een tijdje. Ik geloof dat
we vroeger in dezelfde bar aan de toog gehangen hebben, al kwam ik daar
20 maanden eerder dan jij. Gek, als ik aan jullie denk, zie ik altijd twee
malloten in een teletubbie pak voor me. Om het smartlapperig te zeggen:
‘We hebben heel wat met elkaar mee gemaakt.’ Ik kan alleen maar zeg-
gen: ik hoop dat we nog veel meer met elkaar gaan meemaken!
Dear doctor Monica Glenshaw. In Murambinda Mission Hospital, Zimbab-
we, you taught me obstetrics and how to set up preventive health pro-
grams. I will never forget the look in your eyes when I performed my first
caesarean section with you and I said: “Oh no, I think I cut right to the
placenta!” and you replied: “That is not placenta, that is the baby’s hair!”
Thank you for your inspiration and friendship. I hope that our daughter
Pi Sarah Monica will be a strong and witty person like you.
Lieve familie en vrienden. Het is niet makkelijk om te beschrijven hoezeer ik
geniet van de gezelligheid, vriendschap en humor die we met elkaar
delen. Dank voor al het meeleven in voor- en tegenspoed!
Lieve kleine dochter Pi. In mijn buik heb je de laatste fase van dit proefschrift
opgevrolijkt met intermezzo’s waarin je me het nieuwe spel blaasje tik (jij
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en leuk ik je vind. Ik hoop dat ik nog heel lang, heel veel spelletjes met jou
en Adam mag spelen!
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ben. Ik hoop dat ik nog heel lang en gelukkig met je mag reizen!
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